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1Biomaterials and Regenerative Medicine
Due to a rapidly changing lifestyle and increasing average lifespan, people are subjected to new challenges related to a.o. the emergence of age-associated 
diseases, incidents caused by road traffic, or air pollution in big cities. Due to rising 
living standards, patient expectations are growing as well. As a consequence, diseases 
such as cancer, osteoporosis, diabetes, asthma, or cardiac problems cannot always be 
simply treated based on the use of conventional pharmaceuticals.1 Biology, medicine, 
chemistry, materials science, and many other scientific fields need to join forces and 
create new and more powerful treatment modalities. The field of biomaterials research 
is an emerging scientific field that aims to develop improved materials for use in the 
body.2 Recent advances in this field may lead to a variety of novel therapies to relieve 
suffering and prolong life.1 Biomaterials have a strong impact on human health care 
in applications such as medical devices, diagnostics, sensors, drug delivery systems, 
tissue engineering, and regenerative medicine.3 In regenerative medicine, the body’s 
mechanisms for self-healing are triggered by therapeutic application of cells, artificial 
scaffolds that can store or attract cells and direct cell proliferation and differentiation,4 
and/or therapeutic biomolecules.5
Drug Delivery
The pharmacological efficacy of conventional drug formulations can be improved 
through the use of drug delivery systems.6 Controlled drug delivery systems are 
intended to deliver drugs locally at predetermined rates for predefined periods of 
time.7 By delivering pharmacologically high concentrations of active agents more 
selectively to pathological sites, drug delivery systems aim to improve the balance 
between efficacy and toxicity as compared to systemically administered therapeutics, 
thereby overcoming the shortcomings of systemic delivery of conventional drug 
formulations.7,8 Drug delivery systems are designed to amend the pharmacokinetics 
and biodistribution of incorporated drugs or biomolecules, or to function as reservoirs 
(i.e., as sustained release systems), or both.6
14
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Bone-specific Drug Delivery
Targeted drug delivery entails a selective and effective localization of 
pharmacologically active compounds at pre-defined targeted site(s), thus minimizing 
undesired side effects and maximizing therapeutic efficacy.9 Targeted delivery can 
be achieved by either passive or active targeting.10 Passive targeting involves the use 
of drug delivery carriers or reservoirs (such as nano-carriers), which can be applied 
for local or non-local (systemic administration) delivery.10 Active targeting, on the 
contrary, relies on the use of targeting moieties such as antibodies, peptides, or other 
small molecules with specific binding affinity for certain tissues or organs.11,12 For 
this type of targeting, understanding the interactions between these moieties and the 
targeted tissues is essential.
Although bone is generally regarded as one of the toughest tissues in the body, it can 
be damaged due to either traumatic or non-traumatic causes.13 For instance, bone is a 
frequent site for metastases, which develop in up to 70% of patients with prostate or 
breast cancer,14 and in up to 30% of those with lung, bladder, or thyroid cancer.15 Many 
approaches have been demonstrated for site-specific drug delivery, but strategies to 
obtain bone-specific delivery are still scarce.16,17 In order to design bone-specific 
delivery systems, the cellular and extracellular components of bone tissue should 
be well-understood. Therefore, the interactions between the inorganic and organic 
components of the extracellular matrix of bone tissue have been thoroughly reviewed 
in Chapter 2 of the current thesis. This review was the basis for the design of bone-
specific drug delivery strategies based on the use of bisphosphonates as described in 
this thesis.
Bisphosphonates for Bone-specific Drug Delivery
Only a limited number of molecules exhibit a strong affinity to mineralized tissue,18 
including a.o. heavy metals such as strontium, rhenium, and lead, as well as the 
antibacterial agent tetracycline.19 Conventional therapeutic agents generally do not 
bind to bone tissue, except for bisphosphonates,18 which have been developed for 
15
1the treatment of osteoporosis. These drugs owe their efficacy to both their medicinal 
effects (by inducing osteoclast apoptosis) as well as their bone-seeking properties.20
Bisphosphonate molecules are synthetic analogues for pyrophosphates that display a 
remarkable affinity to bone mineral. This property is mediated through (HO)
2
–OP–C–
PO–(OH)
2
 moieties that act as chelators of Ca2+ cations. Interestingly, the distance 
between deprotonated oxygens in phosphonates is 2.9–3.1 Å, which is in the same 
range as the oxygen anions in the calcium phosphate mineral crystals as present in 
bone tissue.21,22 Apparently, this distance is optimal for the chelation of Ca2+ ions in 
hydroxyapatite.18 These unique properties of bisphosphonates have been used for 
drug delivery purposes via several different approaches. For example, they can be 
used to overcome the inertness of compounds such as poly(ethylene glycol)-modified 
poly(ethylene)imine or to increase the mechanical properties of hydroxyapatite-
containing composite formulations.13 Bisphosphonate molecules can be linked to 
organic compounds by using straightforward chemical approaches.18 This renders 
bisphosphonates ideal for targeted delivery or enhancement of the affinity between 
organic and inorganic phases in next-generation nanocomposites used for local drug 
delivery.13 Bisphosphonates have also been used as moieties for targeted delivery of 
radio-pharmaceuticals, estrogen, corticoids, anti-inflammatory agents, and proteins.23 
Upon conjugation of bisphosphonates to nanomedicines via a degradable linker, they 
become pharmacologically active and can induce synergistic effects when coupled 
with appropriate drugs.23
Bone-specific Delivery of Chemotherapeutic Platinum-
based Drugs
Besides the devastating effect of cancer on bone tissue, current treatment modalities 
that are unspecific to cancer cells result in damaging healthy tissues.24 In fact, a major 
disadvantage of anticancer drugs is their lack of selectivity for tumor tissue, which 
causes severe side effects and results in low cure rates.25 For instance, therapy with 
platinum-based chemotherapeutic molecules such as cisplatin (cis-diamminedichlo
ridoplatinum(II)), which are a group of key drugs used in the treatment of cancers, 
16
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are associated with various secondary effects including anemia, nausea, vomiting, 
neurotoxicity, and nephrotoxicity. These side effects impair the patient’s quality of life 
and can be life-threatening.26–28
To overcome these side effects, a new generation of bisphosphonate-functionalized 
platinum-based complexes (i.e., bis-{ethylenediamineplatinum(II)}-2-amino-1-
hydroxyethane-1,1-diyl-bisphosphonate and bis-{ethylenediamineplatinum(II)}-
medronate)) was recently developed which target traditional anticancer platinum-
based drugs to bone tissue.29–31 Bisphosphonate-functionalized platinum-based 
complexes (Pt-BP) not only target bone as a result of bone-seeking properties of 
bisphosphonate moieties,9,13,32 but also specifically target bone tumors33 due to the 
higher metabolic activity of tumor cells as compared to healthy cells.34 The potential 
use of these anticancer complexes for loading and subsequent release from injectable 
calcium phosphate cements was studied in Chapter 3 of the current thesis. In Chapter 
4 and 5 the covalent linking and release of these complexes from mineral-binding 
gelatin nanoparticles were studied. Finally, the active bone-targeting capacity of these 
complexes was investigated through an in vivo biodistribution study in Chapter 6.
Objectives of This Thesis
Nanotechnology is a field of research at the crossroads of biology, chemistry, 
physics, engineering, and medicine.8 One of the most promising applications of 
nanotechnology within the fields of drug delivery and regenerative medicine involves 
the design of multifunctional nanoparticles capable of targeting specific tissues and 
delivering drugs in a sustained and controlled manner. The main aim of the research 
described in this thesis was to develop bone-specific delivery strategies either by 
linking bisphosphonates to nanoparticles-based drug delivery carriers or directly to 
chemotherapeutic platinum-based drugs.
To this end, the objectives of this thesis were to:
1. review the interactions between the mineral and organic extracellular matrix 
components in bone tissue as a source of inspiration for the design of novel 
17
1nanocomposites and bone-specific drug delivery strategies (Chapter 2);
2. develop chemotherapeutically active calcium phosphate cements by 
incorporating hydroxyapatite nanoparticles loaded with anticancer platinum-
bisphosphonate complexes (Chapter 3);
3. develop bisphosphonate-functionalized gelatin nanoparticles with enhanced 
affinity towards the apatitic mineral phase of bone for bone-specific drug 
delivery (Chapter 4);
4. develop gelatin nanoparticles dual-functionalized with mineral-binding 
bisphosphonate and an anticancer platinum-bisphosphonate complex 
for controlled release of chemotherapeutics from bone-specific gelatin 
nanoparticles (Chapter 5);
5. investigate the in vivo biodistribution of a novel bone-targeted anticancer 
platinum-bisphosphonate complex (Chapter 6).
18
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2
Introduction
Although bone is generally regarded as the toughest tissue in the body, it can be damaged due to either traumatic or nontraumatic causes.1 Autografts (tissue 
from patient’s own body), allografts (tissue from another individual), and xenografts 
(tissue from a different species) are the conventional choices for treating bone defects1; 
autografts are still considered as the clinical gold standard for treatment of critical-
sized2 bone defects.1,3,4 However, complications such as limited availability, additional 
surgeries, donor-site morbidity,5 and thus decreased quality of life for patients6 still 
remain problematic.1,3
These limitations prompted the search for appropriate alternatives, resulting in 
several synthetic biomaterials (alloplasts), including metals,7 ceramics,8 polymers,9 and 
composites thereof.4 Despite their advantages and widespread clinical applications, 
these alloplasts are also associated with considerable drawbacks. In general, synthetic 
materials do not resemble or function like natural bone tissue, primarily due to lack 
of adequate tissue formation in the vicinity of the biomaterial immediately after 
implantation.1 Metallic biomaterials do not have the potential for drug delivery, do not 
degrade4 (with the exception of magnesium and its alloys10–12), and generally display 
elastic moduli significantly higher than bone, which can cause stress shielding.13,14 
Such a stiffness mismatch causes inadequate load transfer from the biomaterial to 
the native bone tissue,14 which leads to complications such as bone resorption13 and 
inflammation due to abrasive particles and leached toxic ions.15,16
Ceramic biomaterials are generally nonresilient17 and very brittle,4,16 which makes 
them prone to mechanical failure,4 whereas the majority of polymeric biomaterials are 
not osteoconductive.18 By benefitting from the favorable properties of each component 
(e.g., formability of polymers and strong mechanical properties of ceramic fillers)18 
and eliminating their unfavorable properties, polymer–filler composites offer a 
solution to overcome some of the aforementioned drawbacks.19
Microstructured composites have been extensively investigated during the last two 
decades by including calcium phosphate (CaP) microparticles into bio- degradable 
polymers, such as collagen, gelatin, chitosan, and poly(lactic-co-glycolic acid).20–26 
26
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However, given that bone is a hierarchically structured nanocomposite comprised 
hydroxyapatite (HA) nanocrystallites dispersed in an organic matrix, it is perceived 
that biomaterials with similar hierarchical nanocomposite structures27 can offer 
improved functional and biological properties in comparison with conventional 
microstructured biomaterials or composites.1
Properties of composites are controlled by the properties of the matrix and dispersed 
phases as well as the interfacial interactions between the two phases. As the size of the 
dispersed phase decreases, the significance of these interfacial interactions increases. 
As a consequence, properties of nanocomposites cannot be predicted anymore by 
applying the rule of mixtures since the composite properties are largely controlled by 
the interfacial interactions.19,28 Hence, to mimic the nanocomposite structure of natural 
bone, a good understanding of the role of these interfacial interactions at the molecular 
and nanoscale level is essential. Therefore, in the current study, we have reviewed the 
interactions between mineral and organic extracellular matrix (ECM) components in 
both the native bone tissue as well as the synthetic, bioinspired inorganic–organic 
nanocomposites developed for bone regeneration.
The first part of this review provides a brief description of bone structure and its 
constituents, followed by an overview of different mechanisms of bone mineralization, 
as well as a description of interactions between CaP nanoparticles and the organic 
matrix in the bone ECM. The second part of this review addresses bioinspired 
synthetic approaches to obtain nanocomposites, with specific focus on chemical 
groups that have affinity for CaPs or are involved in stimulating and controlling 
mineral formation, that is, anionic functional groups including carboxyl, phosphate, 
sulfate, hydroxyl, and catechol groups.
Micro- and Nanostructure of Bone Tissue
Extracellular Matrix
The ECM of bone is a dynamic network composed of a vast variety of organic 
and inorganic constituents, including collagen, elastin, polysaccharides, and 
27
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CaP nanocrystals.29–34 In addition to providing a template for cell attachment and 
proliferation, ECM molecules control cell behavior by regulating cell proliferation 
and differentiation31,35 through a.o. soluble growth factors and cytokines, which are 
stored at minute quantities in the bone ECM.29,32
Collagen
Among more than twenty reported human collagens, collagen type I is the most 
abundant protein present in bone tissue.36,37 Collagen has been regarded as a passive 
scaffold for nucleation of apatite through interactions with noncollagenous proteins 
(NCPs).36,38 However, Nudelman et al.39 recently substantiated a hypothesis40 
suggesting that collagen is actively involved in controlling the mineralization of apatite 
by attraction of negatively charged polyanion-stabilized prenucleation clusters into 
positively charged regions of collagen fibrils.39,41,42 Wang et al.27 also showed recently 
that type I collagen can initiate and direct the growth of carbonated apatite mineral 
in vitro in the absence of any other vertebrate ECM molecules of calcifying tissues. 
Moreover, they revealed that the collagen matrix affects the structural characteristics 
on an atomic scale and controls the size and three-dimensional distribution of apatite.27
Noncollagenous proteins
Bone sialoprotein (BSP), osteonectin, osteopontin, and osteocalcin are the main 
structural NCPs of the bone ECM.29,36 The majority of NCPs contain a high density 
of aspartic acid (Asp) and glutamic acid (Glu) residues, which have high affinity for 
calcium ions (Ca2+) due to their charged carboxyl groups.36
BSP is a phosphoprotein that contains several polyglutamic acid segments 
responsible for binding to apatite43 as well as an RGD (arginylglycylaspartic/Arg-
Gly-Asp acid) integrin-binding sequence at its C-terminus.36,44–48 Osteonectin, an 
acidic protein rich in cysteine, is a glycoprotein present at high concentrations in bone 
tissue. Osteonectin is slightly phosphorylated, while many Asp and Glu residues are 
repeated throughout its structure.36 Osteopontin is a negatively charged protein of 
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~300 amino acid residues with a very high content of Asp and Glu residues49,50 such 
as specific sequences of nine consecutive Asp residues.36,45,51–53 Similar to the role of 
polyglutamic acid segments in BSP,43 the polyaspartic acid segments in osteopontin 
are responsible for the tight binding of the protein to HA.46,54–56 Osteopontin is an 
essential regulator of osteoclast activity, and its phosphorylation level directs the 
inhibition or nucleation of HA.36,45,51,57 It is suggested that partially phosphorylated 
osteopontin can bind to mineral nuclei or small crystals and block crystal growth, but 
completely phosphorylated osteopontin can nucleate mineral at low concentrations.36 
Osteocalcin, a 49-amino acid residue molecule,58 is the most prevalent NCP within the 
extracellular bone matrix, which is synthesized only by osteoblasts.36,59–61 It has a high 
affinity for apatite,62,63 and interacts with HA using γ-carboxyglutamic acid residues.52 
Osteocalcin normally limits bone formation without decreasing bone mineralization 
or resorption.36,61
Inorganic Phase
HA is the major inorganic crystal phase in bone tissue.34 However, bone mineral 
does not consist solely of HA, since the apatitic mineral in bone tissue contains 
impurities such as carbonate ions that substitute the hydroxyl and phosphate groups.29 
Apatitic bone mineral crystals are mainly platelets, the reported dimensions of which 
vary in literature with values ranging between 20–50 nm long, 15–30 nm wide, and 
2–10 nm thick.29,36,37,39,64–66 Carbonate concentrations of 4–6% render bone HA poorly 
crystalline, calcium-deficient, and carbonated.29,37 In addition to carbonate substituting 
for phosphate groups, other substitutions are also reported, such as potassium, 
magnesium, strontium, and sodium for Ca2+, and chloride and fluoride for hydroxyl 
groups.29 Except for fluoride—which mainly increases the crystallinity of apatite—
impurities generally reduce the crystallinity. As a consequence, bone mineral becomes 
more soluble, which is essential for mineral homeostasis and bone remodeling.29
29
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Interactions Between CaP Nanoparticles and Organic 
Matrix in the Bone ECM
A wide variety of models have been proposed to describe the complex process of 
collagen mineralization, but none of them has completely captured all the known 
information,37 and controversies among researchers still exist regarding the mechanism 
of mineralization, the role of gap zones in collagen fibrils, and the shape of crystals in 
bone. In the following section, classical theories on CaP mineralization are reviewed 
first, followed by a separate section, which addresses recently obtained insights on 
mineralization.
Classical Theories on CaP Mineralization
According to classical theories on CaP mineralization, NCPs such as BSP, osteocalcin, 
and osteonectin are strongly and actively involved in the matrix mineralization 
process.36,67,68 In the early 1990s, Hunter and Goldberg45 hypothesized that the 
mineralization effects of BSP are exclusively related to acidic, glutamate-rich peptide 
sequences and proposed that the removal of the phosphate groups on BSP has a minor 
or no effect on mineralization. In a later study, Stubbs et al.69 argued that groups other 
than acidic glutamate residues (such as phosphate, sulfate, and sialic acid groups) are 
also involved in mineral formation, and He et al.70 showed that phosphorylation is an 
essential factor for mineralization of phosphophoryn. Monfoulet et al.71 showed that 
BSP acts as a crystal nucleator.
In the late 1990s, osteocalcin and osteonectin were reported to regulate the size 
and speed of crystal formation.72 In the early 2000s, Hoang et al.73 proposed that 
proteins such as osteocalcin exhibit a specific mechanism for recognition of mineral 
surfaces that allows for biological adjustment of mineral crystal growth. Osteopontin, 
on the other hand, was found74,75 to influence the type of formed crystals and promote 
pathologic mineralization in cartilage. In the late 2000s, Elangovan et al.76 suggested 
that complexes can also be formed between backbone carbonyls of proline residues 
and Ca2+ in the inorganic phase.
30
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The role of NCPs in the mineralization of collagen has been extensively studied, 
resulting into several models. According to one of the most popular models, the acidic 
NCPs exclusively bind to collagen molecules in the gap zone—which is defined as 
a 40 nm zone containing only four molecules and 20% less packing density than 
the overlap zones of 27 nm containing five molecules, within the 67 nm periodic 
displacement pattern of collagen molecules36,66,77,78—and induce crystal nucleation 
inside the collagen fibrils.79 This theory is supported by the hypothesis that the initial 
mineral is deposited in the gap zones and that many noncollagenous acidic molecules 
bind specifically to collagen in these zones.80–82 Moreover, chains of nanometer-sized 
mineral nuclei83,84 fuse together to form elongated initial crystals, with their c-axes 
aligned with the long axes of the collagen fibrils, proposing epitaxial relationships 
between non-collagenous acidic proteins bound to the collagen fibrils and forming 
mineral. Nevertheless, this theory does not address the presence of transient amorphous 
calcium phosphate (ACP) in bone tissues.37
Another theory that is based on the phenomenon of size exclusion proposes that 
large acidic noncollagenous molecules inhibit mineralization outside the collagen 
fibrils, whereas their penetration into the gap zones is inhibited by their too large 
size.85 Consequently, the crystal growth is inhibited everywhere except inside the 
collagen fibril, resulting in initial mineral precipitation in the gap zones within the 
fibrils. This hypothesis, however, does not address the fact that the crystallites in 
the fibril are all coaligned. In addition, this model is unable to justify the presence 
of extrafibrillar crystallites, which encompass a large fraction of mineral in bone 
tissues.37 Another model proposes that mineral–protein complexes can form outside 
the collagen fibrils and subsequently diffuse inside, where they transform into the 
organized crystalline arrays guided by the collagen structure.86,87 This model suggests 
that the initial mineral formed is transient ACP stabilized in supramolecular assemblies 
of noncollagenous acidic proteins. These aggregates bind to collagen fibrils, which 
result in the transformation of the amorphous to crystalline phase. It is hypothesized 
that the NCPs in these protein–mineral aggregates interact with collagen molecules. 
Such interactions can influence the protein conformation, resulting in changes in its 
function from stabilizing ACP to controlling crystal nucleation. Already in the early 
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1990s, it was suggested66,88 that a liquid protein–ACP phase infiltrates the collagen 
fibrils through capillary forces, filling the gap regions and the spaces between the triple 
helices and subsequently transforms into oriented crystals. These studies proposed 
that collagen molecules themselves actively direct the nucleation of oriented crystals.
According to the classical theories, nucleation of inorganic minerals is considered to 
occur in supersaturated solutions of their constituting ions, resulting in the nucleation 
of the solid phase by stochastic solute clustering, and a cluster of critical size is 
regarded as the initial crystal precursor.89,90 Due to this formation mechanism, such 
metastable clusters are a rare species,90 which only become stable when a critical size 
is reached at which the growing surface energy associated to the increasing surface 
area is balanced by the decrease in bulk energy associated to the formation of a crystal 
lattice. The resulting nanoparticles form the critical crystal nuclei, which are the 
starting point for further growth through the associated reduction of the Gibbs free 
energy of the system.89
New Insights on CaP Mineralization
In contrast to classical theories on biomineralization, Gebauer et al.89 showed that 
calcium-based biominerals can be formed through stable prenucleation clusters, which 
aggregate into an amorphous precursor phase that subsequently transforms into a 
crystal.41,90 In this regard, two studies performed by Sommerdijk and his coworkers39,91 
further confirmed that CaP mineralization proceeds by means of prenucleation 
clusters. More specifically, Nudelman et al.39 reported on the influence of structure, 
assembly, and charge distribution of collagen on the formation of bone apatite and 
mineralization in the presence of polyaspartic acid as inhibitor for HA nucleation, 
thereby refuting the hypothesis supporting the passive role of collagen in nucleation 
of apatite for bone and tooth formation.39,41 In a related study, Dey et al.91 revealed that 
the surface-induced formation of apatite from simulated body fluid (SBF) initiates 
with the aggregation of prenucleation clusters resulting in nucleation of ACP before 
the development of oriented apatite crystals.41
Figure 2.1a schematically depicts the development of stable mineral droplets 
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comprising CaP–biopolymer prenucleation clusters, which bind to distinct segments 
on collagen fibers and diffuse inside the fibril, where they solidify and transform into 
an amorphous phase. This amorphous phase is subsequently altered into oriented 
apatite crystals directed by the collagen fibril arrangement.68
Figure 2.1. According to new insights on calcium phosphate (CaP) mineralization, two simultaneously 
occurring processes account for biomineralization of collagen fibers: (a) Direct nucleation of CaP crystals 
onto collagen fibrils; (b) Matrix vesicle-mediated mineralization, which is based on the formation and 
release of intracellular matrix vesicles containing CaP crystals by the outer membranes of osteoblasts.68
Sommerdijk and his coworkers92 recently revealed that CaP prenucleation clusters 
in fact are calcium triphosphate ion-association complexes that can aggregate into 
branched three-dimensional polymeric structures from which nucleation of ACP takes 
place through the simultaneous binding of calcium to form ~1.2 nm postnucleation 
clusters, and their aggregation and precipitation as spherical particles. Continued 
calcium uptake converts ACP into octacalcium phosphate and subsequently into 
apatite. Measuring the rate of CaP nucleation as a function of supersaturation, it was 
shown that ACP formation cannot be directly reconciled with the classical nucleation 
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theory. Nonetheless, theoretically, the thermodynamic barrier for nucleation is 
considerably decreased when the presence of prenucleation complexes and the particle 
size dependence of the interfacial free energy are taken into account. In summary, it 
was demonstrated that the presence of these complexes reduces the energy barrier to 
nucleation and proposes a so-called extended nucleation theory, which unites classical 
and nonclassical nucleation theories.92
Besides the above-mentioned and recently obtained insights on CaP mineralization, 
it should be noted that CaP mineralization in vivo proceeds according to a matrix 
vesicle-mediated93–95 mechanism. Matrix vesicle-mediated mineralization, on the 
other hand, is based on the formation of matrix vesicles by the outer membranes of 
osteoblasts, which act as compartmentalized microreactors for controlled precipitation 
of CaP nanocrystals.68,93 Three mechanisms have been proposed for the initiation of 
matrix vesicle-mediated mineralization (Figure 2.1b)68,96: (i) matrix vesicles only 
regulate ion concentrations, resulting in the development of soluble molecular species, 
which initiate mineral formation in collagen fibrils; (ii) matrix vesicles regulate ion 
concentrations, resulting in the development of intravesicular apatite crystals, which 
leave the vesicle and initiate the mineralization process; (iii) matrix vesicles link 
directly to collagen and facilitate matrix mineralization.68 As mentioned before, a wide 
range of NCPs are strongly involved in the matrix mineralization process.36,67,68 The 
enzyme alkaline phosphatase (ALP) is an important noncollageneous protein which, 
by hydrolyzing pyrophosphate (a mineralization inhibitor) and organic phosphate 
esters,97 provides phosphate ions (PO
4
3−) to promote mineralization.68,98–100 Another 
phosphatase that is highly expressed in bone, PHOSPHO1,101 is present within matrix 
vesicles and has a role in the initiation of mineral formation.68,102
It has to be emphasized that the interactions between inorganic and organic 
components of bone at the molecular or nanoscale level influence the behavior of 
bone at the macroscopic scale as well. The exceptional toughness of the bone tissue 
appears to be related to the interactions between the anionic groups of the ECM 
proteins and the calcium ions provided by the inorganic phase. It has been shown that 
a large amount of energy can be dissipated due to the additional work required for the 
breaking of the reversible, calcium-mediated bonds (sacrificial bonds) in the organic 
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network of the ECM. Osteopontin, in addition to other similar molecules present in 
bone such as BSP, can act as an interfacial glue through the network formation—a 
glue that dissipates energy through the sacrificial bond mechanism and can be used for 
improving the stiffness and toughness of synthetic nanoscale composites as well.54,55
Interactions between CaP Nanoparticles and Organic 
Matrix in Bioinspired Synthetic Nanocomposites
A composite structure comprises at least two phases that are separated by interfaces. 
The characteristics of these interfaces—and thus of the composites—are highly 
affected by parameters such as the filler shape, size and size distribution, ratio between 
the filler and matrix, dispersion of filler particles in the matrix, and the interactions 
between the filler and matrix.103 Regarding the interactions between components, an 
inorganic phase can be introduced into an organic matrix through either covalent 
(irreversible) or noncovalent (reversible) bonds. Depending on these chemical 
interactions, Kickelbick104 classified the mutual arrangement of nanoparticles with 
polymer chains into four groups (Figure 2.2): (i) dispersed inorganic particles in the 
organic continuous phase (blend); (ii) pendant inorganic groups bonded to the polymer 
backbone; (iii) interpenetrating network of inorganic components and polymers; (iv) 
dual inorganic–organic hybrid polymers, where covalent bonds exist between the two 
phases.103,105
This review mainly focuses on inorganic–organic composites (i.e., group one and 
two), which involve noncovalent bonds between the two phases. In addition to the 
classic polymer–ceramic nanocomposites (containing premade CaP nanoparticles), 
emerging approaches toward composite preparation by means of wet chemical 
mineralization of functionalized biomacromolecules have also been applied in the 
field of biomaterials and tissue engineering and will be addressed in this review as 
well, since these functionalized polymers have also become promising candidates 
for the preparation of polymer–ceramic nanocomposites with increased interaction 
between the mineral and organic phases. Notably, the number of studies investigating 
the inorganic–organic interactions in classic nanocomposites was considerably 
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lower than the number of studies on wet chemical mineralization of (functionalized) 
polymers, which stresses the importance of bioinspired, wet chemical synthesis of 
composite materials.
Figure 2.2. Different types of mutual arrangement of nanoparticles with polymer chains: (i) dispersed 
inorganic particles in the organic continuous phase (blend); (ii) pendant inorganic groups bonded to 
the polymer backbone; (iii) interpenetrating network of inorganic components and polymers; (iv) dual 
inorganic–organic hybrid polymers, where covalent bonds exist between the two phases.103,104
There are a number of functional groups that show affinity for either calcium or 
phosphate ions present in different types of CaP (Figure 2.3). As mentioned above, 
the rationale behind the use of different functional groups and molecules to obtain 
nanocomposites inspired by bone mineralization is based on (1) their affinity to 
adsorb to premade CaPs, or (2) their ability to trigger the process of nucleation by 
ionic interaction with either calcium or phosphate ions in the mineralization solution. 
Cationic functional groups with high affinity for phosphate mainly include amines 
but, due to the limited number of relevant studies, they are not addressed in this 
review. So far, the most commonly employed anionic functional groups with high 
affinity for Ca2+ are carboxyl, phosphate/phosphonate, sulfate, hydroxyl, and catechol 
groups.106 These chemical groups are widely employed in inorganic–organic interfaces 
of hybrid biomimetic nanocomposites to modify their ultimate properties, and will 
be separately described further in the following sections. Shen et al.107 carried out 
a systematic study on adsorption and desorption behavior of fibronectin on HA by 
steered molecular dynamics simulations, and reported that charged −COO– and −NH
3
+ 
groups show the highest interaction energy with HA surfaces, with values ranging 
between 70 to 100 kcal∙mol-1. Hydroxyl groups revealed weaker interaction energies 
ranging about 43–45 kcal∙mol-1, whereas neutral amino groups exhibited interaction 
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energies that were about half of charged −NH
3
+ groups. Although these groups showed 
a weaker interaction with the surface compared to –COO– and –NH
3
+ groups, it was 
revealed that they still considerably contribute to the total interaction energy between 
the proteins and HA surfaces.107
Figure 2.3. Functional groups with high affinity for CaP.
The following section highlights how anionic groups can be used to control the 
interfacial interactions between the organic and inorganic phases in nanocomposites, 
that is, how these chemical groups have been exploited for tissue engineering 
applications. The most relevant chemical groups will be addressed in separate 
subsections, which are further subcategorized as sections on classic polymer–ceramic 
nanocomposites versus composites prepared by means of wet chemical mineralization.
Carboxyl Groups
Organic compounds containing carboxyl groups of high affinity for Ca2+ generally 
include full proteins, peptide sequences, single amino acids, and COOH groups.106 
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These different categories will be described in detail in the following subsections.
Proteins
The affinity of certain proteins for HA can be exploited to regulate the nucleation, 
orientation, and growth of bone apatite under physiological conditions.108,109 
The interactions of proteins with HA were first investigated in the 1950s using 
chromatography by Tiselius et al.,110 who found that these interactions were 
mainly electrostatic.109 Later, thorough investigations on HA binding of proteins 
with isoelectric points (pI) ranging from 3.5 to 11.0, basic proteins of high pI were 
suggested to bind HA mainly through nonspecific electrostatic interactions between 
−NH
3
+ groups and anionic moieties on HA surface, whereas acidic proteins of low 
pI were found to bind mainly through complexation between −COO− and Ca2+ in 
HA.111–113 The ionic composition as well as the immediate environment affects the 
interactions of proteins with HA. The presence of Ca2+ in the medium improves the 
binding of acidic proteins to HA.114 Besides the direct influence on HA binding, Ca2+ 
in solution is anticipated to enhance the HA binding efficiency by inducing an optimal 
configuration of protein α-helices.115 The PO
4
3− in solution inhibits the HA binding 
of acidic proteins, most likely through competitive binding of PO
4
3− with Ca2+ on 
HA. It was shown that a decrease in pH generally increases the HA binding in acidic 
proteins.109,116–118 Investigations on the chemical interactions between carboxylate 
groups in the amino acid residues of collagen and the positively charged Ca2+ of HA 
revealed that nucleation of HA crystals on collagen in a supersaturated SBF solution 
is strongly dependent on the carboxylate groups in collagen, which, in turn, depend on 
the charged functional groups present in collagen.119
Mineralized Polymers
Kikuchi et al.16 reported that in nanocomposites synthesized through a simultaneous 
titration coprecipitation method [using Ca(OH)
2
, H
3
PO
4
, and porcine atelocollagen], 
collagen molecules stimulated the alignment of HA nanocrystals through interactions 
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between carboxyl groups on collagen and Ca2+ on the HA crystal surface. Fourier 
transform infrared (FTIR) spectroscopy showed that the asymmetric stretching 
vibration of a dissociated carboxyl group COO−, observed at 1340 cm-1 for pure 
collagen, shifted to lower wave numbers in the composite, indicating that two 
equivalent C−O 1.5-fold bonds in −COO− were weakened due to the formation of 
a new chemical bond between Ca2+ on the HA surface and −COO− on collagen. The 
resulting composite showed a self-organized nanostructure similar to bone assembled 
through the chemical interaction between HA and collagen. The composite was 
resorbed by osteoclast-like cells and stimulated osteoblasts to form new bone in the 
adjacent area.16 Collagen in its denatured form, that is, gelatin, has also been used 
as an organic matrix for preparation of nanocomposites.120–122 Carboxyl ions present 
in gelatin in HA–gelatin nanocomposites [prepared through a precipitation process 
using Ca(OH)
2
 and H
3
PO
4
 as precursors] can be active sites for coordination of Ca2+ 
to form ion complexes, which in turn interact with PO
4
3−. The observed increase in 
decomposition temperatures analyzed by differential thermal/thermal gravimetric 
analysis (DT/TGA) suggests the formation of a primary chemical bond between HA 
and gelatin, which is further supported by FTIR analysis, confirming the induction of 
a red-shift of the 1339 cm-1 band of gelatin due to the chemical bonding between Ca2+ 
of HA and carboxyl ions of gelatin molecules.122
Chirila et al.123 postulated that complex artificial proteins can be synthesized, which 
either accelerate or decelerate mineralization, thereby offering new opportunities for 
modulation of composite properties. To this end, motif-programmed artificial proteins 
were covalently immobilized with mineralization-related activity onto the surface of a 
poly(2-hydroxyethyl methacrylate) (pHEMA) hydrogel, and the influence of assaying 
conditions upon the ability of three artificial proteins (two proteins incorporating 
nacrein repetitive motifs [PS382 and PS458] and one protein incorporating DMP1 
motifs [PS64])124,125 to modulate calcification in vitro was investigated. A long-term 
calcification assay of 9 weeks showed that all proteins increased the uptake of calcium 
by the protein-modified pHEMA hydrogels. For PS382 and PS458, this behavior 
was opposite to that displayed when the same proteins were tested in a free state 
by a rapid solution assay (based on a decrease taking place in the pH upon rapid 
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addition of a solution of CaCl
2
 to a solution of NaHCO
3
 leading to the precipitation 
of CaCO
3
).126 Such a difference was attributed to a restricted mobility of the proteins 
due to immobilization.123
Mineralized polymers can also be synthesized through intrafibrillar mineralization 
of collagen by applying a polymer-induced liquid-precursor (PILP) mineralization 
process. In an in vitro model system, Gower and his coworkers66 used polyaspartate 
to mimic the acidic NCPs engaged in bone formation. It was shown that the anionic 
polypeptide sequesters ions to induce an ACP precursor, and it was hypothesized 
that the early-stage precursor was highly hydrated, enabling fluidic droplets to be 
drawn into the gaps and grooves of collagen fibrils by capillary action. In a related 
study,127 ALP was applied to provide a slow release of inorganic phosphate ions from 
a phosphate ester, mimicking the biochemical processes of ion regulation found in 
natural bone formation. Transmission electron microscopy (TEM) and selected 
area electron diffraction (SAED) showed that nanocrystals of HA were intrafibrillar 
and oriented along the collagen fibril axis within the collagen–HA composites. 
The precursor phase could achieve a good depth of penetration into dense collagen 
scaffolds, supporting the hypothesis that the polymer enters the collagen by means of 
capillary actions and not diffusive transport. A mineral coating was also reported on 
the surface of the collagen fibrils, which was thought to occur once the fibrils have 
become infiltrated with minerals, such that minerals proceed to build up on the exterior. 
Indeed, in natural bone formation, both intrafibrillar and extrafibrillar minerals are 
present. In this system, however, the mineral coating may have formed too rapidly, 
thus blocking subsequent intrafibrillar mineral penetration.127 Summarizing, it was 
shown that through further optimization (e.g., varying the polymer molecular weight), 
a very high degree of mineralization can be obtained, with compositions matching 
that of bone.128
Peptide Sequences
Natural ECM biopolymers and proteins (such as collagen, laminin, fibronectin, and 
elastin) have been widely used for modification of synthetic polymeric biomaterial 
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surfaces to modulate cell–substrate interactions.129 ECM proteins include signaling 
domains that usually comprise only few amino acids (short peptide sequences), 
and are the major interaction sites with cell surface receptors to facilitate cell 
adhesion.130–133 Nevertheless, degradation and purification of proteins can result into 
undesired side effects.134,135 Furthermore, even in the absence of protein degradation, 
conformational changes can compromise the biological efficacy of proteins.136–138 In 
comparison to full-length proteins, the use of short peptide sequences is advantageous 
as peptide sequences are simple, chemically well defined, biologically active, easy 
to synthesize, and simple to use for functionalization of macromers.139–144 As such, 
peptide functionalization allows for greater control over the conjugation chemistry 
using a wide variety of chemical approaches. Nonetheless, in comparison to full-
length proteins, short peptide sequences have disadvantages such as their decreased 
receptor specificity, significantly weaker receptor affinity, and often reduced biological 
efficacy.129
Mineralized Polymers
Itoh et al.145 treated HA surfaces with a E
7
PRGDT peptide of high affinity to HA146,147 
owing to heptaglutamic acid sequence, and showed that attachment of osteoblastic 
cells and the expression of osteoblastic phenotypes, including mineralization, were 
enhanced by the peptide treatment. Inspired by the abundant presence of Glu residues 
in osteonectin, Sarvestani et al.148,149 investigated the calcium-binding capacity of an 
osteonectin-derived hexaglutamic acid sequence (Glu6) to enhance the interaction 
between HA nanoparticles and poly(lactide ethylene oxidefumarate) hydrogels as 
a nanocomposite for bone regeneration. To this end, acrylate-functionalized Glu6 
peptides were used as linkers between inorganic and organic components of the 
composite. It was shown that the presence of Glu6 considerably improved the shear 
modulus of the composite due to increased ionic interactions between the peptide and 
HA nanocrystals (~100 nm), whereas the same treatment applied for HA microparticles 
(5 μm)149 did not show any significant improvement in the shear modulus. It was 
suggested that these findings can be used to develop advanced biomimetic composites 
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for skeletal tissue regeneration.148,149
Culpepper et al.150 investigated the use of a HA-binding domain, heptaglutamate (E7) 
rich in carboxyl groups, to improve the efficacy of coupling of the collagen mimetic 
peptide, DGEA (Asp-Gly-Glu-Ala), to HA-containing materials, and found that the 
E7 domain directed significantly more peptide to the surface of HA and enhanced 
peptide retention both in vitro and in vivo. It was shown that E7–DGEA-coupled HA, 
compared to DGEA–HA, improved the adhesion and osteoblastic differentiation of 
mesenchymal stem cells, and also enhanced new bone formation and directed bone–
implant contact on HA disks that were implanted in vivo. Furthermore, it was suggested 
that the E7 domain can perform as a general means for anchoring a wide variety of 
bone regenerative molecules to any type of HA-containing material, for example, to 
the surface of allografts to reintroduce osteoinductive signals and potentially advance 
allograft treatments.150–152
Single Amino Acids
As mentioned before, single acidic amino acids can also be used to stimulate 
interaction with Ca2+.
Mineralized Polymers
Yang et al.153 investigated the effect of the presence of asparagine (Asn), glycine 
(Gly), and lysine (Lys) on HA crystallization, and showed that all amino acids 
accelerated HA nucleation, while the resulting crystals were smaller than those 
synthesized in the absence of amino acids.154 In a comparable approach, Palazzo et 
al.155 investigated the role of alanine (Ala), arginine (Arg), and aspartic acid (Asp) 
on nucleation, size, and morphology of calcium-deficient HA (CDHA) with a Ca/P 
ratio of 1.53 prepared at pH 10. All particles formed in the presence of amino acids 
showed a thin amorphous layer on the surface, which most likely consisted of the 
respective amino acid. It was argued that alanine binds weakly to the surface of the 
CDHA plates through the interaction between the amino acid carboxylate and calcium 
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sites on the particle surface. Different from alanine, which contains only a C-terminal 
carboxylate, asparagine may form a cooperative link with the same or a neighboring 
calcium surface site engaging the carboxylate side chain as well as the C-terminal 
carboxylate. Arginine binds to the phosphate group using its guanidinium side chain, 
although when the C-terminal carboxylate is already bound to a calcium site.154,155 
Such a model is remarkable due to a simultaneous binding to both the anionic and 
cationic surface sites, which proposes a more specific approach of tailoring CaP 
morphologies and crystal phases than the currently possible approaches with simple 
anionic or cationic additives.154
Boanini et al.156 prepared nanocomposites of HA–aspartic acid and HA–glutamic 
acid through a direct synthesis of HA nanocrystals in the presence of different amounts 
of amino acids in solution. It was discussed that incorporation of Asp and Glu into HA 
crystals decreases the coherent length of the perfect crystalline domains along certain 
planes of apatite crystals, which results in a specific interaction of the amino acids with 
the HA structure. FTIR spectra showed a small shift of the carboxylic stretching band 
to lower wave numbers, consistent with an enhancement of the C−O bond length due 
to interaction with the apatitic phase. The relative amount of Asp incorporation into 
HA nanocrystals in their study was greater compared with Glu, suggesting a greater 
affinity of Asp for HA. Furthermore, it was revealed that the presence of amino acids 
stimulated the growth of osteoblast-like cells (MG-63) in vitro and improved their 
differentiation, compared to HA without the presence of amino acids.156
Furuichi et al.157 prepared hierarchically organized structures of nanocrystalline HA 
through periodic precipitation in a nonequilibrium reaction system with diffusion 
of Ca2+ into a poly(acrylic acid) (PAA) matrix, which contains one carboxyl 
group per monomer.158 The diffusion of Ca2+ into the carboxyl-rich PAA hydrogel 
containing PO
4
3− stimulated the calcification of the hydrogel matrix and gave rise to 
a hierarchically structured nanocomposite that resembled bone.157,159 To investigate 
the effect of organic molecules on the crystal growth of CaP, gelatin was added to 
replace acrylic acid in the precursor solution (up to 40 wt%), whereas equal amounts 
of aspartic acid and glutamic acid were added to study the influence of single amino 
acids in gelatin molecules on the morphology of mineralization. The substitution of 
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Asp and Glu for 40 wt% PAA gel showed a similar influence on the morphology at 
nanoscopic and microscopic scales as compared to the polymer gelatin, since both 
amino acids and gelatin macromolecules stimulated the formation of HA and its one-
dimensional arrangement in the fibrous morphology of the synthesized hydrogel. It 
was suggested that the laminated HA–polymer composites could have potential for 
applications in tissue engineering due to the similarity in mechanical properties to 
bone tissue. The hierarchical porous HA architectures could be useful as adsorbents 
and as scaffolds for tissue engineering.157
Single Carboxyl Groups
Similar to exploiting carboxyl groups as present in larger entities such as proteins, 
peptide sequences, and amino acids, single carboxyl groups can also be used for 
increasing the binding affinity of macromolecules to CaP. Compared to proteins 
or peptides, the use of single carboxyl groups offers improved control over the 
presentation of calcium-binding groups owing to the adjustable density of COOH 
groups and the absence of other functional groups, which might interfere with the 
desired Ca2+–COOH interaction.
Mineralized Polymers
Citrate molecules are known to be abundantly present at the interface between 
collagen and apatite crystals in bone,160 and have the ability to strongly bind to apatite 
and cover the surface with a density of one citrate molecule per 4 nm2.161 This density 
is approximately one-sixth of the available area of the apatite surface.160,161 Citrate 
molecules in bone account for ~80% of the total weight of citrate as present in the 
human body, thereby being the main source of carboxylate groups in bone. As such, 
carboxylate groups appear to have a pivotal role in regulating the process of apatite 
nucleation.161 Inspired by the in vitro studies on the bonding between citrate anions 
and bone mineral,162,163 Hu et al.161 proposed that the addition of citrate (containing 
three carboxyl groups per molecule)164 in the bottom-up synthesis of self-assembled 
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pluronic polymer–HA nanocomposites allows for molecular control over the growth 
of the apatite crystal size, comparable to mineralization in native bone. It was 
expected that the biocompatibility of biosynthetic materials can be improved through 
incorporation of citrate within the nanocomposites to produce similarly structured 
HA nanocrystals as in bone apatite. Citrate molecules were shown to be capable to 
stabilize extremely small HA crystals of 2 nm size, while the HA crystal size could 
be fine-tuned at nanoscale by changing the citrate concentration.161 It is also known 
that specific adsorption of citrate anions onto CaP nanocrystals in CaP–gelatin 
nanocomposites results in negatively charged CaP particles and accordingly enhances 
repulsive interparticle forces that are able to stabilize CaP suspensions and reduce 
agglomeration and sedimentation of apatitic nanoparticles in lyophilized gelatin 
matrices.165
Phadke et al.166 synthesized bone-like composites by using synthetic hydrogels, 
including pendant side chains functionalized with COOH groups as templates for 
mineralization. The influence of matrix hydrophobicity on the nucleation of apatite-
like phases on a polymeric substrate was investigated by utilizing poly(ethylene 
glycol) (PEG) hydrogels modified with anionic pendant side chains of variable 
length (CH
2
=CHCONH(CH
2
)nCOOH, where n = 1, 3, 5, and 7).
167,168 The pendant 
side chains contained Ca2+-binding carboxyl groups, which provided nucleation sites 
for the formation of crystalline CaP. Changing the number of CH
2
 groups allowed 
for systematic modification of matrix hydrophobicity without varying the terminal 
functional group. Binding of Ca2+ to functional groups of the matrix resulted in 
nucleation of mineral phases.166
Traditionally, the mineralizing capacity of acrylated polymers has been extensively 
investigated in view of the abundant presence of carboxyl groups. The pHEMA 
hydrogel scaffold, for instance, has been used to expose carboxylate groups on 
the surface of crosslinked pHEMA, thereby promoting nucleation and growth of 
CaP crystals on the surface as well as in the hydrogel interior.169 The influence of 
polyacrylate on the biomimetic growth of HA on gelatin films was studied by Bigi et 
al.,170 since polyacrylate is a carboxylate-rich polyelectrolyte, which would resemble 
the presence of the acidic macromolecules in the ECM of bone. The results suggested 
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that the combined effect of stretching and the presence of carboxylate groups 
promoted the nucleation and ordered growth of HA crystals inside gelatin.170 Besides 
synthetic carboxyl-rich polymers such as polyacrylates, carboxyl groups as present in 
natural biopolymers such as alginate can also be used to increase the interaction with 
calcium ions. By chemically crosslinking poly(propylene glycol) monomethacrylate, 
PEG monomethacrylate, and methacrylic alginate, Cha et al.171 synthesized 
nanoporous and microporous hydrogels, which were incubated in modified SBF to 
induce mineralization of the gel matrices. It was demonstrated that carboxylic groups 
in alginate induced the deposition of Ca2+ in both hydrogel types, resulting in the 
accumulation of mineral ions.171
Phosphate and Phosphonate Groups
Besides carboxyl groups, phosphate and phosphonate groups can also be used to 
increase the affinity of polymers to mineral fillers.
Phosphate Groups
Mineralized Polymers
Suzuki et al.172 prepared block copolymers consisting of poly(monoacryloxyethyl 
phosphate) (PMAEP) or poly(2-(methacryloyloxy)ethyl phosphate) (PMOEP) and 
poly(2- (acetoacetoxy)ethyl methacrylate), and immobilized them on aminated 
slides. It was revealed that both soluble PMAEP polymers and crosslinked PMOEP 
gels facilitated the formation of crystalline CaP deposition.172 Using a comparable 
chemistry, Chirila et al.173 introduced phosphate groups into carboxylate-rich 
pHEMA hydrogels by copolymerization with mono(2-acryloyloxyethyl) phosphate 
or mono(2-methacryloyloxyethyl) phosphate. It was shown that the introduction of 
these phosphate groups decreased the calcification capacity of pHEMA hydrogels, 
stressing that the mere presence of phosphate groups is not a guarantee for increased 
mineralization of polymers.173
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Kim et al.174 used a urea-mediated solution precipitation technique to precipitate 
CaP crystals on the surface and interior of a PEG-based hydrogel. The hydrogel was 
synthesized by radical crosslinking polymerization of PEG fumarate in the presence 
of ethylene glycol methacrylate phosphate as an attempt to use phosphate groups 
to stimulate the formation of apatitic crystalline platelets.159 To provide the apatite-
nucleating function of phosphorylated proteins in the collagen-associated ECM, 
phosphoryl anionic functionality was introduced in the PEG-based hydrogels during 
crossliking polymerization.174 Since ester groups and amide groups in hydrogels were 
not expected to nucleate apatite crystals,175 the observed apatite formation on the 
hydrogels was ascribed to the presence of acidic phosphorylated groups. In vitro cell 
experiments revealed that the cell adhesion/proliferation on the mineralized hydrogel 
was more pronounced than on the pure polymer hydrogel.174
Studying the influence of phosphorylation and sequence scrambling on peptide 
adsorption to four different apatites (bone-like mineral, and three types of apatite 
containing carbonate contents of 0%, 5.6%, and 10.5%) has shown that phosphorylation 
of the VTKHLNQISQSY peptide (VTK peptide) can result in a 10-fold increase in 
peptide adsorption (in comparison to the nonphosphorylated peptide) to bone-like 
mineral, and a twofold increase in adsorption to carbonated apatite; however, no 
influence of phosphorylation on peptide affinity to pure HA (without carbonate) was 
observed. Computational modeling of peptide–mineral interactions also revealed a 
favorable change in binding energy upon phosphorylation, which was unchanged by 
scrambling. In summary, phosphorylation of serine residues could enhance peptide 
specificity for bone-like mineral.176
Sailaja et al.177 evaluated the in vitro functionality of phosphorylated pHEMA-co-
methyl methacrylate [poly(HEMA-co-MMA)] to induce bioinspired mineralization 
of the CaP phase, and revealed that the primary nucleation of CaP on the surface 
of the phosphorylated copolymer occurred within 3 days of immersion in 1.5 SBF 
and the degree of mineralization was proportional to the methacrylate content in the 
copolymer. The concentration of calcium in the coating increased with increasing 
the HEMA content in the copolymer. Consequently, the surface phosphorylated 
poly(HEMA-co-MMA) could be proposed as a potential substrate capable of inducing 
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in vitro mineralization of HA.177 The possibility of using sodium trimetaphosphate 
(STMP), a chemical phosphorylating reagent, as a functional analog of matrix 
phosphoproteins for biomimetic remineralization of resin-bonded dentin has also 
been studied. Equilibrium adsorption and desorption studies of STMP were carried 
out using demineralized dentin powder (DDP), and an analysis of saturation binding 
curves confirmed the presence of irreversible phosphate-binding sites on the surface 
of DDP. FTIR spectroscopy provided further evidence for chemical interactions 
between trimetaphosphate and dentin powder, with enhancement in peak intensities of 
the P=O and P−O−C stretching modes. These peaks returned to their initial intensities 
after ALP treatment.178
Phosphonate Groups
Mineralized Polymers
By crosslinking collagen with carbodiimide (EDC), Gu et al.179 could enhance 
the sieving property of collagen, enabling polyvinylphosphonic acid (PVPA) to 
be immobilized within collagen. A concentration range for immobilized PVPA to 
template intrafibrillar apatite deposition was set up and validated using a single-layer 
reconstituted type I collagen mineralization model. In the presence of a PAA-containing 
mineralization medium, optimal intrafibrillar mineralization of the EDC-crosslinked 
collagen was obtained using 500 and 1,000 mg∙ml-1 PVPA. The mineralized fibrils 
showed a hierarchical order of intrafibrillar mineral infiltration, as noticeable by the 
appearance of electron-dense periodicity within unstained fibrils. It was suggested 
that appreciating the basic processes in intrafibrillar mineralization of reconstituted 
collagen could create opportunities for the design of tissue engineering materials for 
hard tissue repair and regeneration.179
Bisphosphonates (BPs) are synthetic analogues for pyrophosphates that display a 
remarkable affinity to bone mineral. This property is mediated through (HO)
2
−OP−
C−PO−(OH)
2
 moieties that act as chelators of Ca2+ cations. Interestingly, the distance 
between deprotonated oxygens is 2.9–3.1 Å, which is in the same range as the oxygen 
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ions in HA,180,181 and is therefore likely the optimum distance for the chelation of Ca2+ 
ions in HA.109 BPs can be linked to organic compounds using straightforward chemical 
approaches,109 which render BPs ideal for targeted delivery purposes or alternatively 
as CaP-binding moieties to serve as a strong linkage between organic and inorganic 
phases in next generation nanocomposites. Yang et al.182 synthesized an injectable in 
situ forming hybrid hydrogel by preparing a hyaluronic acid (HAc) derivative, dually 
functionalized with crosslinkable hydrazide groups and BP ligands (HAc–hy–BP), 
and subsequent mixing of the HAc–hy–BP solution and the Ca2+ ions containing a 
solution of aldehyde-derivatized HAc (HAc-al). It was shown that the conjugation 
of BP to the hydrogel matrix can stimulate an efficient and fast mineralization of 
the matrix. The mineralization was promoted by the strong interaction between BP 
residues and Ca2+ ions that serve as nanometer-sized nucleation sites for further CaP 
deposition within the HAc hydrogel.182
Classic Nanocomposites
BPs can also be used to overcome the inertness of certain compounds, such as PEG-
modified polyethyleneimine (PEI). Despite the significant potential of PEI to interact 
with charged surfaces183,184 and its high affinity to bone mineral HA,185 Wang et al.186,187 
noticed that PEG-modified PEI significantly loses its inherent ability of binding to HA 
as a function of PEG substitution degree. In a later study,188 this lack of HA affinity was 
compensated through further conjugation with BP. In a related study,189 a conjugate 
of distearoylphosphoethanolamine (DSPE)–PEG with 2-(3-mercaptopropylsulfanyl)
ethyl-1,1-bisphosphonic acid (SH–BP) was also synthesized and incorporated into 
micelles and liposomes to produce mineral-binding nanocarriers for therapeutic 
agents, and the in vitro affinity of the micellar and liposomal formulations to HA 
was investigated. It was shown that all SH–BP-incorporated nanocarriers exhibited a 
stronger HA affinity compared to their counter-parts without SH–BP. Furthermore, the 
SH–BP-decorated liposomes showed a strong binding to a collagen–HA composite 
scaffold in vitro, and gave increased retention in the collagen–HA scaffolds after 
subcutaneous implantation in vivo.189 Boanini et al.190 successfully synthesized HA– 
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alendronate composites at different BP contents up to about 7 wt%, and showed that 
BPs not only inhibit bone dissolution, but can also influence the deposition of the 
bone mineral phase. It was suggested that alendronate-containing nanocrystals offer a 
relevant tool in view of the possible applications of these composites as biomaterials 
for hard tissue repair.190
Hydroxyl Groups
Hydroxyl groups (including hydroxyl-containing groups, such as catechols or 
fenols) are anionic functional groups with high affinity for Ca2+. For instance, the 
affinity of BPs for Ca2+ is greater if the side chain contains a hydroxyl group, such as 
in etidronate,191 because this allows tridentate coordination to Ca2+.192
Mineralized Polymers
Hutchens et al.193 synthesized a nanocomposite comprised CDHA biomimetically 
deposited in a bacterial cellulose hydrogel.159 CDHA was formed in bacterial cellulose 
by alternate incubation with calcium and phosphate solutions. FTIR spectroscopy 
showed that CDHA is bonding with the bacterial cellulose through hydroxyl groups of 
the cellulose. It was stated that cellulose hydroxyl groups possessed a strong negative 
dipole that could chelate free Ca2+ in the CaCl
2
 solution and form a coordinated bond, 
after which PO
4
3− could bond with the cellulose-associated calcium to form CaP. The 
synthesis of the composite mimicked the natural biomineralization of bone signifying 
that bacterial cellulose can be applied as a template for biomimetic apatite formation. 
The discussed composite offers a potential use as an orthopedic biomaterial.193
The apatite-forming ability of polyamide (containing carboxyl groups) modified 
with different amounts of silanol groups has also been studied.194 It was found that 
the rate of apatite formation was enhanced with the increasing content of silanol 
groups in the polyamide films, which was attributed to the enhancement of dipole 
interactions, that is, the lower electronegativity of silicon compared to carbon enabled 
calcium ions to access near lone electron pairs of oxygen atoms in silanol groups 
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in a dipole interaction.194 Ryu et al.195 showed that catechol groups as present in 
polydopamine layers were able to nucleate HA by concentrating Ca2+ at the interface. 
As deposition of polydopamine layers is essentially a simple dip coating procedure at 
alkaline conditions, this procedure would be suitable to mineralize a wide variety of 
biomaterials.195 Douglas et al.,196 for instance, observed that enzymatic mineralization 
of gellan gum hydrogels was improved by incorporation of polydopamine.
Sulfate Groups
In addition to the above-mentioned anionic functional groups, sulfate ions have been 
found to show affinity for CaP as well.
Classic Nanocomposites
In view of the mineral-binding affinity of sulfate groups, Chang et al.197 prepared 
a HA–gelatin nanocomposite in which the gelatin matrix was modified by the 
introduction of chondroitin sulfate (ChS) aiming to obtain a strongly organized 
composite body. It was shown that CaP was strongly bound to the ChS-modified 
gelatin macromolecules, and the matrix of the gelatin–ChS molecules was mineralized 
by HA nanocrystallites. It was claimed that the HA–gelatin–ChS nanocomposites 
were formed by the interaction between the critically small size of HA crystallites and 
the interpenetrating network structure of the gelatin–ChS complex. A small amount of 
ChS significantly enhanced the organic–organic interaction between gelatin and ChS, 
indicating the formation of the interpenetrating network structure of the gelatin–ChS 
complex, which chemically interacted with the calcium and phosphate ions to form 
HA.197
Conclusions
This review highlighted the inorganic–organic interactions in the ECM of bone as 
well as synthetic nanocomposites whose design was inspired by the nanostructure of 
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bone tissue. Biomacromolecules functionalized to induce mineralization in a polymer 
matrix were also addressed, due to their potential for interacting with CaP nanoparticles. 
Anionic (and/or cationic) functional groups of the organic matrix with high affinity 
for binding either calcium or phosphate ions of bone apatite are responsible for these 
interactions. Anionic functional groups—more specifically, carboxyl-containing and 
calcium-binding moieties, including proteins, peptide sequences, single amino acids, 
and COOH groups—are the most extensively investigated chemical groups that can 
be instrumental to improve the interaction between inorganic and organic phases in 
synthetic nanocomposites for bone regeneration. However, other anionic groups such 
as phosphates, phosphonates, sulfates, and hydroxyl groups are also gaining interest.
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Introduction
In adults, healthy bone tissue exhibits a remarkable regenerative capacity owing to the concerted action of bone-forming osteoblasts and bone-resorbing osteoclasts.1 
However, large critical-sized bone defects need to be filled with bone grafts to facilitate 
tissue regeneration.2,3 The treatment of such large bone defects is more challenging 
for medically compromised patients, such as those affected by bone cancer. In fact, 
bone is not only the most common tissue affected by metastatic cancer but also the 
site that produces the greatest morbidity for patients.1,4,5 Treatment of bone tumors is 
highly dependent on the type of tumor and may include (a combination of) surgery, 
chemotherapy, and/or radiotherapy.6–10
Local surgical therapy is generally preferred if a margin of tumor-free tissue can be 
preserved around the tumor site, since intralesional surgery will lead to a very high 
risk of local recurrence, irrespective of preoperative chemo- or radiotherapy.11 After 
tumor resection by curettage or aspiration, a large defect remains, which needs to be 
filled using autografts, allografts, or alloplasts. Currently, autologous bone harvested 
from the fibula or iliac crest is the gold standard of care to fill large bone defects.3,13 
Nevertheless, surgical treatments, such as tumor resection and/or autologous bone 
graft harvesting, are often intolerable for patients with comorbid conditions and 
limited life expectancy.12 In addition to the devastating effect of cancer on bone tissue, 
treatment modalities that are not specific to cancer cells also damage healthy tissues.14
Local targeted delivery of chemotherapeutics would allow efficient delivery of 
anticancer drugs at the tumor site and minimize toxic side effects in tissues unaffected by 
tumor growth. To this end, novel biomaterials that are able to drive tissue regeneration 
in bone defects—created by tumor resection—and release chemotherapeutic drugs 
locally in a controlled and sustained manner are strongly required.10
Injectable, apatitic, self-setting calcium phosphate cements (CPCs) have been 
developed as synthetic bone substitutes in view of their similarity to the mineral 
component of bone tissue.15 These CPCs can be molded to fill irregularly-shaped 
defects and have been advocated as drug delivery systems.15,16 During the past 
decades, CPCs have been rendered biologically active by incorporating drugs that 
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targeted specific therapeutic needs (e.g., antibiotics, anticancer and antiosteoporotic 
drugs, and osteogenic growth factors).15,16
Usually, drugs can be included into CPCs by (i) blending the drug powder with the 
solid phase or dissolving it within the liquid phase or (ii) impregnation of preset CPC 
solid blocks or granules with a drug solution, such as that described by Lopez-Heredia 
et al.10 for paclitaxel-loaded CPCs. However, none of these methods has shown to 
achieve a complete loading of the drug into the injectable CPCs. Moreover, the total 
amount of drug release has often been limited and released in a burst-type manner.
Recently, the use of nanoparticles has emerged as an additional tool to improve the 
efficacy of drug delivery systems for cancer therapies. Iafisco et al.17,18 recently developed 
several types of hydroxyapatite nanoparticles (HA NPs) as carriers for the local and 
sustained delivery of two novel chemotherapeutic platinum-bisphosphonate (Pt-BP) 
complexes17,19,20: bis-{ethylenediamineplatinum(II)}-2-amino- 1-hydroxyethane-1,1-
diyl-bisphosphonate (complex A) and bis-{ethylenediamineplatinum(II)}-medronate 
(complex B).
Both Pt-BP complexes were developed to target traditional anticancer cisplatin-
based drugs to bone tissue.21 Interestingly, the mineral-binding affinity of the 
bisphosphonate ligands on the Pt-BP complexes can be used to facilitate efficient 
loading of high doses of these complexes onto the surface of synthetic HA NPs due to 
the strong affinity of bisphosphonates with Ca ions.18 The binding affinity of complex 
A to HA NPs was shown to be higher than that of complex B due to the presence of 
amino groups, which confirmed that binding and release of Pt-BP complexes can be 
tuned by varying the composition of the ligands. Drug-loaded HA NPs, however, 
cannot be injected directly into bone defects due to the risk of excessive leakage of 
the nanoparticles into the surrounding tissues.
In this study, we present a method to release Pt-BP drugs from CPCs to render these 
injectable bone substitutes chemotherapeutically active. To this end, HA NPs loaded 
with Pt-BP complexes were added to the cement powder phase at different amounts 
ranging from 5 to 20wt%. Poly(D,L-lactic-co-glycolic acid) (PLGA) microspheres 
were used as porogens to accelerate the degradation of CPCs. Release kinetics of 
the Pt-BP complexes was investigated in vitro using Inductively Coupled Plasma 
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Optical Emission Spectroscopy (ICP-OES). Finally, the antiproliferative activity of 
the Pt-BP complexes and their releasates from the CPCs were evaluated using both 
human osteosarcoma cancer cells (MG-63) and primary human bone marrow-derived 
mesenchymal stromal cells (h-BMMSCs).
Material and Methods
Materials
The powder phase of the CPCs consisted of a mixture of α-tricalcium phosphate 
(α-TCP; CAM Bioceramics) and hydroxyapatite (HA; prepared in our laboratory, see 
the ‘‘Preparation and Characterization of HA NPs’’ section for further details). Na
2
HPO
4
 
was purchased from Merck. PLGA (Purasorb® PDLG 5002A, Mw = 17 kDa, acid-
terminated, L:G = 50:50) was obtained from Corbion Purac Biomaterials. Polyvinyl 
alcohol (PVA; 88% hydrolyzed, Mw = 22 kDa) was obtained from Acros, while 
isopropanol (IPN; analytical grade) and dichloromethane (DCM; analytical grade) 
were obtained from Merck. 2-Ammonium-1-hydroxyethane-1,1-diyl-bisphosphonic 
acid (AHBP-H
5
), [PtCl
2
(en)], and [Pt(OSO
3
)(OH
2
)(en)] (en = ethylenediamine) were 
prepared following the procedures reported previously.19 Milli-Q water was used to 
dissolve the compounds. All other reagents were purchased from Sigma-Aldrich.
Preparation and Characterization of Platinum Species
Bis-{ethylenediamineplatinum(II)}-2-amino-1-hydroxy-ethane-1,1-diyl-
bisphosphonate ([{Pt(en)}
2
(μ-AHBP-H
2
)] (HSO
4
), complex A, Figure 3.1) was 
prepared according to an already reported method22 with some modifications. Briefly, 
2-ammonium-1-hydroxyethane-1,1-diyl-bisphosphonic acid (AHBP-H
5
) (0.055 
g, 0.246 mmol) was dissolved in Milli-Q water (18 ml), and the resulting solution, 
maintained at 40 °C, was first partially neutralized with Ba(OH)
2
∙8H
2
O (0.082 g, 
0.258 mmol) and subsequently treated with a solution of [Pt(OSO
3
)(OH
2
)(en)] (0.200 
g, 0.541 mmol, in14 ml Milli-Q water).
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Figure 3.1. Chemical structures of Pt-BP complexes A and B.
The resulting suspension was kept under magnetic stirring at 40 °C overnight and 
then cooled down in an ice bath for 1h. The white solid (BaSO
4
) was removed from 
the suspension by filtration through a plug of Celite®, and the filtrate was concentrated 
to a volume of ~2 ml. The pH of the concentrated solution was adjusted to ~1.0 by 
addition of H
2
SO
4
 (1 M), and the acidic solution was treated with methanol, which 
induced precipitation of the desired product. The precipitate was left standing at 4 
°C for 3 h and subsequently isolated by filtration, washed with methanol and diethyl 
ether, and dried under vacuum.
Electrospray ionization–mass spectrometry (ESI-MS) was carried out using an 
electrospray interface and ion trap mass spectrometer (1100 series LC/MSD trap 
system; Agilent). Elemental analyses were carried out using a Hewlett Packard 185 
C, H, and N analyzer. Obtained 0.183 g (85% yield). Anal. Calc. for [{Pt(en)}
2
(μ-
AHBP-H
2
)](HSO
4
)∙3H
2
O (C
6
H
29
N
5
O
14
P
2
Pt
2
S, Mw = 879.4 g∙mol
-1): C, 8.19%; H, 
3.32%; and N, 7.96%. Found: C, 8.49%; H, 3.19%; and N, 7.64%. ESI-MS: calc. for 
[{Pt(en)}
2
(μ-AHBP-H
2
)]+ ([C
6
H
22
N
5
O
7
P
2
Pt
2
]+) = 728.03; found: m/z (% relative to the 
base peak) = 727.8 (100) [M]+.
Bis-{ethylenediamineplatinum(II)}-medronate ([{Pt(en)}
2
 (MED)]; MED = 
medronate; complex B, Figure 3.1), medronic acid (methylene diphosphonic acid; 
0.043 g, 0.243 mmol), was dissolved in 7 ml Milli-Q water, and the pH of the resulting 
solution was brought to ~6.0 by addition of NaOH (0.1 M). This latter solution was 
added to a solution of [Pt(OSO
3
)(OH
2
)(en)] (0.200 g, 0.541 mmol in 40 ml Milli-Q 
water) kept under magnetic stirring at 40 °C. The reaction mixture was kept under 
magnetic stirring at 40 °C, and the pH was monitored and maintained at a constant 
value of ~6.0 by addition of NaOH (0.1 M), when required. The end of the reaction 
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was evidenced by pH stability (after ~4 h). The reaction was then stopped, and the 
yellow solution was cooled down to room temperature, concentrated to one third of 
the initial volume, and kept at 4 °C overnight.
The obtained yellow-green crystalline precipitate was isolated by filtration, washed 
with a few drops of ice-cold Milli-Q water, and dried under vacuum. Obtained 0.134 
g (81% yield). Anal. Calc. for [{Pt(en)}
2
(MED)] (C
5
H
18
N
4
O
6
P
2
Pt
2
, Mw = 682.34 
g∙mol-1): C, 8.80%; H, 2.66%; and N, 8.21%. Found: C, 8.61%; H, 2.86%; and N, 
7.81%.
The spectroscopic characterization of the Pt-BP complexes was consistent with 
literature data (1H and 13P nuclear magnetic resonance (NMR) spectroscopy and 
Fourier transform infrared spectroscopy (FTIR)). The two dinuclear Pt-BP complexes 
A and B were found to be stable in neutral aqueous solution even after standing for 
several months at room tem- perature, as evidenced by NMR spectroscopy (data not 
shown).
Preparation and Characterization of HA NPs
HA NPs were synthesized according to a method reported by Liou et al.23 and 
Iafisco et al.18 Briefly, HA NPs were precipitated by slow addition (1 drop∙s-1) of an 
aqueous solution of H
3
PO
4
 (50 mM) to a suspension of Ca(CH
3
COO)
2
 (83 mM) at a 
stoichiometric Ca/P ratio (1.67) while keeping the pH at a constant value of ~10 by 
addition of an (NH
4
)OH solution at 25 °C. The reaction mixture was stirred at room 
temperature for ~24 h, after which the mixture was left standing for 2 h to sediment 
the nanoparticles. Subsequently, the suspension was centrifuged (5,000 rpm for 10 
min, Eppendorf Centrifuge 5804 R, Hamburg, Germany) in Falcon 50-ml conical 
centrifuge tubes and washed with Milli-Q water for three cycles.
Approximately half of the reaction product was suspended in Milli-Q water, while 
the rest was lyophilized (no cryoprotectant applied; Freezone 4.5, Labconco) for ~24 
h. Dry HA NP powder was grinded in a planetary ball milling machine (Pulverisette 
6, FRITSCH, Germany) for 1 h at 500 rpm to obtain a homogeneous particle size 
distribution.
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Analysis of the lyophilized powders using X-ray diffraction (XRD, Bruker D8 
Advance Diffractometer equipped with a Lynx-eye position-sensitive detector 
using Cu Kα radiation [λ = 1.54178 Å] generated at 40 kV and 40 mA), FTIR 
(Thermo Scientific Nicolet 380 FTIR Spectrometer), and transmission electron 
microscopy (TEM; Philips CM 100) confirmed that platelet-shaped carbonated HA 
NPs with dimensions of ~25×15×8 nm (length×width×thickness) were synthesized 
(Supplementary Figure S3.1A–C, respectively).
Preparation and Characterization of Drug-loaded HA NPs
Pt-BP complexes were loaded onto either lyophilized or non-lyophilized HA NPs. 
Briefly, for the lyophilized HA NPs, an aliquot (1.5 ml) of Pt-BP complex solution (0.5 
mg∙ml-1) was added to 10 mg HA NPs in a 20-ml glass tube. For the nonlyophilized 
HA NPs, the concentration of the HA NP suspension was established by weighing the 
residual material of a known volume of HA NP suspension after lyophilization (n = 
3). Subsequently, the HA NP suspension was diluted to obtain a 1.5 ml suspension 
containing 10 mg HA NPs (~6.67 mg∙ml-1) in a 20-ml glass tube to which 0.75 mg 
Pt-BP complex (0.5 mg∙ml-1) was added.
The glass tubes containing either lyophilized or non-lyophilized HA NPs were then 
vortexed for 15 s, and the suspensions were maintained in a bascule bath at 37 °C 
shaking at 60 rpm for 1 week. Subsequently, the suspensions were centrifuged for 3 
min at 5,000 rpm in Falcon 15-ml conical centrifuge tubes, followed by removal of 
the supernatant and washing (2x using Milli-Q water) of the drug-loaded HA NPs.
The platinum species in both the supernatant and the washing Milli-Q waters were 
quantified by Inductively Coupled Plasma Optical Emission Spectroscopy (ICP-
OES; Liberty 200, Varian, Clayton South, Australia; for the platinum assay, the 
selected analytical wavelength was 265 nm), and the residual drug (calculated as the 
difference between the total adsorbed drug and the drug removed by washing steps) 
was considered to be effectively bound to HA NPs. The total adsorption of Pt-BP 
complexes onto HA NPs was quantified after dissolving 10 mg drug-loaded HA NPs 
in 1 wt% nitric acid. After complete dissolution of these drug-loaded nanoparticles, 
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the concentration of calcium and platinum ions was determined by ICP-OES analysis.
The lyophilized HA NP powders loaded with Pt-BP complexes were characterized 
by powder XRD and FTIR. The morphology and size of the drug-loaded HA NPs 
were investigated by TEM. Since the amount of drug attached to HA NPs relative to 
the HA matrix itself was very low, the obtained XRD and FTIR spectra as well as the 
morphology observed by TEM were identical to the spectra and micrographs obtained 
for drug-free HA NPs (reported in Supplementary Figure S3.1).
Preparation and Characterization of PLGA Microspheres
Dense PLGA microspheres were prepared by a single emulsion technique, as 
previously reported.24,25 Briefly, 0.2 g PLGA was dissolved in 2 ml DCM in a 20-ml 
glass tube. This solution was transferred into a stirred beaker containing 100 ml 0.3% 
PVA solution. Subsequently, 50 ml 2% IPN solution was added. The solution was 
stirred for 1h. The microspheres were allowed to settle for 1 h, and the clear solution 
was decanted. The remaining suspension was centrifuged, and the clear solution on 
top was aspirated. Finally, the microspheres were lyophilized for ~24 h and stored 
at -20 °C. The average size of the PLGA microspheres was determined as 95±15 
μm by an optical microscope equipped with a digital camera (Leica/Leitz DM RBE 
Microscope System; Leica Microsystems AG, Wetzlar, Germany) using a sample size 
of at least 300 microspheres.
Preparation of CPCs
The cement precursor powder (α-TCP) was grinded in a planetary ball milling 
machine for 5.5 h at 500 rpm, yielding a particle size of 8.7–3.0 mm as determined 
by laser diffraction (Mastersizer-2000; Malvern Inst. Ltd.). Lyophilized HA NPs were 
added to the cement powder phase at various weight ratios ranging between 5 and 
20 wt% (see Table 3.1 for an overview of the abbreviations and compositions of the 
experimental groups). The PLGA content was fixed at 40 wt%, while PLGA-free 
CPCs were included as controls.
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CPC pastes were obtained by homogeneous mixing of precursor powders with a 
3% Na
2
HPO
4
 solution at a liquid-to-powder ratio (L/P) of 0.40 ml∙g-1. Briefly, 1 g 
of precursor powder was placed in an exit-closed 2-ml syringe (orifice diameter 1.7 
mm). Subsequently, the solution was added to the powder. The syringe was placed 
in a mixing apparatus (Silamat®; Vivadent, Liechtenstein) and mixed for 30 s. 
After mixing, a paste was obtained and injected into Teflon® molds of 5×3.85 mm 
(diameter×height) to obtain cylindrical CPC samples. The samples were left in the 
Teflon® molds to set at 37 °C.
Physicochemical Characterization of CPCs
The initial and final setting times of the various CPC formulations were assessed 
using the Gillmore needles according to ASTM C266. A bronze block containing six 
holes (6×12 mm, diameter×height) was used as the mold. The mold was placed in a 
water bath at body temperature (37 °C). Samples of each formulation were mixed 
and injected into the mold. The Gillmore needles were carefully lowered onto the 
surface of the freshly shaped cement paste and kept there for 3 s. The setting time was 
recorded when penetration was not observed anymore (n = 3).
The crystal structure of the CPCs with/without PLGA microspheres was evaluated 
as a function of soaking time after crushing preset samples before and after soaking 
for 28 days in 10 ml HEPES buffer saline (10 mM) containing sodium chloride ions 
(NaCl, 0.2 M) at 37 °C using XRD (PW 1830, Panalytical). XRD was also used to 
analyze the effect of PLGA microspheres on set CPC compositions. XRD analysis 
was performed using Cu Kα radiation having a wavelength of 1.54 Å at a voltage of 
40 kV and a current of 30 mA. Patterns were collected from 2θ = 10° to 40°, a step 
size of 0.05°, and a counting time of 20 s per step. The morphology of the set CPCs 
was evaluated by scanning electron microscopy (SEM; JEOL 6301). Before SEM 
examination, all samples were mounted on aluminum stubs using carbon tape and 
sputter coated with gold-palladium.
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Table 3.1. Abbreviations, compositions, and setting times of the various CPC formulations.
Abbreviation1 α-TCP (wt%)
PLGA 
(wt%)
Drug-
free HA 
(wt%)
Drug-loaded 
HA2 (wt%)
Setting time3 (min)
Initial Final
HA5 95 - 5 - 3.3±0.5 5±1
HA5[A/B] 95 - - 5 3.5±0.5 5.5±1
PLGA40-HA5 55 40 5 - 4.5±0.5 18±1
PLGA40-HA5[A/B] 55 40 - 5 4.5±0.5 21±2
HA10 90 - 10 - 6±1 39.5±1
HA10[A/B] 90 - - 10 6±0.5 41±2
PLGA40-HA10 50 40 10 - 5±1 38±3
PLGA40-HA10[A/B] 50 40 - 10 8.5±0.3 45±6
HA20 80 - 20 - 4±0.3 26±3
HA20[A/B] 80 - - 20 4.2±0.5 28±2
PLGA40-HA20 40 40 20 - 3.5±0.5 14±3
PLGA40-HA20[A/B] 40 40 - 20 8±0.4 55±12
1 PLGA: poly(D,L-lactic-co-glycolic acid); HA: hydroxyapatite nanoparticles; [A/B]: containing 
hydroxyapatite nanoparticles loaded with complex A or B.
2 Hydroxyapatite nanoparticles were loaded with either complex A or B.
3 Initial and final setting times did not depend on the type of loaded drug (complex A or B); therefore, 
values are only given for CPCs loaded with complex A.
In Vitro Quantification of Platinum and Calcium Release from 
CPCs
To evaluate the in vitro release of platinum and calcium from the CPCs, hardened 
CPCs were soaked in 10 ml HEPES-buffered saline (10 mM, pH 7.0) containing 
sodium chloride ions (NaCl, 0.2 M) and maintained in a bascule bath at 37 °C shaking 
at 60 rpm. After 1, 3, 5, 9, 18, and 28 days of soaking, buffers were removed to 
determine platinum and calcium concentrations and replaced with fresh buffer. The 
platinum and calcium concentrations in the buffers were quantified using ICP-OES. 
Cumulative platinum release was calculated relative to the total amount of platinum 
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adsorbed onto HA NPs before incorporation into the CPCs (see the ‘‘Preparation and 
Characterization of Drug-loaded HA NPs’’ section).
To compare the release behavior of Pt-BP from CPCs with or without the use of 
HA NPs as drug carriers, equivalent amounts of complexes (A or B) were added 
directly to the CPC formulations without HA NPs (see Supplementary Table S3.1 
for an overview of the abbreviations used for CPC formulations without HA NPs, 
their compositions, and the corresponding CPCs containing HA NPs). The equivalent 
amounts of complexes (A or B) were calculated based on the amounts added to the 
corresponding CPCs containing HA NPs, and the complexes (A or B) were directly 
mixed with the grinded α-TCP.
In Vitro Proliferation Test
Hardened, drug-loaded CPCs were soaked in 10 ml of supplemented cell culture 
medium (minimal essential medium (α-MEM); see the ‘‘Cell Cultures’’ section for 
the cell culture medium composition) in a bascule bath at 37 °C shaking at 60 rpm for 
up to 7 days. Subsequently, the cell culture media were separated from the CPCs by 
centrifugation (1500 rpm for 10 min).
To compare the antiproliferative activity of solutions containing free complex A 
or B with the releasates from the CPCs, different concentrations of [PtCl
2
(en)] (a 
synthesized analog of the releasates from the CPCs) and the solutions containing free 
Pt-BP complexes at various concentrations (10, 100, and 1,000 mM Pt) were tested 
for antiproliferative activity. α-MEM was used as the positive control, and a solution 
of 5% dimethyl sulfoxide (DMSO) in α-MEM was used as the negative control.
Platinum content in the releasates from CPCs to cell culture media (after 7 days of 
incubation) was evaluated using ICP-OES. All cell culture media were filtered through 
sterile cellulose acetate membrane (0.2 mm pore size) before their application to cells. 
To evaluate the effect of filtration, platinum concentration in all the cell culture media 
was also quantified after filtration using ICP-OES analysis and compared with the 
concentrations obtained before filtration. A human osteosarcoma cell line (MG-63) 
and primary h-BMMSCs were selected as cancer and primary cells, respectively. 
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Their proliferative capacity was evaluated based on their DNA content.
Cell Cultures
α-MEM (Gibco-BRL) supplemented with 10 v/v% fetal bovine serum (FBS; 
Lonza), 0.2 mM ascorbic acid (Sigma), 2 mM ʟ-glutamine (Gibco-BRL), 100 
units∙ml-1 penicillin (Gibco-BRL), 10 mg∙ml-1 streptomycin (Gibco-BRL), and 10-3 
mg∙ml-1 basic fibroblast growth factor (Invitrogen) was used as the proliferation 
medium. Before seeding, cells were washed twice with phosphate-buffered saline 
(PBS), enzymatically detached for 5 min with trypsin–ethylenediaminetetraacetic 
acid (trypsin–EDTA: 0.25 w/v% trypsin and 0.02 w/v% EDTA), and resuspended at 
36,000 cells∙ml-1 in the proliferation medium.
Cells were precultured for 1 day at 37 °C in a humidified atmosphere with 5% CO
2
. 
Subsequently, the cell culture media were removed, and freshly prepared media were 
added to the respective experimental groups (triplicate cultures were established for 
each treatment) at day 0. Cell proliferation was assessed after 1, 3, and 7 days of 
culture. For the latter time point, media were replaced after 3 days of culture.
The MG-63 cell line was obtained from the American Type Culture Collection 
(ATCC® CRL-1427™; LGC Standards GmbH). Human iliac bone was obtained 
from residual tissue after reconstructive surgery following informed consent from 
patients in the Oral and Maxillofacial Surgery Department at the Radboud University 
Medical Center (Radboudumc). h-BMMSCs were isolated and expanded as described 
previously.26,27 Briefly, iliac bone was chopped into small pieces and put into Falcon 
50-ml tubes. The tubes with minced bone and α-MEM were shaken vigorously, and 
medium with cells was collected and plated in T175 culture flasks (Greiner Bio-One). 
Cells were then expanded in FBS-supplemented proliferation medium and passaged 
at a density of 5,000 cells∙cm-2. h-BMMSCs of passage 3 and MG-63 cells of passage 
36 were used in the experiments.
MG-63 cells and h-BMMSCs were monocultured at densities of 10,000 cells∙cm-2 in 
48-well plates in the proliferation medium and observed with an inverted microscope 
(Leica) on days 0, 1, 3, and 7. DNA content at days 1, 3, and 7 was measured to 
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evaluate the proliferative capacity of the cells. All results were represented as DNA 
content normalized against DNA content of the positive control (α-MEM) at day 1. 
DNA content was measured using the Quant-iT™ Picogreen Kit (Invitrogen) according 
to the instructions of the manufacturer.
Samples were prepared by washing the cell layers twice with PBS and adding 1 
ml Milli-Q water to each well, after which repetitive freezing (-80 °C) and thawing 
(37 °C) cycles were performed. For standard curve, serial dilutions of dsDNA stock 
were prepared to final concentrations of 0–2,000 ng∙ml-1. Subsequently, 100 ml 
of either sample or standard was added to the wells, followed by 100 ml working 
solution. Then, the plates were incubated in the dark for 5 min at room temperature. 
The absorbance of the samples was measured using a microplate reader (Bio-Tek 
Instruments, Inc.) at 450 nm.
Statistical Analyses
All results are depicted as mean ± standard deviation. The statistical analyses 
were performed using GraphPad Prism (version 5.03) software. Differences among 
groups were determined by one-way analysis of variance with a Bonferroni (multiple 
comparisons) post hoc test, and a value of p < 0.05 was considered as significantly 
different.
Results and Discussion
Preparation and Characterization of Pt-BP Complexes
In this study, we ameliorated the synthesis of the already reported dinuclear bis-
{ethylenediamineplatinum(II)}-2-amino-1-hydroxyethane-1,1-diyl-bisphosphonate 
(complex A, Figure 3.1) and bis-{ethylenediamineplatinum(II)}-medronate (complex 
B, Figure 3.1).19,20,28 Concerning the synthesis of complex A, we first prepared the 
barium salt of the amino-bisphosphonate, which was subsequently treated with two 
equivalents of [Pt(OSO
3
)(OH
2
)(en)], and the reaction mixture was left under magnetic 
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stirring for a shorter reaction time (overnight) at a higher temperature (40 °C). 
Complex A was obtained in higher yields in comparison to the previously reported 
synthesis procedure (approximately +8%).19,20,28
In the new procedure adopted for the synthesis of complex B, we avoided the use of 
the intermediate barium salt of medronic acid. Moreover, a careful control of the pH 
of the reaction allowed the coordination of medronate to [Pt(OSO
3
)(OH
2
)(en)] and 
the synthesis of complex B in higher yields in comparison to the previously reported 
synthesis procedure.20 For both complexes A and B, the elemental analysis and the 
spectroscopic features were consistent with the data reported in the literature (data 
not shown).19,20,28
Adsorption of Pt-BP Complexes onto HA NPs
Previously, adsorption of Pt-BP complexes onto HA NPs was carried out using 
lyophilized HA NP powders,18 whereas nonlyophilized HA NPs in suspension may 
offer higher surface area (since they are less agglomerated) and hence higher loading 
efficiency.29
To evaluate the effect of lyophilization on adsorption efficiency, in this work, Pt-BP 
complexes were loaded onto either lyophilized or nonlyophilized HA NPs. ICP-OES 
analysis revealed that 1mg nanoparticles contained either 34.3 ± 1.9 mg complex A 
(~3.4 wt%) or 20.3 ± 2.1 mg complex B (~2.0 wt%) after loading these complexes 
to lyophilized HA NPs. Considering that the amount of initially added platinum was 
35.4 ± 2 and 42.9 ± 3 mg for complexes A and B, respectively, the loading efficiency 
was 96.7% ± 1.9% and 47.3% ± 3.3% for positively charged complex A versus neutral 
complex B, respectively (Figure 3.2).
These values were slightly lower than previous findings by Iafisco et al.,18 who 
observed that ~100% of complex A and 60% of complex B were loaded onto HA NPs 
within 6 days. We did not sieve the HA NP powder after/before drug loading and only 
used ultrasonication for redispersing the NPs, whereas Iafisco et al.18 used the HA 
granular fraction having dimensions ranging from 100 to 150 μm, which might have 
contributed to differences in specific surface area and corresponding drug adsorption.
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Figure 3.2. Adsorption efficiencies of complexes A and B onto non-lyophilized (suspension) and 
lyophilized (powder) HA NPs (* p < 0.05).
Loading of Pt-BP complexes onto non-lyophilized HA NPs revealed that 1 mg HA 
NPs contained 34.2 ± 2.4 mg complex A (~3.4 wt%) and 35.7 ± 3.8 mg complex B 
(~3.6 wt%). Since the amount of initially added platinum was 35.4 ± 2 and 42.9 ± 
3 mg for complexes A and B, respectively, the loading efficiency of the complexes 
onto nonlyophilized HA NPs was calculated as 96.6% ± 5.0% and 83.3% ± 5.9% 
for complexes A and B, respectively (Figure 3.2). Loading efficiency for complex A 
did not depend on lyophilization and was similar to previous findings.18 For complex 
B, however, a considerably higher loading efficiency was obtained by loading the 
complex into the nonlyophilized HA NPs rather than the lyophilized powders, which 
was attributed to reduced agglomeration and higher specific surface area of the non- 
lyophilized nanoparticles.29
According to Iafisco et al.,18 complex A had a stronger affinity for HA NPs compared 
to complex B in terms of both total uptake and adsorption rate. Herein, the reduced 
specific surface area of lyophilized nanoparticles was compensated by the high 
adsorption rate of complex A, which was not the case for complex B, resulting in 
lower adsorption efficiency of complex B onto both lyophilized and non-lyophilized 
HA NPs. Consequently, Pt-BP complexes A and B were loaded onto suspensions of 
non-lyophilized HA NPs for the drug release experiments and cell proliferation tests, 
as described in the following sections.
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Preparation and Physicochemical Characterization of CPCs
All CPC formulations used in this study were injectable through syringes. The 
shortest setting times (i.e., 4–5 and 18–21 min for initial and final settings, respectively) 
were observed for drug-free CPCs and CPCs containing 5 wt% of drug-loaded HA 
NPs (Table 3.1). Setting times of the CPC pastes increased with increasing amount 
of drug-loaded HA NPs up to the initial and final setting times of 8 and 55 min, 
respectively. Changing the type of Pt-BP complex (A versus B) loaded onto HA NPs, 
however, did not affect the setting times of the CPCs.
Panzavolta et al.30 previously showed that bisphosphonates have an inhibitory effect 
on the setting times of CPCs containing aminobisphosphonates, namely alendronate 
and pamidronate. Our results, however, indicate that high drug loading (i.e., 10 or 20 
wt% drug-loaded HA NPs) only delays the setting times considerably when PLGA 
microspheres are present. This difference, compared to Panzavolta et al.,30 could be 
due to the fact that in the current study Pt-BP complexes were not added as free 
molecules but attached to HA NPs.
The crystal structure of the different CPC formulations was evaluated as a function 
of soaking time using XRD. Figure 3.3 shows the XRD patterns of the CPCs before 
(Figure 3.3A) and after (Figure 3.3B) hardening for 28 days in HEPES buffer (pH = 
7.0) at 37 °C. The XRD patterns of the CPCs containing complex B are not shown in 
Figure 3.3 since no noticeable differences were observed between CPCs containing 
complex A or B. Furthermore, since no noticeable differences were observed between 
the XRD patterns obtained from the CPCs containing 10 and 20 wt% HA NPs, only 
the XRD patterns of the latter are shown in Figure 3.3, which represent the CPC 
formulations with ‘‘high drug loading’’ versus CPCs containing 5 wt% HA NPs 
representing the CPC formulations with ‘‘low drug loading.’’
The typical reflection peaks characteristic for HA NPs at 2θ = 31.7° (112) and 25.9° 
(002) appeared after 28 days of incubation for all the experimental groups (Figure 
3.3B), confirming that the hardening reaction proceeded by hydrolysis of α-TCP into 
poorly crystalline HA. The presence of drug-loaded HA NPs at high contents of Pt-BP 
complexes (i.e., 10 and 20 wt% of drug-loaded HA NPs) delayed the transformation 
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from α-TCP toward poorly crystalline HA, as evidenced by the presence of intense 
reflection peaks characteristic of α-TCP after 28 days of incubation. This phenomenon, 
however, was more evident in the presence of PLGA microspheres in the CPC 
formulation and related to the inhibitory effect of bisphosphonates on HA formation 
at molecular level.
Figure 3.3. XRD patterns of CPCs (A) after setting and (B) after soaking/hardening in HEPES buffer 
for 28 days.
In contrast, this phenomenon did not significantly affect the setting time of CPCs 
in the absence of PLGA microspheres. It is worth mentioning that the evaluation of 
setting time is a macroscopic measure, compared to XRD analysis, and related to a 
number of reactions rather than only hydrolysis of α-TCP.31–33
Figure 3.4 shows representative scanning electron micrographs of CPCs with PLGA 
microspheres (PLGA40-HA20[A]: 40 wt% PLGA and 20 wt% HA NPs loaded with 
complex A) or without PLGA microspheres (HA20[A]: 20 wt% HA NPs loaded with 
complex A) before and after soaking in HEPES buffer for 28 days. After setting, 
PLGA microspheres embedded in the CPCs were clearly visible; however, after 
28 days of incubation, the microspheres were not observed anymore. Degradation 
of PLGA microspheres resulted in formation of a macroporous morphology in the 
CPCs, including PLGA microspheres, whereas the CPCs without PLGA microspheres 
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exhibited a dense morphology either before or after soaking in HEPES buffer.
Figure 3.4. Scanning electron micrographs of PLGA40-HA20[A] (40 wt% PLGA and 20 wt% complex 
A-loaded HA NPs) and HA20[A] (no PLGA, 20wt% complex A-loaded HA NPs) after setting (day 0) 
and 28 days of soaking in HEPES buffer (day 28; pH = 7.0, 37 °C) (scale bar = 100 μm)
In Vitro Quantification of Platinum and Calcium Release from 
CPCs
The in vitro release experiments showed that the release of calcium ions from all CPCs 
increased with increasing incubation time (Figure 3.5A and B). The incorporation 
of PLGA microspheres resulted in considerably higher amounts of calcium release, 
which was attributed to the stimulatory effect of PLGA degradation on the dissolution 
of the HA matrix.24,34,35
The release of platinum increased with increasing amount of drug-loaded HA NPs 
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(Figure 3.5C and D). Nevertheless, the affinity of Pt-BP complexes to HA NPs (i.e., 
the chemical properties of the complexes) was the main parameter controlling the 
kinetics of platinum release. After 28 days of incubation in HEPES buffer, 93 ± 3 
wt% of the initially loaded platinum was released from PLGA-containing CPCs with 
maximum loading of complex B (PLGA40-HA20[B]), whereas only 40 ± 2 wt% 
of the initially loaded platinum was released from CPCs with maximum loading of 
complex A (PLGA40-HA20[A]; Supplementary Figure S3.2B).
Figure 3.5. Cumulative release of total amount of (A) Ca (mg) from CPCs without PLGA microspheres, 
(B) Ca (mg) from CPCs with PLGA microspheres, (C) Pt (μg) from CPCs without PLGA microspheres, 
and (D) Pt (μg) from CPCs with PLGA microspheres as a function of soaking time in HEPES buffer. 
These results correspond to earlier findings of Iafisco et al.,18 who observed that 
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the affinity of complex A for HA NPs was greater than that of complex B owing to 
the positively charged NH
3
+ group of complex A. Similar to previous findings,18 the 
release of the platinum species from the CPCs into cell culture medium followed a 
pattern opposite to that observed for the adsorption process in Milli-Q water. Due to 
the amine group present on the bisphosphonate of complex A, adsorption of complex 
A onto the HA matrix was more pronounced, resulting in decreased desorption into 
the culture medium.
It should be emphasized that this result is not negative. In fact, the different affinities 
of complexes A and B for HA NPs is a key parameter for tailoring and controlling 
the release kinetics of the active platinum species from the inorganic matrices for 
personalized therapeutic applications. It is also worth mentioning that in vitro and in 
vivo studies cannot be correlated due to the large differences with respect to perfusion. 
Therefore, the release rates of complexes A and B from CPCs should be further 
monitored by means of animal experimentation.
Compared to CPCs, containing HA NPs, CPCs without HA NPs showed burst-type 
release patterns for both com- plexes A and B irrespective of the presence or absence 
of PLGA microspheres (Supplementary Figure S3.2A and B). In contrast, a sustained 
release behavior was observed for the CPCs containing drug-loaded HA NPs. These 
results confirmed that adsorption of Pt-BP complexes onto HA NPs and their affinity 
to HA NPs were crucial to obtain a sustained and controlled release of platinum from 
the CPC formulations.
Figure 3.5C, D revealed that the release rate of platinum did not depend on the 
incorporation of PLGA microspheres into the CPCs. To have a release pattern 
controlled by PLGA microspheres, the drugs have to be linked to the polymeric matrix 
of PLGA.34,36 Therefore, it can be concluded that platinum release was not controlled 
by the degradation of the CPC matrix but by the diffusion of the platinum species 
through the CPCs. Similar diffusion-dependent release was reported by Margiotta et 
al.19 for the release of platinum species from Pt-BP complexes loaded onto calcium-
free or calcium-containing silica xerogels.
Figure 3.5C indicated that the total cumulative platinum release from the CPCs 
containing complex B-loaded HA NPs after 28 days of soaking increased from ~50 
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to ~184 μg by increasing the amount of drug-loaded HA NPs from 5 to 20 wt%, 
respectively. A similar linear trend was observed for the CPCs containing complex 
A-loaded HA NPs (Figure 3.5C), as well as PLGA-containing CPCs loaded with 
either complex A or B (Figure 3.5D). These findings confirmed that the release of 
platinum species proceeded in a dose-dependent manner.
Since the incorporation of PLGA microspheres into the CPCs did not affect the rate 
or extent of platinum release, the CPC formulations, including PLGA microspheres, 
were excluded from the in vitro proliferation experiments, as described in the ‘‘In 
vitro Proliferation Test’’ section.
In Vitro Proliferation Test
Previous studies showed that antitumor active [PtCl
2
(en)] or related solvato species 
were released from HA-bound Pt-BP complexes after breakage of the Pt-BP bonds 
upon the entrance of chloride ions (present at high concentration in both HEPES 
buffer and cell culture medium) into the platinum coordination sphere.17,28 There are 
a few examples of Pt(II) complexes with bisphosphonate ligands bound to the metal 
through the phosphonate oxygen atoms. In particular, bisphosphonate partial esters 
have been used by the group of Nakatake to increase the stability of Pt-BP complexes, 
which were tested for their in vitro cytotoxicity against four human tumor cell lines, 
showing an activity similar to that of the clinically used cisplatin.37
Here, we tested the antiproliferative activity of CPC formulations containing drug-
free or drug-loaded HA NPs by culturing human osteosarcoma cells (MG-63 cell line) 
or h-BMMSCs in media containing these platinum releasates. The antiproliferative 
activity of these CPCs was compared with that of free complexes A and B as well as 
[PtCl
2
(en)] (a synthetic analog of the platinum species released from CPCs). A range 
of concentrations of these dissolved compounds was selected to match to the platinum 
concentrations released from the CPCs (see Figure 3.6 for platinum concentrations 
measured in the releasates after 7 days).
ICP-OES analysis confirmed that calcium concentrations in the cell culture media as 
well as in the releasates did not change upon filtration (Supplementary Figure S3.3). 
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Moreover, the platinum concentration was not affected significantly upon filtration, 
except for solutions containing free complex B, where a 40% decrease in platinum 
concentration was revealed after filtration (Supplementary Figure S3.3).
Figure 3.6. Platinum content in the releasates (cell culture media) from CPCs after 7 days of incubation. 
The decrease in platinum concentration of free complex B upon filtration could be 
attributed to the low solubility of complex B in both Milli-Q water and proliferation 
medium (~2 mg∙ml-1), which was further affected by the temperatures used to store 
the solutions (~4 °C) before application. This phenomenon was not observed for 
complex A due to its higher solubility (~30 mg∙ml-1). To reduce this effect, a heated 
ultrasonication bath (at 37 °C) was used for both complexes to further increase 
the solubility. To obtain the desired platinum concentration after filtration, 40% of 
additional filtrated complex B was supplemented to the initial solution to compensate 
for this effect. This was only performed for solutions used for the experimental groups 
in contact with free complex B solutions since the filtration effect was not observed 
for complex B releasates, complex A releasates, or free complex A solutions.
The proliferative capacity of the primary cell type (h-BMMSCs) and the osteosarcoma 
cell line (MG-63) was evaluated by assessing their DNA content. Figure 3.7A shows 
the DNA content of h-BMMSCs, which were cultured for 3 days in proliferation 
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media containing free compounds. Additional information on the DNA contents at 
days 1, 3, and 7 can be found in Supplementary Figure S3.4A.
Figure 3.7. DNA content at day 3 normalized against the DNA content of positive control (α-MEM) 
at day 1 (%) for (A) h-BMMSCs in contact with free drug solutions, (B) MG-63 cells in contact with 
free drug solutions, (C) h-BMMSCs in contact with releasates from CPCs, and (D) MG-63 cells in 
contact with releasates from CPCs (*p < 0.05; comprehensive statistical analysis can be found in 
Supplementary Table S3.2). α-MEM, minimal essential medium; h-BMMSCs, human bone marrow-
derived mesenchymal stromal cells. 
Similar to the findings of Iafisco et al.18 using human cervical (HeLa), colon (LoVo), 
and lung (A549) cancer cells, as well as osteosarcoma (U2Os) cells, the reduction in 
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proliferation of h-BMMSCs as caused by media containing a low concentration of 
free complex A (10 μM Pt) was statistically insignificant (p > 0.05). By increasing 
the platinum concentration of free complex A up to 100 and 1,000 μM, however, cell 
proliferation decreased significantly by factors 2.4 and 12.4, respectively (p < 0.05). 
In contrast to complex A, free complex B decreased the proliferation of h-BMMSCs 
by factor 2.1 already at the lowest concentration of 10 μM Pt.
This observation indicated that similar to the findings of Iafisco et al.,18 free complex 
B was more antiproliferative than free complex A. By increasing the concentration 
of free complex B in contact with h-BMMSCs up to 100 and 1,000 μM Pt, cell 
proliferation decreased even more by factors 2.5 and 8.1, respectively (p < 0.05). 
Comparable to free complex B solution, the proliferation of h-BMMSCs decreased 
by factors 2.5 and 5.4 (p < 0.05) in the presence of [PtCl
2
(en)] solutions containing 
10 and 100 μM Pt, respectively. At the highest concentration of [PtCl
2
(en)] of 1,000 
μM Pt, no DNA was detected anymore, corresponding to complete inhibition of 
cell proliferation. Generally, [PtCl
2
(en)] was more antiproliferative than both free 
complexes A and B at all platinum concentrations investigated (Figure 3.7A).
Figure 3.7B shows the DNA content of MG-63 cells, which were cultured for 3 
days in proliferation media containing free drugs. Additional information on the DNA 
contents at days 1, 3, and 7 can be found in Supplementary Figure S3.4B.
Similar to the results obtained using h-BMMSCs (Figure 3.7A) and the findings of 
Iafisco et al.,18 the reduced proliferation of MG-63 cells as caused by media containing 
a low concentration of free complex A (10 μM Pt) was statistically insignificant (p > 
0.05). By increasing the concentration of free complex A up to 100 and 1,000 μM Pt, 
however, cell proliferation decreased significantly by factors 1.6 and 13.1, respectively 
(p < 0.05). In contrast to free complex A, free complex B decreased the proliferation 
of MG-63 cells by factor 3.7 already at the lowest concentration of 10 μM Pt.
These results confirmed that free complex B was more antiproliferative than free 
complex A, which corresponded to the findings by Iafisco et al.18 as well as the above- 
described results using h-BMMSCs (Figure 3.7A). By increasing the concentration 
of free complex B up to 100 and 1,000 μM Pt, the proliferation of MG-63 cells 
decreased even more by factors 12.2 and 42.8, respectively (p < 0.05). Comparable to 
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free complex B solution, the proliferation of MG-63 cells decreased by factor 6.0 (p < 
0.05) in the presence of [PtCl
2
(en)] solutions containing 10 μM Pt. The proliferation 
of MG-63 cells in contact with [PtCl
2
(en)] solutions containing 100 μM Pt decreased 
by factor 24.9 (p < 0.05), whereas no DNA was detected anymore by increasing the 
concentration of [PtCl
2
(en)] up to 1,000 μM Pt, indicating complete inhibition of cell 
proliferation.
Similar to the results obtained in this study using h-BMMSCs (Figure 3.7A), 
[PtCl
2
(en)] was more antiproliferative than both free complexes A and B at all 
platinum concentrations investigated (Figure 3.7B).
Comparing the antiproliferative effect of free complex A in contact with h-BMMSCs 
versus MG-63 cells (Figure 3.7A versus 3.7B), we did not observe a detectable 
selectivity for a specific cell type, whereas free complex B and [PtCl
2
(en)] solutions 
showed a higher antiproliferative activity on MG-63 cells compared to h-BMMSCs. 
Our results are similar to those of Margiotta et al.,28 who evaluated the growth 
inhibitory effect of four different platinum complexes toward 13 human tumor cell 
lines of multiple origins. The lower antiproliferative effect of complex A compared 
to complex B can be due to the lower stability of complex A at higher pH due to 
the tendency of its dangling amine group to coordinate to platinum by displacing a 
phosphonate oxygen.38 Another likely explanation can be a better cellular uptake of 
neutral complex B compared to that of positively charged complex A.
Figure 3.7C shows the DNA content of h-BMMSCs, which were cultured for 3 days 
in proliferation media containing releasates from CPCs. Additional information on 
the DNA contents at days 1, 3, and 7 can be found in Supplementary Figure S3.4C.
Releasates from CPCs loaded with 5 wt% complex B-loaded HA NPs (HA5[B] 
containing ~24.7 μM Pt) reduced the proliferation of h-BMMSCs by factor 1.9 (p < 
0.05), whereas CPCs loaded with drug-free HA NPs (HA5) and CPCs loaded with the 
lowest amount of complex A-loaded HA NPs (HA5[A] containing ~1.6 μM Pt) did 
not affect the proliferation of h-BMMSCs. Releasates from CPCs loaded with 20 wt% 
complex A-loaded HA NPs (HA20[A] containing ~8.4 μM Pt), however, reduced the 
proliferation of h-BMMSCs by factor 2.0 (p < 0.05). Proliferation of h-BMMSCs was 
decreased by factor 3.1 (p < 0.05) by releasates from CPCs loaded with the highest 
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amount of complex B-loaded HA NPs (HA20[B] containing ~115.3 μM Pt). Similar to 
HA5, HA20 did not decrease the proliferation of h-BMMSCs significantly compared 
to the positive control.
Figure 3.7D shows the DNA content of MG-63 cells, which were cultured for 3 days 
in proliferation media containing releasates from CPCs. Additional information on 
the DNA contents at days 1, 3, and 7 can be found in Supplementary Figure S3.4D.
Releasates from CPCs loaded with 5 wt% complex B-loaded HA NPs (HA5[B] 
containing ~24.7 μM Pt) reduced the proliferation of MG-63 cells by factor 3.0 (p 
< 0.05), whereas CPCs loaded with drug-free HA NPs (HA5) and CPCs loaded with 
the lowest amount of complex A-loaded HA NPs (HA5[A] containing ~1.6 μM Pt) 
did not affect the proliferation of MG-63 cells. Releasates from CPCs loaded with 
20 wt% complex A-loaded HA NPs (HA20[A] containing ~8.4 μM Pt), however, 
reduced the proliferation of MG-63 cells by factor 3.3 (p < 0.05). Proliferation of 
MG-63 cells was decreased by factor 8.7 (p < 0.05) by releasates from CPCs loaded 
with the highest amount of complex B-loaded HA NPs (HA20[B] containing ~115.3 
μM Pt). Similar to HA5, HA20 did not decrease the proliferation of MG-63 cells 
significantly compared to the positive control.
Comparing the antiproliferative effect of releasates from CPCs loaded with the 
lowest amount of complex A (HA5[A]) in contact with h-BMMSCs versus MG-63 
cells (Figure 3.7C versus 3.7D), we did not observe a detectable selectivity upon 
cell type, whereas releasates from CPCs loaded with the lowest amount of complex 
B-loaded HA NPs (HA5[B]) showed considerably higher antiproliferative activity on 
MG-63 cells compared to h-BMMSCs.
Comparing the antiproliferative effect of releasates from CPCs loaded with complex 
A versus free complex A and [PtCl
2
(en)] in contact with h-BMMSCs (Figure 3.7A 
versus 3.7C), the releasates from CPCs loaded with complex A (HA20[A] containing 
~8.4 μM Pt) were ~20% more antiproliferative than free complex A at 10 μM Pt 
and ~20% less antiproliferative than [PtCl
2
(en)] at 10 μM Pt. Comparing the same 
solutions and releasates in contact with MG-63 cells (Figure 3.7B versus 3.7D), the 
releasates from CPCs loaded with complex A (HA20[A] containing ~8.4 μM Pt) 
were ~61% more antiproliferative than free complex A at 10 μM Pt and ~45% less 
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antiproliferative than [PtCl
2
(en)] at 10 μM Pt.
Regarding the antiproliferative effect of releasates from CPCs loaded with complex 
B versus free complex B and [PtCl
2
(en)] in contact with h-BMMSCs (Figure 3.7A 
versus 3.7C), the releasates from CPCs loaded with complex B (HA20[B] containing 
~115.3 μM Pt) were ~19% more antiproliferative than free complex B at 100 μM Pt 
and ~43% less antiproliferative than [PtCl
2
(en)] at 100 μM Pt. Comparing the same 
solutions and releasates in contact with MG-63 cells (Figure 3.7B versus 3.7D), the 
releasates from CPCs loaded with complex B (HA20[B] containing ~115.3 μM Pt) 
were ~29% and ~65% less antiproliferative than free complex B and [PtCl
2
(en)] at 
100 μM Pt, respectively.
In summary, the drug-loaded CPCs were chemotherapeutically active. Releasates 
from CPCs loaded with complex A were more antiproliferative than free complex 
A but less antiproliferative than [PtCl
2
(en)], whereas those from CPCs loaded with 
complex B were less antiproliferative than both free complex B and [PtCl
2
(en)].
Although these results are partly in agreement with the previous findings that 
showed platinum species released from complexes A and B loaded on HA NPs is 
[PtCl
2
(en)] (or related solvato species),17,18 they might indicate that the release of Pt-
BP complexes from HA NP-loaded CPCs into cell culture media (instead of HEPES 
buffer, as previously studied17,18) only partially occurs in the form of [PtCl
2
(en)]. 
Due to interference with the contents of the cell culture medium, however, we were 
not able to confirm the presence of free Pt-BP complexes, along with [PtCl
2
(en)] (or 
related solvato species), in the pharmacologically active releasates. Finally, this study 
demonstrated that both free Pt-BP complexes and their releasates from the CPCs 
showed considerably higher antiproliferative activity on human osteosarcoma cell 
line (MG-63) than on h-BMMSCs.
Conclusions
The current study demonstrated that lyophilization of HA NPs decreases the loading 
capacity for chemotherapeutic Pt-BP complexes. Furthermore, it was shown that Pt-
BP complexes can be released in a sustained manner from CPCs containing drug-
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loaded HA NPs. The drug release kinetics can be tuned by varying the HA-binding 
affinity of the Pt-BP complexes as well as the amount of drug-loaded HA NPs.
The drug-loaded CPCs were chemotherapeutically active. Releasates from CPCs 
containing complex A-loaded HA NPs were more antiproliferative than free complex 
A but less antiproliferative than [PtCl
2
(en)]. Releasates from CPCs loaded with 
complex B-loaded HA NPs were less antiproliferative than both free complex B and 
[PtCl
2
(en)]. Furthermore, this study demonstrated that both Pt-BP complexes and 
their releasates from the CPCs showed higher antiproliferative activity on human 
osteosarcoma cell line (MG-63) compared to h-BMMSCs. In summary, these results 
can be highly instrumental for development of chemotherapeutically active bone 
substitutes for specific and personalized therapeutic needs.
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Supplementary Data
Figure S3.1. (A) XRD pattern, (B) FTIR spectra, and (C) TEM micrograph of HA NPs (scale bar = 100 
nm).
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Table S3.1. Abbreviations used for CPC formulations without HA NPs (presented in Supplementary 
Figure S3.2), their compositions, and the corresponding CPCs containing HA NPs).
Abbreviation1 α-TCP (wt%) PLGA (wt%) Corresponding CPC Containing HA
α-5[A/B] 100 - HA5[A/B]
α-PLGA40-5[A/B] 60 40 PLGA40-HA5[A/B]
α-10[A/B] 100 - HA10[A/B]
α-PLGA40-10[A/B] 60 40 PLGA40-HA10[A/B]
α-20[A/B] 100 - HA20[A/B]
α-PLGA40-20[A/B] 60 40 PLGA40-HA20[A/B]
1 α: α-tricalcium phosphate; PLGA: poly(D,L-lactic-co-glycolic acid); [A/B]: containing complex A or 
B; Figures 5, 10, and 20 represent equivalent amounts of complex A/B added to the CPC formulations 
with no HA NPs as compared to the corresponding CPCs containing HA NPs.
Figure S3.2. Cumulative release of total amount of platinum relative to initially loaded Pt from (A) CPCs 
without PLGA microspheres and (B) CPCs with PLGA microspheres as a function of soaking time in 
HEPES buffer.
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Figure S3.3. Platinum and calcium content in different cell culture media after filtration (normalized 
against the initial concentration (%)) measured by ICP-OES analysis.
Table S3.2. Comprehensive statistical analysis of (A) Figure 3.7A, (B) Figure 3.7B, (C) Figure 3.7C, and 
(D) Figure 3.7D (*: p < 0.05; NS: not statistically different).
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Figure S3.4. DNA content at days 1, 3, and 7 normalized against the DNA content of positive control 
(α-MEM) at day 1 (%) for (A) h-BMMSCs in contact with free drug solutions, (B) MG-63 cells in 
contact with free drug solutions, (C) h-BMMSCs in contact with releasates from CPCs, and (D) MG-63 
cells in contact with releasates from CPCs. α-MEM, minimal essential medium; h-BMMSCs, human 
bone marrow-derived mesenchymal stromal cells.
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Introduction
Intrinsic biocompatibility, biodegradability, and ease of functionalization of natural polymers are of great potential value for applications in tissue engineering, 
regenerative medicine, pharmaceutics, and drug delivery.1,2 Natural polymers, such as 
collagen and gelatin, contain peptide sequences, such as arginine-glycine-aspartic acid, 
which can modulate cell adhesion and improve the cellular behavior in comparison 
to polymers that lack these cell-recognition sites.1,3 Gelatin is a particularly attractive 
candidate material for drug delivery, since it is a low-cost proteinaceous biopolymer 
that has been extensively used for biomedical purposes due to its biocompatible, 
biodegradable, and nontoxic properties.2,4–7
Different types of gelatin can offer various physicochemical properties to allow 
modification using simple functionalization schemes.5 Gelatin can be tuned with 
respect to its drug loading efficiency,8 degradation rate, and release kinetics,7,9 which 
renders gelatin a remarkably tunable drug delivery carrier for a wide variety of 
biomedical applications.9,10 Targeted drug delivery entails a selective and effective 
localization of pharmacologically active compounds at pre-defined targeted site(s), 
thus minimizing undesired side effects and maximizing therapeutic efficacy.11,12 The 
ease of functionalization of gelatin facilitates the introduction of specific motifs for 
selective targeting to specific organs,7 such as airway epithelium cells,13 lungs,14,15 
eyes,16 neurons,17 brain,18 lymphatic system,19–22 intestinal tract,23 bladder,24 or other 
specific organs.25–28 However, successful targeting of gelatin to bone tissue has not 
been reported before.
For applications as a drug delivery vehicle, gelatin has been processed into different 
shapes and forms, such as hydrogels,23,24 sponges,18–20,29 coatings or films,15,16,30 
microparticles,14,17,25–27 and nanoparticles.13,21,22,28,31,32 Microparticles lack the mobility 
and size required for targeted delivery and are often entrapped in non-target organs.25 
Sub-micron or nanoparticles, on the contrary, have gained increased research interest,33 
due to their significantly smaller size and thus increased specific surface area, which 
facilitates targeted delivery to specific tissues.34
Bisphosphonates are widely applied for treatment of osteoporosis. They have also been 
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used as moieties for targeted delivery of radio-pharmaceuticals, estrogen, corticoids, 
anti-inflammatory agents, and proteins.35 Upon conjugation of bisphosphonates to 
nanomedicines via a degradable linker, they become pharmacologically active and 
can induce synergistic effects when coupled with appropriate drugs.35 In addition, the 
locally delivered bisphosphonates might have medicinal effects by inducing osteoclast 
apoptosis.36 Using bisphosphonates, Boanini and Bigi37 functionalized gelatin 
microparticles stabilized by alginate dialdehyde in order to induce the formation 
of a calcium phosphate (CaPO
4
) coating on top of gelatin microparticles. Given the 
strong affinity of bisphosphonate groups to the mineral phase of bone tissue,38,39 we 
hypothesized that the affinity of gelatin nanoparticles to pre-fabricated CaPO
4
 could be 
greatly enhanced by functionalizing these nanoparticles with bisphosphonate groups. 
These gelatin nanoparticles with higher affinity to CaPO
4
 were hypothesized to have 
great potential for use in bone regeneration (e.g., development of organic–inorganic 
nanocomposites) or bone-specific drug delivery.
To develop mineral-binding gelatin nanoparticles with enhanced affinity to CaPO
4
, 
we conjugated amino-bisphosphonate alendronate to glutaraldehyde (GA)-crosslinked 
gelatin nanoparticles. Previously, the residual reactivity of unreacted aldehyde groups 
in gelatin nanoparticles was blocked using glycine. Here, we exploited this residual 
reactivity of unreacted aldehyde groups to link the primary amino group of alendronate 
to gelatin nanoparticles. The conjugation reaction was studied using 13C and 31P solid-
state Nuclear Magnetic Resonance (SS-NMR) spectroscopy and Inductively Coupled 
Plasma-Optical Emission Spectrometry (ICP-OES). The efficacy of conjugation 
was investigated as a function of pH, GA crosslinking density, and alendronate 
concentration using ICP-OES. Finally, the affinity of the gelatin nanoparticles to 
CaPO
4
 was assessed using macroscopic evaluation, Dynamic Light Scattering (DLS), 
fluorescent microscopy, and Atomic Force Microscopy (AFM).
113
4
Material and Methods
Materials
Gelatin type A (from porcine skin, 300 Bloom, average molecular mass: ~100 kDa, 
isoelectric point (pI): ~9, ~28.6,40 and 78–80 millimoles of free amino and carboxyl 
groups per 100 g gelatin, respectively) and Gelatin type B (from bovine skin, 225 
Bloom, average molecular mass: ~50 kDa, pI: ~5, ~33,41 and 100–115 millimoles of 
free amino and carboxyl groups per 100 g gelatin, respectively) were purchased from 
Sigma-Aldrich. GA (25 wt% solution in water) was purchased from Acros Organics. 
Alendronic acid (ALN, (4-amino-1-hydroxy-butylidene)diphosphonic acid) was 
purchased from AK Scientific, Inc. (AKSci, Union City, CA, USA). Acetone was 
purchased from Boom BV (Meppel, the Netherlands). Aldehyde-functionalized glass 
slides (SuperAldehyde) were purchased from Arrayit Corporation (Sunnyvale, CA, 
USA). Spherical polycrystalline hydroxyapatite/calcium phosphate (CaPO
4
) particles 
with diameters of ~35 ± 4 μm and hydroxyapatite (Ca
10
(PO
4
)
6
(OH)
2
) granules with 
diameters of 0.5–1.0 mm were obtained from CAM Bioceramics BV (Leiden, the 
Netherlands). All other materials were purchased from Sigma-Aldrich.
Preparation of Unfunctionalized Gelatin Nanoparticles
Gelatin nanoparticles (Gel) were prepared using a two-step desolvation method as 
reported previously.42,43 Subsequently, GA was used to crosslink gelatin nanoparticles 
with a molar ratio of GA relative to the amine groups in gelatin (GA/NH
2
) of 2. 
After crosslinking at room temperature for 16 h (although 3–4 h crosslinking was 
sufficient to obtain stable nanoparticles, to obtain the highest yield the reaction was 
aged for 16 h), 100 ml of 100 × 10-3 M glycine solution was added to the gelatin 
nanoparticles suspension to block the unreacted aldehyde groups. After three cycles 
of centrifugation (5,000 rpm for 60 min using a Universal 32 R Hettich Centrifuge, 
Tuttlingen, Germany) and resuspension in Milli-Q water by vortexing, the pH 
of the suspension was adjusted to 7.0. To investigate the properties of the gelatin 
114
Chapter 4 | Bisphosphonate-functionalized Gelatin Nanoparticles
nanoparticles in swollen state, small fractions of the suspension were stored at 4 °C 
until further use, whereas the rest of the gelatin nanoparticles were lyophilized (no 
cryoprotectant applied; Freezone 4.5, Labconco, USA) and stored at 4 °C.
Preparation of Alendronate-functionalized Gelatin 
Nanoparticles
Using a two-step desolvation method, gelatin nanoparticles were prepared as 
described previously.42,43 Subsequently, GA was used to crosslink gelatin nanoparticles 
with a GA/NH
2
 molar ratio of 2. Residual aldehyde groups from the GA crosslinking 
reaction were used for further conjugation with the amine (NH
2
) group of alendronate. 
To optimize the alendronate conjugation reaction as well as the physiochemical 
properties of the resulting gelatin nanoparticles, two different timepoints were chosen 
for the addition of alendronate to the gelatin nanoparticles suspension.
Since gelatin types A and B demonstrated a similar behavior with respect to 
alendronate functionalization, gelatin type B was used for a systematic investigation 
on the conjugation reaction (unless stated otherwise). Table 4.1 provides an overview 
of the abbreviations, compositions, and timepoints of alendronate addition (either 
during GA crosslinking reaction (simultaneous functionalization; Gel∙ALN-Sim) or 
after aging the crosslinking reaction for 16 h (post-functionalization; Gel∙ALN)). 
Both conjugation reactions were carried out at room temperature with a molar ratio 
of alendronate relative to GA (ALN/GA) of 5 and aged for 16 h. After three cycles of 
centrifugation (5,000 rpm for 60 min) and resuspension in Milli-Q water by vortexing, 
the pH of the suspension was adjusted to 7.0. To investigate the properties of the 
functionalized gelatin nanoparticles in swollen state, small fractions of the suspension 
were stored at 4 °C until further use, whereas the rest of the gelatin nanoparticles were 
lyophilized and stored at 4 °C.
As a control experiment, similar amounts of alendronate (ALN/GA molar ratio 
= 5) were adsorbed onto a suspension of unfunctionalized gelatin nanoparticles 
(GA/NH
2
 molar ratio = 2; crosslinked at room temperature for 16 h; unreacted 
aldehyde groups were blocked with 100 ml of 100 × 10-3 M glycine solution; three 
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cycles of centrifugation (5,000 rpm for 60 min) and resuspension in Milli-Q water 
by vortexing). After addition of alendronate to the suspension of unfunctionalized 
gelatin nanoparticles, the mixture was left stirring at room temperature for 16 h. The 
alendronate-adsorbed gelatin nanoparticles (Gel∙ALN-Ads) were then centrifuged 
(5,000 rpm for 60 min) and resuspended in Milli-Q water by vortexing for three cycles. 
The pH of the final suspension was adjusted to 7.0. To investigate the properties of 
the nanoparticles in swollen state, small fractions of the suspension were stored at 4 
°C until further use, whereas the rest of the gelatin nanoparticles were lyophilized and 
stored at 4 °C.
Table 4.1. Abbreviations, compositions, and functionalization parameters.
a) No alendronate-functionalization carried out for Gel; b) No alendronate-functionalization, but only 
physical adsorption, carried out for Gel∙ALN-Ads.
The efficiency of the conjugation reaction was investigated at acidic, neutral, and 
basic pH values (4, 7, and 10, respectively; original pH after GA crosslinking was ~4; 
changing pH up to 7 or 10 was carried out after GA crosslinking using 1 M and 0.1 
M NaOH solutions), at low, medium, and high crosslinking densities (GA/NH
2
 molar 
ratios of 1, 2, and 4, respectively), and at low, medium, and high alendronate densities 
(ALN/GA molar ratios of 3, 5, and 10, respectively). Table 4.1 shows an overview of 
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all the varied functionalization parameters, namely ALN/GA molar ratio, pH, and GA/
NH
2
 molar ratio.
Characterization of Gelatin Nanoparticles
Electron Microscopy
The morphology and size of the gelatin nanoparticles were characterized in 
lyophilized and swollen state using Scanning Electron Microscopy (SEM, JEOL 
6340F; all samples were mounted on aluminum stubs using carbon tape and sputter-
coated with gold-palladium) and cryo-Transmission Electron Microscopy (cryo- 
TEM, JEOL 2100; nanoparticles dispersed in Milli-Q water, solid content 0.5 w/v%), 
respectively. Digital image analysis software (Image J, NIH) was applied to analyze 
the diameter of at least 200 nanoparticles using SEM and cryo-TEM micrographs in 
lyophilized and swollen state, respectively.
Water Content and Degree of Crosslinking
To study the influence of alendronate functionalization on the crosslinking efficiency 
of the gelatin nanoparticles, their water content was measured by soaking ~10 mg of 
gelatin nanoparticles overnight at room temperature in 2 ml of Milli-Q water while 
agitated on a shaking table at 90 rpm. The swollen nanoparticles were collected after 
24 h on filter paper to remove surface water and placed in a vial of known weight 
(W
vial
). The weight of the vial including the swollen nanoparticles was then recorded 
(W
swollen+vial
). After lyophilizing for 24 h, the weight of the vial including the dry 
nanoparticles was recorded (W
dry+vial
). Accordingly, the water content (%) of gelatin 
nanoparticles was calculated as follows
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This parameter provides an indication of the water uptake (wt%) of the gelatin 
nanoparticles. Five samples were measured for each experimental group.
The degree of crosslinking was quantitatively determined by quantifying the amount 
of free amino groups using the reaction of 2, 4, 6-trinitrobenzenesulfonic acid (TNBS) 
with amino groups of the gelatin nanoparticles, as described previously.44 Briefly, to 
a sample of ~5 mg gelatin nanoparticles, 1 ml of 4 w/v% NaHCO
3
 solution (pH 8.5) 
and 1 ml of freshly prepared 0.5 w/v% TNBS solution in Milli-Q water were added. 
After allowing the reaction to take place for 2 h at 40 °C, 2ml of 6 N HCl was added, 
and the temperature was raised to 60 °C. Hydrolysis of gelatin nanoparticles was 
achieved within ~90 min. The resulting solution was diluted with 4 ml of Milli-Q 
water. 1 ml samples of the final solution were transferred to 48-well plates, and the 
absorbance was measured at 346 nm using a spectrophotometer microplate reader 
(Bio-Tek Instruments, Inc.). The degree of crosslinking of gelatin nanoparticles was 
expressed as percentage of free primary amino groups available after crosslinking 
relative to free primary amino groups available before crosslinking.
Dynamic Light Scattering and Laser Doppler Velocimetry
DLS and Laser Doppler Velocimetry (LDV) were performed on a Zetasizer Nano-S 
(Malvern Instruments Ltd.) to characterize the hydrodynamic size (dispersed in 
Milli-Q water, solid content 0.01 w/v%) and ζ-potential (dispersed in 5 × 10-3 M 
HEPES buffer at pH 7.0) of the gelatin nanoparticles, respectively.
Elemental Analysis
ICP-OES (iCap 6300) was used to quantify the degree of functionalization with 
alendronate as well as the retention of alendronate to the gelatin nanoparticles. To 
quantify the degree of alendronate-functionalization, the nanoparticles were digested 
in concentrated nitric acid (at 37 °C overnight on a shaking table) and subsequently 
diluted to 1% nitric acid solutions for ICP-OES analysis of the phosphorus content.
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Solid-state Nuclear Magnetic Resonance Spectroscopy
The conjugation reaction was investigated using 13C and 31P SS-NMR spectroscopy. 
All 31P solid-state spectroscopy experiments were performed on Varian NMR 
spectrometer operating at proton frequency of 850 MHz. Samples were measured 
using a 1.6 mm Magic Angle Spinning (MAS) probehead at a spinning frequency of 
35 kHz. 31P chemical shifts were referenced to the known resonance of H
3
PO
4
 (0 ppm). 
The temperature was stabilized at 298 K. Single pulse excitation was used as a pulse 
sequence for obtaining 31P spectra; no proton decoupling was applied. The recycle delay 
was 60 s to make sure that the samples can be interpreted quantitatively. 13C solid-state 
Cross-Polarization Magic Angle Spinning (CPMAS) spectra were measured by means 
of a 400 MHz Varian NMR spectrometer. Samples were packed into 3.2 mm rotors, 
employing a MAS rate of 10 kHz. A 90° proton pulse of 2.6 μs excited transverse 
proton magnetization, then 5 ms cross-polarization pulses were simultaneously applied 
on both—proton and carbon channels—to induce magnetization transfer. Two-pulse 
phase-modulated (TPPM) decoupling45 at a radiofrequency-field strength of 100 kHz 
was used during acquisition. Carbon chemical shifts were referenced with respect to 
tetramethylsilane (TMS) using the adamantane signals as a secondary reference.
To further understand the 13C CPMAS spectrum obtained from ALN (purchased from 
AKSci), spectra of monosodium alendronate (purchased from Sigma-Aldrich) were 
also measured. In addition, ALN (purchased from AKSci) was analyzed by X-ray 
diffraction (XRD, using a Bruker D8 Advance in a reflection mode—monochromator 
was used to prevent overlapping of different difractograms—and compared with 
known spectra from ALN and monosodium alendronate.
ALN (as reference) was crushed to increase the surface of alendronate crystals. 
As control experiments, crushed ALN was mixed with unblocked or glycine-
blocked unfunctionalized gelatin nanoparticles in dry state. In addition, the control 
experiment was also carried out by analyzing physical mixtures, which were obtained 
through lyophilizing unfunctionalized gelatin nanoparticles re-suspended in a 
solution containing a known amount of alendronate (equal to the detected amount of 
alendronate in alendronate-functionalized gelatin nanoparticles).
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Retention of Alendronate to Gelatin Nanoparticles
To evaluate the stability of the alendronate–gelatin conjugation reaction as well as 
the extent at which alendronate was covalently linked to post-functionalized gelatin 
nanoparticles (Gel∙ALN), the retention of alendronate to gelatin nanoparticles was 
evaluated in Milli-Q water as a function of soaking time (1, 3, 7, and 14 days). Briefly, 
10 mg of lyophilized Gel∙ALN (GA/ NH
2
 molar ratio = 2; pH
functionalization
 = 4; ALN/GA 
molar ratio = 5) was added to 10 ml of Milli-Q water at 37 °C on a shaking table (70 
rpm). At each timepoint, the suspensions were centrifuged at 5,000 rpm for 60 min. 
The gelatin pellet was separated from the supernatant and resuspended in 10 ml of 
fresh Milli-Q water for further timepoints. The supernatant was mixed with nitric acid 
to prepare a 1% nitric acid solution for further elemental analysis of the phosphorus 
content using ICP-OES. The retention of alendronate to alendronate-adsorbed gelatin 
nanoparticles (Gel∙ALN-Ads) was evaluated similarly as a control experiment.
Phosphate buffered saline (PBS), cell culture medium, or similar phosphorus-
containing media could not be used for this experiment, since the high phosphate 
concentration in the media did not allow for detection and differentiation of phosphorus 
released from alendronate-functionalized gelatin nanoparticles using ICP-OES.
Preparation of Calcium Phosphate Nanoparticles
A homogeneous suspension of CaPO
4
 nanoparticles with needle-like morphology 
was prepared according to an established wet chemical precipitation method as 
described previously.46,47 Briefly, 25 ml of H
3
PO
4
 (1.78 M) solution was added drop-
wise (at a rate of ~1–2 drops∙s-1) to a solution of continuously stirred Ca(OH)
2
 (2.96 
M) while the temperature was kept at 60 °C. The ratio between the elements was 
stoichiometric with respect to hydroxyapatite (Ca/P ratio of 1.67) according to the 
following reaction
 5Ca(OH)
2
 + 3H
3
PO
4
 → Ca
5
(PO
4
)
3
(OH) + 9H
2
O
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The product was then aged for ~16–18 h at 60 °C, followed by three cycles of 
centrifugation (3,000 rpm for 2 min) and resuspension in Milli-Q water. After adjusting 
the pH to 7.0, the CaPO
4
 nanoparticles were stored as an aqueous suspension (40 
mg∙ml-1).
Characterization of Calcium Phosphate Nanoparticles
The lyophilized CaPO
4
 powders were characterized by Attenuated Total Reflectance-
Fourier Transform Infrared spectroscopy (ATR-FTIR, Spectrum One, Perkin 
Elmer) and powder XRD (PW 1830, Panalytical). ζ-potential measurements were 
performed by LDV using a Zetasizer Nano-S in suspension (dispersed in Milli-Q 
water, solid content 0.01 w/v%). The morphology and size of the nanoparticles were 
investigated by TEM (JEOL 1010) and cryo-TEM. The size of CaPO
4
 nanoparticles 
was determined by averaging the length and width of at least 200 nanoparticles using 
TEM micrographs by digital image analysis software (Image J, NIH).
Affinity of Gelatin Nanoparticles to Calcium Phosphate
Dynamic Light Scattering and Macroscopic Evaluation
The affinity of gelatin nanoparticles to needle-shaped CaPO
4
 nanoparticles was 
investigated by monitoring the changes in particle size after mixing dilute dispersions 
of CaPO
4
 and gelatin nanoparticles (solid content: 0.02 w/v%; CaPO
4
/gelatin w/w 
ratio: 2; dispersed in 5 × 10-3 M HEPES buffer at pH 7.0) using macroscopic evaluation 
(at room temperature) as well as DLS (at 37 °C) as a function of time (up to 20 min).
Fluorescence Microscopy of Calcium Phosphate-coated Titanium 
Disks and Gelatin Nanoparticles
Commercially available titanum disks of 12 mm diameter and 1.5 mm thickness were 
grit-blasted by using aluminum oxide particles, cleaned ultrasonically in isopropanol 
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(~15 min), and air-dried overnight. The surface roughness of the titanium disks (Ra 
= 2.0 ± 0.2 μm) was measured using a universal surface tester (Innowep GmbH, 
Würzburg, Germany). Titanium disks were subsequently coated with a thin CaPO
4
 
film (1.5 ± 0.1 μm) using a commercially available radiofrequent magnetron sputter 
deposition system (Edwards High Vacuum ESM 100 system, Crawford, England) as 
described previously.48,49 The target materials were hydroxyapatite (Ca
10
(PO
4
)
6
(OH)
2
) 
granules (diameter: 0.5–1.0 mm; CAM Biocer- amics BV, Leiden, the Netherlands). 
The disks were mounted on a rotating water-cooled substrate holder. The distance 
between target and implant holder was 80 mm. Before sputtering, the disks were 
cleaned by etching for ~10 min with argon ions. During deposition (7.5 h), the argon 
pressure was kept at 5 × 10-3 mbar and the sputter power of 2 times 400 W with 
a coating thickness of ~1 μm was used. After deposition, the coated implants were 
subjected to an additional infrared heat treatment for 30 s at 650 °C (Quad Ellipse 
Chamber, Model E4-10-P, Research Inc.) as previously described.50 The titanium 
disks were eventually cleaned ultrasonically in isopropanol for ~15 min to remove 
any unbound particles, air-dried, and stored at room temperature. The coatings were 
characterized by thin film XRD (PW 1830, Panalytical) and ATR-FTIR.
The affinity of gelatin nanoparticles to CaPO
4
 was evaluated by immersing the 
hydroxyapatite-coated titanium disks overnight in 2 ml of gelatin nanoparticles 
suspension (dispersed at 2.5 mg∙ml-1 in 5 × 10-3 M HEPES buffer) at 37 °C on a 
shaking plate. The titanium disks were horizontally placed at the bottom of 24-well 
cell culture plates without any constraint for horizontal movement within the well. The 
autofluorescence of gelatin was exploited to quantify the amount of surface-bound 
gelatin nanoparticles by fluorescence microscopy using an automated axio Imager 
Z1 microscope (Carl Zeiss Micro Imaging GmbH, Göttingen, Germany) and digital 
image analysis (Image J, NIH) after thoroughly rinsing the disks with Milli-Q water 
to remove the unbound gelatin nanoparticles. The affinity of gelatin nanoparticles to 
the hydroxyapatite surfaces was quantified by dividing the areas covered by gelatin 
nanoparticles to the entire hydroxyapatite-covered surface area of the titanium disks 
using the autofluorescence detected from gelatin nanoparticles.
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Atomic Force Microscopy
An Atomic Force Microscope (AFM; NanoWizard III AFM, JPK Instruments AG, 
Germany) equipped with an inverted optical microscope (Olympus IX71, Germany) 
was used in combination with colloidal probes to quantitatively measure the 
interactions between gelatin nanoparticles and hydroxyapatite microparticles in PBS 
at room temperature. The spring constant of the cantilever (μMash, CSC38/tipless/
No Al) was calculated using the thermal noise method. Hydroxyapatite microparticles 
(spherical shape with average diameter of ~35 ± 4 μm; CAM Bioceramics BV (Leiden, 
the Netherlands)) were used for this experiment.
Gelatin nanoparticles (type A) were linked to aldehyde-functionalized glass slides 
(Superaldehyde; ArrayIt, Sunnyvale, CA) to form a close-packed layer. In order to 
achieve the linkage, the reactive side of the glass slides was covered with concentrated 
suspensions of gelatin nanoparticles at room temperature for 1 h. Thereafter, 
the substrates were rinsed with Milli-Q water to remove the unattached gelatin 
nanoparticles. Subsequently, the substrates were immersed in glycine solution (100 × 
10-3 M) for 1 h to block the possible unreacted aldehyde groups on the glass slides. The 
substrates were afterward rinsed with Milli-Q water to wash out the glycine residues. 
Colloidal probes were prepared by gluing single hydroxyapatite microparticles to a 
tipless AFM cantilever using epoxy resin (UHU Plus Schnellfest, UHU GmbH & 
Co. KG, Germany) and used as colloidal AFM probes (Supplementary Figure S4.1). 
Pull-off forces were calculated as the difference between the point of maximum 
adhesion and the zero deflection point of each force-distance curve. The pull-off force 
between the gelatin nanoparticle substrate and the hydroxyapatite colloidal probe was 
determined via force mapping of 35 spots. As a control experiment, the effect of free 
alendronate molecules (at different alendronate concentrations: 10-1, 102, 105, and 
108 × 10-9 M) on the specific binding between gelatin and hydroxyapatite particles 
was determined similarly. The pull-off measurements were carried out using a force 
setpoint of 3.5 × 10-9 N with 5 s contact time between the colloidal probe and the 
substrate surface and an extension/retraction velocity of 1 μm∙s-1.
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Statistical Analysis
All results were depicted as mean ± standard deviation. The statistical analyses 
were performed using GraphPad Prism (version 5.03) software. Differences among 
groups were determined by one-way analysis of variance (ANOVA) with a Bonferroni 
(multiple comparisons) post hoc test, and a value of p < 0.05 was considered as 
significantly different.
Results and Discussion
Preparation and Characterization of Gelatin Nanoparticles
Effect of Functionalization Timepoint
Gelatin nanoparticles (either functionalized or unfunctionalized) were prepared 
using an established two-step desolvation method42,43 resulting in the formation of 
spherical nanoparticles. Average diameters of the nanoparticles in lyophilized and 
swollen state are provided in Table 4.2. To optimize the alendronate conjugation 
reaction as well as the physiochemical properties of the resulting nanoparticles, two 
different timepoints were chosen for the addition of alendronate to the suspension of 
gelatin nanoparticles (Table 4.1): during GA crosslinking reaction (simultaneously-
functionalized; Gel∙ALN-Sim) or after aging the crosslinking reaction for 16 h (post-
functionalized; Gel∙ALN).
SEM micrographs revealed that the morphology and size of either post-functionalized 
or simultaneously-functionalized gelatin nanoparticles in lyophilized state did not 
change upon functionalization with alendronate, as compared to the unfunctionalized 
gelatin nanoparticles (Gel) (Figure 4.1A–C). DLS measurements confirmed that the 
size of post-functionalized gelatin nanoparticles (Gel∙ALN) in swollen state did not 
change upon alendronate functionalization. However, simultaneously-functionalized 
gelatin nanoparticles (Gel∙ALN-Sim) showed an increased size in swollen state (Table 
4.2), which was further confirmed by analyzing the cryo-TEM micrographs obtained in 
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swollen state (Figure 4.1D–F). Similar results were obtained for gelatin nanoparticles 
that were lyophilized and rehydrated/resuspended either in Milli-Q water, 5 × 10-3 M 
HEPES buffer, or PBS.
Table 4.2. ζ-potential and particle size of unfunctionalized (Gel), post-functionalized (Gel∙ALN), and 
simultaneously functionalized (Gel∙ALN-Sim) gelatin nanoparticles.
a) Particle sizes of lyophilized gelatin nanoparticles were measured by analyzing at least 200 particles 
using electron microscopy, while the diameters of swollen nanoparticles were determined by DLS.
b) Denotes statistical differences versus the other two experimental groups within the same row (p < 0.05).
Figure 4.1. A–C) Scanning electron micrographs of unfunctionalized (Gel), post-functionalized 
(Gel∙ALN), and simultaneously functionalized (Gel∙ALN-Sim) gelatin nanoparticles, respectively; D–F) 
Cryo-TEM micrographs of Gel, Gel∙ALN, and Gel∙ALN-Sim, respectively (scale bar = 500 nm).
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The size difference between Gel∙ALN-Sim versus Gel∙ALN in swollen state was 
attributed to the interfering effect of alendronate on the GA crosslinking reaction 
(Supplementary Table S4.1). This phenomenon was not observed for Gel∙ALN, since 
alendronate was added after completion of the crosslinking reaction. The significantly 
higher water content of Gel∙ALN-Sim compared to Gel further confirmed that the 
presence of alendronate during GA crosslinking compromised the crosslinking of 
gelatin nanoparticles. No significant difference was observed between Gel∙ALN and 
Gel (Figure 4.2A). This implied that alendronate functioned mainly as a blocking 
agent for the unreacted aldehyde groups for Gel∙ALN, whereas for Gel∙ALN-Sim, 
in addition to the blocking role, alendronate interfered with the crosslinking reaction 
(Supplementary Table S4.1). Moreover, for both Gel∙ALN-Sim or Gel∙ALN, glycine 
was not required to block the unreacted aldehyde groups. For Gel, however, the 
addition of glycine was necessary to prevent severe agglomeration upon centrifugation/
resuspension or lyophilization. Nevertheless, to ensure that no unreacted GA is 
remained, glycine may also be used after alendronate-functionalization.
Our observations evidenced that glycine addition after alendronate-functionalization 
does not have an effect on the efficiency of the conjugation reaction. In our previous 
works we demonstrated that colloidal gels made of gelatin nanoparticles crosslinked 
with GA and blocked with glycine not only do not exhibit cytotoxicity but also 
support attachment, spreading, and proliferation of cultured primary bone marrow 
stem cells.43 It has already been shown that the presence of alendronate as conjugate 
does not influence the biocompatibility of polymeric micelles.51 Therefore, it can be 
expected that alendronate-functionalization, particularly in very low concentrations of 
alendronate, would not influence the biocompatibility of gelatin nanoparticles.
To be consistent with our previous works,3,42,43 the experiments and the results shown 
in Table 4.2 and Figure 4.1 are only related to gelatin nanoparticles prepared with an 
acetone flow rate of 2 ml∙min-1; however, by increasing the flow rate up to 4 ml∙min-1 
it was possible to decrease the average size of the gelatin nanoparticles down to ~107 
± 8 and 226 ± 14 nm in dry and swollen state, respectively.
Swelling ratio of gelatin nanoparticles that were lyophilized and rehydrated/
resuspended in Milli-Q water was similar to those presented in Figure 4.2A.
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Figure 4.2. A) Water content (%) of gelatin nanoparticles; B) the presence of phosphorus in gelatin 
nanoparticles measured by ICP-OES (left Y-axis represents wt% of alendronate present in gelatin 
nanoparticles, whereas right Y-axis represents the molar ratio of alendronate relative to gelatin) (p < 
0.05).
As shown in Figure 4.2B, ICP-OES measurements confirmed the presence of 
phosphorus in the alendronate-functionalized gelatin nanoparticles after their 
complete dissolution in nitric acid. At a GA/NH
2
 molar ratio of 2, an ALN/GA molar 
ratio of 5, and a reaction pH of 4, it was possible to link ~10.8 moles of alendronate 
to one mole of gelatin by using the post-functionalization method (Gel∙ALN), 
whereas by using the simultaneous functionalization method (Gel∙ALN-Sim) 
a higher amount of alendronate (~17.6 moles per one mole gelatin) was linked to 
gelatin nanoparticles. The difference in conjugation efficiency was attributed to the 
difference in the availability of free aldehyde groups during the two functionalization 
methods. For the simultaneous functionalization method, a higher concentration of 
unreacted aldehyde groups was available for alendronate conjugation, whereas more 
aldehyde groups were consumed during crosslinking of gelatin nanoparticles for 
post- functionalized gelatin nanoparticles. These findings corresponded to the results 
obtained from the ζ-potential measurements (Table 4.2), where post-functionalization 
of gelatin nanoparticles (Gel∙ALN) resulted into more negatively charged gelatin 
nanoparticles compared to unfunctionalized (Gel) or simultaneously-functionalized 
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(Gel∙ALN-Sim) nanoparticles. Although alendronate-functionalization generally 
rendered the gelatin nanoparticles more negatively charged, this phenomenon was less 
pronounced for Gel∙ALN-Sim. It is known that decreased crosslinking density renders 
gelatin nanoparticles less negatively charged.42 Consequently, this phenomenon was 
attributed to the lower crosslinking density (Supplementary Table S4.1), which was 
resulted from the consumption of aldehyde groups by alendronate instead of gelatin 
molecules. Due to the interfering effect of alendronate on the crosslinking of gelatin 
nanoparticles using the simultaneous functionalization method (Gel∙ALN-Sim), the 
post-functionalization method (Gel∙ALN) was selected for further experiments.
We studied the conjugation reaction of alendronate to gelatin nanoparticles in more 
detail by means of 13C and 31P solid-state NMR. Due to the low concentration of 
alendronate compared to gelatin, 13C spectra were not informative—spectra of pure 
gelatin overlapped with those of alendronate conjugated to the gelatin nanoparticles. 
Using 31P spectroscopy, however, alendronate could be selectively detected in 
functionalized gelatin nanoparticles since phosphorus was only present in alendronate. 
31P NMR spectra of pure alendronate are shown in Supplementary Figure S4.2. As 
previously reported in literature,52 the 31P spectrum of monosodium alendronate is 
represented by two signals at 17.4 and 22.1 ppm with equal intensities. One signal 
corresponds to sodium attached to phosphorus and the second originates from the 
H
2
PO
3
 group. These signals appeared in our spectrum as well, but we also detected a 
peak at ~15.3 ppm. To understand the origin of the additional signal, we compared the 
13C CPMAS spectrum of ALN to monosodium alendronate (Supplementary Figure 
S4.3), and observed differences between the two spectra. This was followed by XRD 
analysis, which revealed the existence of a mixture of monosodium alendronate and 
ALN in the alendronate (ALN purchased from AKSci) used for functionalization of 
gelatin nanoparticles in this study (Supplementary Figure S4.4).
Alendronate-functionalized gelatin nanoparticles gave rise to a single broad peak 
at 18–19 ppm in 31P NMR spectra (Figure 4.3A). The significant line broadening can 
be explained by either (i) heterogeneity of phosphorus microenvironments due to the 
interaction with the surfaces of the nanoparticles or (ii) the chemical bond between 
aldehyde and alendronate. To exclude the influence of the first factor, we prepared 
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physical mixtures of crushed (to increase the possible surface interactions) alendronate 
and unfunctionalized gelatin nanoparticles (either glycine-blocked or unblocked) in 
dry state. 31P spectra of these samples were identical (Figure 4.3B). Identical spectra 
were obtained with lyophilized unfunctionalized gelatin nanoparticles (Gel), which 
were re-suspended in a solution containing ~1.5 wt% alendronate (Supplementary 
Figure S4.5). This means that the presence of alendronate in the vicinity of gelatin 
nanoparticles without conjugation does not induce any line broadening or shifting. 
Therefore, we attribute the line broadening and shift of the 31P-NMR signal as 
observed in Figure 4.3A to the formation of a possible covalent bond between the 
alendronate molecules and the free aldehyde groups on gelatin nanoparticles. Similar 
observations were reported previously for alendronate binding to polymer51 and bone 
mineral52 by means of NMR spectroscopy. In both studies, the authors reported a 
significant line broadening as a result of the chemical bonding process, implying that 
there is a distribution in bond angles and/or bond lengths in these systems.
Figure 4.3. 31P solid-state NMR spectra of pure crushed alendronic acid versus A) alendronic acid 
bound to aldehyde linked to gelatin nanoparticles; B) physical mixtures of crushed alendronic acid with 
unfunctionalized gelatin nanoparticles in dry state (red: unblocked (72 wt% alendronate); blue: glycine-
blocked (61 wt% alendronate)).
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Effect of ALN/GA Molar Ratio
To investigate the effect of alendronate concentration (expressed as ALN/GA 
molar ratio) on the efficiency of the conjugation reaction, Gel∙ALN was prepared 
at low, medium, and high alendronate densities (ALN/GA molar ratios of 3, 5, and 
10, respectively (Table 4.1)), and subsequently analyzed for their phosphorus content 
using ICP- OES. Figure 4.4A shows the effect of increasing the ALN/GA molar ratio on 
the efficiency of alendronate-functionalization of gelatin nanoparticles. By increasing 
the ALN/GA molar ratio from 3 to 5, the ALN/Gel molar ratio increased ~1.8-fold 
(from ~6.0 to ~10.8), whereas by increasing the ALN/GA molar ratio from 5 to 10 the 
ALN/Gel molar ratio increased only 1.1-fold (from ~10.8 to ~12.0). Accordingly, the 
ALN/GA molar ratio of 5 was selected as the optimum ratio for further preparations.
Effect of pH and GA/NH2 Molar Ratio
To investigate the effect of the reaction pH and GA concentration (expressed as GA/
NH
2
 molar ratio) on the efficiency of the conjugation reaction, Gel∙ALN was prepared 
at acidic, neutral, and basic pH values (4, 7, and 10, respectively (Table 4.1); original 
pH after GA crosslinking was ~4) as well as at low, medium, and high crosslinking 
densities (GA/NH
2
 molar ratios of 1, 2, and 4, respectively (Table 4.1)). The resulting 
nanoparticles were analyzed subsequently for their water and phosphorus content.
ICP-OES analysis of Gel∙ALN showed that the efficiency of the conjugation reaction 
increased following a twofold increase in the GA/NH
2
 molar ratio (GA/NH
2
 = 2 versus 
1), whereas a fourfold increase in GA/NH
2
 molar ratio (GA/ NH
2
 = 4) not only did 
not further increase the conjugation efficiency but also led to a decreased conjugation 
efficiency in comparison to GA/NH
2
 = 2 (Figure 4.4B). This was attributed to the 
competition between the excess of freely available aldehyde groups in solution and 
the limited number of free unreacted aldehyde groups linked to gelatin molecules, i.e., 
a high fraction of alendronate was consumed by the freely available aldehyde groups 
in solution instead of the free unreacted aldehyde groups linked to gelatin molecules. 
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Figure 4.4. Effect of A) ALN/GA molar ratio and B) pH and GA/NH
2
 molar ratio on the efficiency 
of alendronate-functionalization of gelatin nanoparticles measured by ICP-OES (left Y-axis represents 
wt% of alendronate present in gelatin nanoparticles, whereas right Y-axis represents the molar ratio of 
alendronate relative to gelatin); C) Water content (%) of functionalized and unfunctionalized gelatin 
nanoparticles. Three different pH values (pH 4 = acidic; pH 7 = neutral; pH 10 = basic) and GA/NH
2 
molar ratios (1; 2; 4) were selected to evaluate the optimal condition (p < 0.05).
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The efficiency of the alendronate-functionalization reaction was lowest at neutral pH 
(pH 7), which was attributed to the lack of electrostatic repulsion between the gelatin 
nanoparticles, that in turn reduced the yield of gelatin nanoparticle production by 
severe agglomeration. Despite the slightly higher functionalization efficiency at pH 10 
compared to pH 4, pH 4 was chosen as the optimum pH for the post-functionalization 
of gelatin nanoparticles, since no pH alteration was needed for the conjugation reaction 
under acidic conditions, while still obtaining a significantly higher production yield. 
Figure 4.4C shows that by changing the functionalization pH from acidic to basic the 
water content of the nanoparticles decreased. This could be attributed to the higher 
activity of GA at basic pH values,53 which resulted in a higher crosslinking density and 
accordingly lower water content. By neutralizing the reaction pH, the water content 
decreased, except for the nanoparticles crosslinked at a GA/NH
2
 molar ratio of 1. 
This phenomenon resulted from the low amount of GA and lack of repulsive forces 
between the gelatin nanoparticles, which in turn resulted into a very low production 
yield, severe agglomeration, and a higher swelling ratio in comparison to the other 
groups.
The amount of alendronate that could be linked to gelatin nanoparticles by varying 
the aforementioned parameters (i.e., functionalization timepoint, pH, and ALN/GA 
and GA/NH
2
 molar ratio) was generally lower compared to that reported in literature 
for gelatin microparticles (maximum ALN/gelatin wt% of ~2.2 for nanoparticles 
versus 4.837 for microparticles). This can be attributed to several factors, including the 
different reaction media and reactant concentrations, reactivity of alginate-dialdehyde 
compared to GA in the reaction, and availability of unreacted aldehyde groups on 
alginate-dialdehyde-crosslinked gelatin microparticles versus GA-crosslinked gelatin 
nanoparticles.
Retention of Alendronate to Gelatin Nanoparticles
To evaluate the stability of the alendronate–gelatin conjugation reaction as well as 
the extent at which alendronate was covalently linked to gelatin nanoparticles, the 
retention of alendronate to gelatin nanoparticles was studied in Milli-Q water as a 
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function of soaking time. Retention tests showed that up to 70 wt% of the alendronate 
initially present on Gel∙ALN was retained to the nanoparticles after 7 days of soaking 
(Figure 4.5). No significant amount of detached alendronate was detected in the 
supernatant by ICP-OES thereafter up to 14 days. On the contrary, Gel∙ALN-Ads 
showed a poor retention of alendronate in comparison to Gel∙ALN. Not more than 
5 wt% of the initially bound alendronate was retained to Gel∙ALN-Ads after only 3 
days of soaking (Figure 4.5), and no significant amount of detached alendronate was 
detected in the supernatant by ICP-OES thereafter up to 14 days.
Figure 4.5. Weight percentage of alendronate retained in gelatin nanoparticles as a function of soaking 
time. Letters “a” and “b” denote statistical differences versus all the other timepoints within the same 
group (p < 0.05).
These results suggest that the conjugation reaction considerably improved the 
retention of alendronate to gelatin nanoparticles by formation of covalent imine 
linkages between aldehyde and amino groups with a hydrolytic stability of at least two 
weeks, which is sufficient for the intended applications. The burst release of alendronate 
from Gel∙ALN-Ads was consistent with the broadly reported burst release of various 
biomolecules adsorbed onto or encapsulated inside gelatin nanoparticles22,54–56 as a 
result of the absence of covalent bonds between the biomolecules and the gelatin 
macromers. Similarly, the 30 wt% detachment of alendronate from Gel∙ALN within 
the first 3 (up to 7) days was attributed to the physically entrapped alendronate rather 
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than the cleavage of imine bonds.
Affinity of Gelatin Nanoparticles to Calcium Phosphate
Macroscopic Evaluation and Dynamic Light Scattering
The affinity of gelatin nanoparticles to needle-shaped calcium phosphate (CaPO
4
) 
nanoparticles was investigated by monitoring the changes in particle size after mixing 
dilute dispersions of CaPO
4
 and gelatin nanoparticles (solid content: 0.02 w/v%; 
CaPO
4
/gelatin w/w ratio: 2; dispersed in 5 × 10-3 M HEPES buffer at pH 7.0) using 
macroscopic evaluation as well as DLS as a function of mixing time (up to 20 min).
CaPO
4
 nanoparticles were successfully synthesized using an established wet 
chemical neutralization reaction between calcium hydroxide and phosphoric acid.46,47 
The apatitic nature of the synthesized nanoparticles was confirmed by XRD. Main 
reflection peaks were observed at 25.9° and 31.9° 2θ corresponding to an apatitic 
CaPO
4
 phase (Supplementary Figure S4.6A). Corresponding ATR-FTIR analyses 
showed that the CaPO
4
 nanoparticles consisted of hydroxyapatite with clear phosphate 
absorption peaks at 563, 601, 963, and 1027 cm-1 and a hydroxyl absorption peak 
at 630 cm-1 (Supplementary Figure S4.6B). From representative TEM images, the 
average diameter and length of the needle-shaped nanoparticles were estimated to be 
around 20 and 80 nm, respectively (Supplementary Figure S4.6C).
Macroscopic CaPO
4
-binding tests at dilute conditions showed that Gel∙ALN formed 
agglomerates with CaPO
4
 nanoparticles which sedimented after 20 min (Figure 4.6A), 
whereas Gel remained stable in suspension without visually detectable agglomeration 
or sedimentation. Figure 4.6B shows a representative cryo-TEM micrograph of 
a dilute mixture of Gel∙ALN in the presence of CaPO
4
 nanoparticles, in which the 
interstitial spaces between gelatin nanoparticles are filled with smaller-sized electron- 
dense CaPO
4
 nanoparticles.
To investigate the interactions between gelatin and CaPO
4
 nanoparticles in more 
details, DLS was applied to measure the particle size of Gel and Gel∙ALN in the 
presence or absence of CaPO
4
 nanoparticles as a function of time (Figure 4.6C). For 
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either Gel or Gel∙ALN, the particle size did not change in time in the absence of 
CaPO
4
 nanoparticles. Upon addition of CaPO
4
 nanoparticles, on the contrary, particle 
size increased considerably for Gel∙ALN+CaPO
4
 , resulting in heteroaggregation of 
gelatin and CaPO
4
 nanoparticles, whereas the particle size did not change in time for 
Gel+CaPO
4
. This was attributed to the higher affinity of Gel∙ALN to CaPO
4
 compared 
to Gel.
Figure 4.6. Affinity of gelatin nanoparticles to CaPO
4
 nanoparticles at dilute condition as a function of 
mixing time (solid content: 0.02 w/v%; CaPO
4
/gelatin w/w ratio: 2; dispersed in 5 × 10-3 M HEPES buffer 
at pH 7.0). A) Macrograph of the samples after 20 min of equilibration;B) representative cryo-TEM 
image of adilute mixture of alendronate-functionalized gelatin nanoparticles (Gel∙ALN) in the presence 
of CaPO
4
 nanoparticles (scale bar = 500 nm); C) particle size of unfunctionalized (Gel) and alendronate-
functionalized (Gel∙ALN) gelatin nanoparticles in the presence or absence of CaPO
4 
nanoparticles as 
monitored by means of DLS.
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Affinity of Gelatin Nanoparticles to Hydroxyapatite-coated 
Titanium Disks
To investigate the affinity of gelatin nanoparticles to CaPO
4
 surfaces, 
hydroxyapatite-coated titanium disks (corresponding XRD and ATR-FTIR spectra 
shown in Supplementary Figure S4.7A and B, respectively) were immersed in gelatin 
nanoparticle suspensions. Titanium disks, hydroxyapatite coating, and alendronate 
did not demonstrate any autofluorescence; therefore, all the detected fluorescence was 
attributed to the autofluorescence of gelatin nanoparticles. Digital image analysis of 
fluorescence micrographs of hydroxyapatite-coated titanium disks (Figure 4.7A and 
B) revealed that Gel∙ALN bind more effectively to hydroxyapatite surfaces (Figure 
4.7B) compared to Gel (Figure 4.7A), as demonstrated by a sixfold higher fluorescence 
intensity on the hydroxyapatite surfaces for Gel∙ALN compared to Gel (Figure 4.7B).
Figure 4.7. Fluorescence images of hydroxyapatite-coated titanium disks immersed in suspensions of 
A) unfunctionalized (Gel), and B) alendronate-functionalized (Gel∙ALN) gelatin nanoparticles (scale bar 
= 2 mm). C) Quantification of the fluorescence inten- sity derived from the autofluorescence of surface-
bound gelatin nanoparticles (p < 0.05).
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Atomic Force Microscopy
An AFM equipped with an inverted optical microscope was used as a colloidal 
probe to quantitatively measure the interactions between gelatin nanoparticles and 
hydroxyapatite microparticles (corresponding XRD and ATR-FTIR spectra shown in 
Supplementary Figure S4.8A and B, respectively) in PBS at room temperature. Figure 
4.8 shows the maximum pull-off force between the hydroxyapatite microparticle and 
gelatin nanoparticles at different concentrations of free alendronate molecules in the 
solutions. As illustrated in Figure 4.8, Gel∙ALN showed an approximately twofold 
higher average pull-off force from the hydroxyapatite microparticle compared to 
Gel. However, in the presence of free alendronate molecules in the solutions, the 
pull-off force values from the hydroxyapatite microparticle decreased. When the 
concentration of free alendronate in PBS exceeded 102 × 10-9 M, the pull-off force 
values for Gel∙ALN decreased to approximately the same value as for Gel in pure PBS. 
The decrease in pull-off force values resulting from the presence of free alendronate 
molecules was attributed to a competition between free and gelatin-linked alendronate 
for binding the surface of hydroxyapatite microparticle.
Figure 4.8. Maximum pull-off force between the hydroxyapatite microparticle and gelatin nanoparticles 
at different concentrations of free alendronate molecules in the solutions, measured by atomic force 
microscopy (p < 0.05).
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Conclusions
This study presents a simple method for the preparation of alendronate-functionalized 
gelatin nanoparticles through conjugation of alendronate to residual aldehyde 
groups present after incomplete crosslinking of gelatin nanoparticles. The degree of 
functionalization could be tuned by varying the glutaraldehyde crosslinking density, 
the molar ratio between alendronate and glutaraldehyde, as well as the pH of the 
functionalization reaction. Furthermore, this study provided firm evidence that gelatin 
nanoparticles show significantly higher affinity to calcium phosphate as a result of 
functionalization with alendronate. Consequently, it can be concluded that gelatin 
nanoparticles have been developed, which exhibit great potential for use in bone-
specific drug delivery and regenerative medicine.
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Supplementary Data
Figure S4.1. Colloidal AFM probe prepared by gluing a single hydroxyapatite microparticle (yellow 
dotted circle) to a tipless AFM cantilever using epoxy resin (scale bar = 30 µm).
Table S4.1. Degree of crosslinking of gelatin nanoparticles expressed as percentage of free primary amino 
groups available after crosslinking relative to free primary amino groups available before crosslinking.
Gel Gel∙ALN Gel∙ALN-Sim
Available primary amino groups (%) 17.8 ± 0.3 17.5 ± 0.8 12 ± 1.1a
a denotes statistical differences versus the other two experimental groups ( 0.05).
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Figure S4.2. 31P solid-state NMR spectra of neat and crushed alendronic acid.
Figure S4.3. 13C spectra of alendronic acid (black: purchased from AKSci) and monosodium alendronate 
(red: purchased from Sigma-Aldrich).
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Figure S4.4. XRD spectrum of alendronate purchased by AKSci. Black: experimental spectrum of 
alendronic acid (AKSci); red and blue: known spectra of alendronate and alendronic acid, respectively.
Figure S4.5. 31P solid-state NMR spectra of physical mixtures of lyophilized unfunctionalized gelatin 
nanoparticles (Gel) re-suspended in a solution containing ~1.5 wt% alendronate.
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Figure S4.6. Characterization of the crystal phase, molecular structure, and morphology of calcium 
phosphate nanoparticles: (A) X-Ray Diffraction (* shows the main reflection peaks of hydroxyapatite); 
(B) ATR-FTIR spectra (v
1
, v
3
 and v
4
 refer to the phosphate absorptions, and # is attributed to hydroxyl 
groups); (C) Transmission Electron Microscopy (scale bar = 100 nm).
148
Chapter 4 | Bisphosphonate-functionalized Gelatin Nanoparticles
Figure S4.7. (A) XRD pattern (* shows the main reflection peaks of hydroxyapatite; ● indicates 
titanium), and (B) ATR-FTIR spectra (# shows the characteristic phosphate absorptions) of calcium 
phosphate sputter coating on titanium discs.
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Figure S4.8. (A) XRD pattern (* shows the main reflection peaks of hydroxyapate), and (B) ATR-FTIR 
spectra (v
1
, v
3
 and v
4
 refer to the phosphate absorptions, and # is attributed to hydroxyl groups) of 
hydroxyapatite microparticles.
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Introduction
Bone is a frequent site for metastases, which develop in up to 70% of patients with prostate cancer and breast cancer,1 and in up to 30% of those with cancers of the 
lung, bladder, and thyroid.2 Bone metastases are a health and economic burden as they 
are associated with numerous skeletal-related issues including pathological fractures, 
spinal cord compression, pain, and need for radiation therapy or surgery to bone.3 
Besides the devastating effect of cancer on bone tissue, current treatment modalities 
not specific to cancer cells result in damaging normal cells and healthy tissues.4 In 
fact, a major disadvantage of anticancer drugs is their lack of selectivity for tumor 
tissue, which causes severe side effects and results in low cure rates.5 For instance, 
therapy with platinum-based chemotherapeutic molecules (e.g., cisplatin (cis-diam
minedichloridoplatinum(II)), which are a group of key drugs used in the treatment 
of cancers, are associated with various secondary effects including anemia, nausea, 
vomiting, neurotoxicity, and nephrotoxicity. These side effects impair the patient’s 
quality of life and can even be life-threatening.6–8
To overcome these side effects, the design of a new generation of molecules 
to target traditional anticancer platinum-based drugs to bone tissue is 
strongly required.8 To this end, platinum-bisphosphonate complexes (i.e., bis-
{ethylenediamineplatinum(II)}-2-amino-1-hydroxyethane-1,1-diyl-bisphosphonate 
(Pt-BP) and bis-{ethylenediamineplatinum(II)}-medronate)) were recently 
developed.9–11 Bisphosphonate-functionalized platinum-based molecules not only 
target bone as a result of the bone-seeking properties of bisphosphonate moieties,12–14 
but also specifically target bone tumors15 due to their higher metabolic activity as 
compared to healthy cells.16
Traditional systemic delivery of chemotherapeutics, however, entails high systemic 
drug elimination through renal and urinary excretion and limited circulation time.17 
On the contrary, chemotherapeutic drugs would be delivered more efficiently to bone 
tumors upon bone-specific and sustained delivery from suitable carriers,18,19 thereby 
reducing toxic side effects in unaffected tissues. To this end, novel and more effective 
drug delivery vehicles should be developed that have strong and specific affinity 
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to mineralized tissue and are able to release chemotherapeutic drugs locally in a 
controlled and sustained manner.5,20
The intrinsic biocompatibility, biodegradability, and ease of functionalization of 
natural polymers are of great potential value for applications in tissue engineering, 
regenerative medicine, pharmaceutics, and drug delivery.21,22 Gelatin is a particularly 
attractive candidate material for drug delivery, since it is a low-cost proteinaceous 
biopolymer that has been extensively used for biomedical purposes due to its 
biocompatible, biodegradable, and non-toxic properties.18,22–25 Gelatin can be 
tuned with respect to its drug loading efficiency,26 degradation rate, and release 
kinetics,25,27 which renders gelatin a remarkably versatile drug carrier for a wide 
variety of biomedical applications.27,28 For applications as a drug delivery vehicle, 
gelatin has been processed into different shapes and forms, such as hydrogels,29,30 
sponges,31–34 coatings or films,35–37 microparticles,38–42 and nanoparticles.6,43–47 Gelatin 
microparticles have been used as drug delivery carriers for anticancer drugs such as 
cisplatin.48,49 Although cisplatin was only adsorbed onto gelatin microparticles, the 
anticancer effect was enhanced and prolonged as compared to carrier-free delivery 
of cisplatin alone.48 Microparticles, however, lack the mobility and size required 
for targeted delivery and are often entrapped in non-target organs.38 Sub-micron or 
nanoparticles, on the contrary, have gained increased research interest,50 due to their 
significantly smaller size and thus increased specific surface area, which enhances the 
drug payload and facilitates targeted delivery to specific tissues.51
Gelatin nanoparticles have been used for the delivery of both hydrophilic and 
hydrophobic anticancer drugs.18,52 Drug-loaded gelatin nanoparticles have also 
demonstrated rapid uptake and long-term retention in the tumor after administration.18,19 
The superior efficacy of anticancer drug-loaded gelatin nanoparticles compared to 
free drug has been manifested both in vitro (in cancer cell lines) and in vivo (in tumor-
bearing animal models).18,19,52–55 Cytotoxicity analysis of anticancer drug-loaded 
gelatin nanoparticles against different cancer cell lines has shown higher anticancer 
activity compared to free drug which has been attributed to greater endocytotic uptake 
of gelatin nanoparticles in cancer cells.52,56,57 Gelatin nanoparticles, however, have not 
yet been developed for bone-specific drug delivery.
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Recently, we developed mineral-binding gelatin nanoparticles with enhanced 
affinity to calcium phosphate (CaP).12 Herein, we have rendered these mineral-
binding gelatin nanoparticles potentially chemotherapeutically active by covalent 
linking of anticancer Pt-BP drugs. The functionalization reactions were studied using 
different functionalization schemes and molar ratios between reactants. The efficacy 
of conjugation as well as the retention and release properties of the Pt-BP-loaded 
gelatin nanoparticles were investigated using Inductively Coupled Plasma-Optical 
Emission Spectrometry (ICP-OES). Finally, the influence of dual functionalization 
with Pt-BP and ALN on the affinity of gelatin nanoparticles to CaP was assessed using 
fluorescent microscopy.
Material and Methods
Materials
Gelatin type B (from bovine skin, 225 Bloom, average molecular mass: ~50 kDa, 
pI: ~5, ~33 millimoles of free amino groups58 and 100–115 millimoles of carboxyl 
groups per 100 g gelatin) was purchased from Sigma-Aldrich. Glutaraldehyde (GA, 
25 wt% solution in water) was purchased from Acros Organics. Alendronic acid 
(ALN, (4-amino-1-hydroxy-butylidene)diphosphonic acid) was purchased from 
AK Scientific, Inc. (AKSci, Union City, CA, USA). Acetone was purchased from 
Boom BV (Meppel, the Netherlands). 2-Ammonium-1-hydroxyethane-1,1-diyl-
bisphosphonic acid (AHBP-H
5
) and [Pt(OSO
3
)(OH
2
)(en)] (en = ethylenediamine) 
were prepared following procedures reported previously.9 Milli-Q water was used to 
dissolve the platinum compounds. All other reagents were purchased from Sigma-
Aldrich.
Preparation and Characterization of Pt-BP Complex
[{Pt(en)}
2
(µ-AHBP-H
2
)](HSO
4
) (bis-{ethylenediamineplatinum(II)}-2-amino-1-
hydroxyethane-1,1-diyl-bisphosphonate, Pt-BP (Figure 5.1), was prepared according 
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to already reported methods.16,59 Briefly, 2-ammonium-1-hydroxyethane-1,1-diyl-
bisphosphonic acid (AHBP-H
5
) (0.055 g, 0.246 mmol) was dissolved in Milli-Q water 
(18 ml) and the resulting solution, maintained at 40 °C, was first partially neutralized 
with Ba(OH)
2
∙8H
2
O (0.082 g, 0.258 mmol) and subsequently treated with a solution of 
[Pt(OSO
3
)(OH
2
)(en)] (0.200 g, 0.541 mmol, in 14 ml of Milli-Q water). The obtained 
suspension was kept under magnetic stirring at 40 °C overnight and then cooled down 
in an ice bath. The white precipitate (BaSO
4
) was removed by filtration through a plug 
of Celite® and the filtrate was concentrated to a volume of approximately 2 ml. The pH 
of the concentrated solution was adjusted to ~1.0 by addition of H
2
SO
4
 (1 M) and the 
acidic solution was treated with methanol, which induced precipitation of the desired 
product. The precipitate was left standing at 4 °C for 3 h and then isolated by filtration, 
washed with methanol and diethyl ether, and dried under vacuum. Obtained 0.183 g 
(85% yield). Anal. Calc. for [{Pt(en)}
2
(μ-AHBP-H
2
)](HSO
4
)∙3H
2
O (C
6
H
29
N
5
O
14
P
2
Pt
2
S, 
Mw = 879.4 g∙mol
-1): C, 8.19%; H, 3.32%; N, 7.96%. Found: C, 8.49%; H, 3.19%; N, 
7.64%. ESI-MS: calc. for [{Pt(en)}
2
(μ-AHBP-H
2
)]+ ([C
6
H
22
N
5
O
7
P
2
Pt
2
]+) = 728.03; 
found: m/z (% relative to the base peak) = 727.8 (100) [M]+.
The spectroscopic characterization of Pt-BP was consistent with literature data (1H 
and 13P Nuclear Magnetic Resonance (NMR) spectroscopy and Fourier Transform 
Infrared spectroscopy (FTIR)). Electrospray Ionisation-Mass Spectrometry (ESI-
MS) was carried out using an electrospray interface and ion trap mass spectrometer 
(1100 Series LC/MSD Trap system Agilent, Palo Alto, CA). Elemental analyses were 
carried out using a Hewlett Packard 185 C, H, and N analyzer.
The dinuclear Pt-BP complex was found to be stable in neutral aqueous solution 
even after standing for several months at room temperature, as evidenced by NMR 
spectroscopy (data not shown).
Preparation of Unfunctionalized Gelatin Nanoparticles
Gelatin nanoparticles (Gel) were prepared using a two-step desolvation method as 
reported previously.12,60,61 Subsequently, GA was used to crosslink gelatin nanoparticles 
with a molar ratio of GA relative to the amine groups in gelatin (GA/NH
2
) of 2. After 
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crosslinking at room temperature for 16 h (although 3–4 h crosslinking was sufficient 
to obtain stable nanoparticles, to obtain the highest yield the reaction was aged for 
16 h), 100 ml of glycine solution (100 mM) was added to the gelatin nanoparticles 
suspension to block the unreacted aldehyde groups. After three cycles of centrifugation 
(5,000 rpm for 60 min, Universal 32 R Hettich Centrifuge, Tuttlingen, Germany) and 
resuspension in Milli-Q water by vortexing, the pH of the suspensions was adjusted 
to 7.0. To investigate the properties of the gelatin nanoparticles in swollen state, small 
fractions of the suspension were stored at 4 °C until further use, whereas the rest of the 
nanoparticles were lyophilized (no cryoprotectant applied; Freezone 4.5, Labconco, 
USA) and stored at 4 °C.
Preparation of ALN-functionalized Gelatin Nanoparticles
ALN-functionalized gelatin nanoparticles (Gel∙ALN) were prepared according to 
an already reported method.12 Briefly, using a two-step desolvation method, gelatin 
nanoparticles were prepared as described previously.12,60,61 Subsequently, GA was 
used to crosslink gelatin nanoparticles with a GA/NH
2
 molar ratio of 2. Residual 
aldehyde groups from the GA crosslinking reaction were used for further conjugation 
with the amine (NH
2
) groups of ALN. ALN was added to the gelatin nanoparticles 
suspension after aging the crosslinking reaction for 16 h (post-functionalization, no pH 
manipulation (pH ~4)). The conjugation reaction was carried out at room temperature 
with molar ratios of ALN relative to GA (ALN/GA) of 0.12, 2.5, and 5. After three 
cycles of centrifugation (5,000 rpm for 60 min) and resuspension in Milli-Q water by 
vortexing, the pH of the suspension was adjusted to 7.0. To investigate the properties 
of the functionalized gelatin nanoparticles in swollen state, small fractions of the 
suspension were stored at 4 °C until further use, whereas the rest of the nanoparticles 
were lyophilized and stored at 4 °C.
Preparation of Pt-BP-functionalized Gelatin Nanoparticles
Gelatin nanoparticles were prepared using a two-step desolvation method as reported 
158
Chapter 5 | Dual-functionalized Gelatin Nanoparticles
previously.12,60,61 Subsequently, GA was used to crosslink gelatin nanoparticles with a 
GA/NH2 molar ratio of 2. Residual aldehyde groups from the GA crosslinking reaction 
were used for further conjugation with the amine (NH
2
) groups of Pt-BP. Pt-BP was 
added to the gelatin nanoparticles suspension after aging the crosslinking reaction 
for 16 h (post-functionalization, no pH manipulation (pH ~4)). The conjugation 
reaction was carried out at room temperature. The efficiency of the conjugation 
reaction was investigated at Pt-BP/GA molar ratios of 0.06, 0.12, 0.24, and 0.48. After 
three cycles of centrifugation (5,000 rpm for 60 min) and resuspension in Milli-Q 
water by vortexing, the pH of the suspensions was adjusted to 7.0. To investigate the 
properties of the functionalized gelatin nanoparticles in swollen state, small fractions 
of the suspension were stored at 4 °C until further use, whereas the rest of the gelatin 
nanoparticles were lyophilized and stored at 4 °C.
Preparation of Dual-functionalized Gelatin Nanoparticles
Gelatin nanoparticles were prepared using a two-step desolvation method as reported 
previously.12,60,61 Subsequently, GA was used to crosslink gelatin nanoparticles with a 
GA/NH
2
 molar ratio of 2. Residual aldehyde groups from the GA crosslinking reaction 
were used for further conjugation with the amine (NH
2
) groups of both ALN and Pt-
BP. To evaluate and optimize the dual conjugation reaction, different functionalization 
schemes and molar ratios between the reactants were selected for the addition of ALN 
and Pt-BP to the suspension of gelatin nanoparticles (see Table 5.1 for an overview of 
the abbreviations, compositions, and functionalization parameters):
• gelatin nanoparticles functionalized with ALN only (Gel∙ALN);
• gelatin nanoparticles functionalized with Pt-BP only (Gel∙Pt);
• gelatin nanoparticles simultaneously functionalized with ALN and Pt-BP 
(Gel∙ALN∙Pt-Sim);
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• gelatin nanoparticles sequentially functionalized with ALN and Pt-BP 
(Gel∙ALN//Pt);
• gelatin nanoparticles sequentially functionalized with Pt-BP and ALN (Gel∙Pt//
ALN).
Table 5.1. Abbreviations, compositions, and functionalization parameters of unfunctionalized and 
(dual-)functionalized gelatin nanoparticles.
1 No ALN- or Pt-BP-functionalization carried out for Gel.
2 No ALN- or Pt-BP-functionalization, but only physical adsorption, carried out for Gel∙Pt-Ads and 
Gel∙Pt//ALN-Ads.
All functionalization schemes were carried out after aging the GA crosslinking 
reaction for 16 h. All conjugation reactions were carried out at room temperature. After 
three cycles of centrifugation (5,000 rpm for 60 min) and resuspension in Milli-Q by 
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vortexing, the pH of the suspension was adjusted to 7.0. To investigate the properties 
of the functionalized gelatin nanoparticles in swollen state, small fractions of the 
suspension were stored at 4 °C until further use, whereas the rest of the nanoparticles 
were lyophilized and stored at 4 °C.
As a control experiment, similar amounts of Pt-BP and ALN (Table 5.1) were 
physically adsorbed onto a suspension of unfunctionalized gelatin nanoparticles (GA/
NH
2
 molar ratio = 2; crosslinked at room temperature for 16 h; blocked with 100 ml 
of 100 mM glycine solution). After addition of Pt-BP and/or ALN to the suspension 
of unfunctionalized gelatin nanoparticles, the mixture was left stirring at room 
temperature for 16 h, after which the gelatin nanoparticles were centrifuged (5,000 
rpm for 60 min) and resuspended in Milli-Q water by vortexing three times. The 
pH of the final suspension was adjusted to 7.0. To investigate the properties of the 
nanoparticles in swollen state, small fractions of the suspension were stored at 4 °C 
until further use, whereas the rest of the nanoparticles were lyophilized and stored at 
4 °C.
Characterization of Gelatin Nanoparticles
Electron Microscopy
The morphology and size of the gelatin nanoparticles were characterized in 
lyophilized state using Scanning Electron Microscopy (SEM, JEOL 6340F; all samples 
were mounted on aluminum stubs using carbon tape and sputter-coated with gold-
palladium). Digital image analysis software (Image J, NIH) was applied to analyze 
the diameter of at least 200 nanoparticles using scanning electron micrographs in 
lyophilized state.
Water Content
To study the influence of Pt-BP functionalization as well as the dual functionalization 
on the crosslinking efficiency of the gelatin nanoparticles, their water content was 
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measured according to a method described previously.12 Briefly, ~10 mg of gelatin 
nanoparticles were soaked overnight at room temperature in 2 ml of Milli-Q water 
while agitated on a shaking table at 90 rpm. The swollen nanoparticles were collected 
after 24 h on filter paper to remove surface water and placed in a vial of known 
weight (W
vial
). The weight of the vial including the swollen nanoparticles was then 
recorded (W
swollen+vial
). After lyophilizing for 24 h, the weight of the vial including 
the dry nanoparticles was recorded (W
dry+vial
). Accordingly, the water content (%) of 
gelatin nanoparticles was calculated as follows
This parameter provides an indication of the water uptake (wt%) of the gelatin 
nanoparticles. Five samples were measured for each experimental group.
Dynamic Light Scattering and Laser Doppler Velocimetry
Dynamic Light Scattering (DLS) and Laser Doppler Velocimetry (LDV) were 
performed on a Zetasizer® Nano-S (Malvern Instruments Ltd.) to characterize 
the hydrodynamic size (dispersed in Milli-Q water, solid content 0.01 w/v%) and 
ζ-potential (dispersed in 5 mM HEPES buffer at pH 7.0) of the gelatin nanoparticles, 
respectively.
Elemental Analysis
Inductively Coupled Plasma-Optical Emission Spectrometry (ICP-OES, iCap 
6300) was used to quantify the degree of functionalization with Pt-BP, dual 
functionalization (Pt-BP and ALN), as well as the retention of Pt-BP and ALN to the 
gelatin nanoparticles. To quantify the degree of functionalization, the nanoparticles 
were digested in concentrated nitric acid (at 37 °C overnight on a shaking table) and 
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subsequently diluted to 1% nitric acid solutions for ICP-OES analysis of the platinum 
and phosphorus content.
Retention of Alendronate and Pt-BP to Gelatin Nanoparticles
The retention of Pt-BP and/or ALN to gelatin nanoparticles was evaluated in Milli-Q 
water as a function of soaking time (1, 3, 7, and 14 days). Phosphate buffered saline 
(PBS), cell culture medium, or similar phosphorus-containing media could not be 
used for this experiment, since the high phosphate concentration in the media did not 
allow for detection and differentiation of phosphorus released from dual- or Pt-BP-
functionalized gelatin nanoparticles using ICP-OES.
Briefly, 10 mg of lyophilized functionalized gelatin nanoparticles (GA/NH
2
 molar 
ratio = 2; pH
functionalization
 = 4) was added to 10 ml of Milli-Q water at 37 °C on a shaking 
table (70 rpm). At each time point, the suspensions were centrifuged at 5,000 rpm for 
60 min. The gelatin pellet was separated from the supernatant and re-suspended in 10 
ml of fresh Milli-Q water for further time points. After the last time point, to quantify 
the retained Pt-BP and/or ALN, the gelatin pellet was digested in concentrated nitric 
acid (at 37 °C overnight on a shaking table) and subsequently diluted to 1% nitric 
acid solutions for ICP-OES analysis of the platinum and phosphorus content. The 
supernatants were also mixed with nitric acid to prepare a 1% nitric acid solution 
(and kept at 37 °C overnight on a shaking table) for further elemental analysis of the 
platinum and phosphorus content using ICP-OES. The retention of Pt-BP and/or ALN 
to gelatin nanoparticles with adsorbed Pt-BP (and/or ALN) was evaluated similarly as 
a control experiment.
Affinity of Gelatin Nanoparticles to Calcium Phosphate
Commercially available titanium disks of 12 mm diameter and 1.5 mm thickness 
were grit-blasted with aluminum oxide particles, cleaned ultrasonically in isopropanol 
(~15 min), and air-dried overnight. The surface roughness of the Ti disks (Ra = 2.0 ± 
0.2 µm) was measured using a universal surface tester (Innowep GmbH, Würzburg, 
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Germany). Titanium disks were subsequently coated with a thin hydroxyapatite film 
(1.5 ± 0.1 µm) using a commercially available radiofrequency magnetron sputter 
deposition system (Edwards High Vacuum ESM 100 system, Crawford, England) as 
described previously.62,63 The target materials were hydroxyapatite (Ca
10
(PO
4
)
6
(OH)
2
) 
granules (diameter: 0.5–1.0 mm; CAM Bioceramics BV, Leiden, the Netherlands). The 
disks were mounted on a rotating water-cooled substrate holder. The distance between 
target and implant holder was 80 mm. Before sputtering, the disks were cleaned by 
etching for ~10 min with argon ions. During deposition (7.5 h), the argon pressure 
was kept at 5 × 10-3 mbar and the sputter power of 2 times 400 W with a coating 
thickness of ~1 µm was used. After deposition, the coated implants were subjected to 
an additional infrared heat treatment for 30 s at 650 °C (Quad Ellipse Chamber, Model 
E4-10-P, Research Inc.) as previously described.64 The titanium disks were eventually 
cleaned ultrasonically in isopropanol for ~15 min to remove any unbound particles, 
air-dried, and stored at room temperature. The coatings were characterized by thin 
film XRD (PW 1830, Panalytical) and ATR-FTIR (Spectrum One™, Perkin Elmer).
The affinity of gelatin nanoparticles to CaP was evaluated by immersing the 
hydroxyapatite-coated titanium disks for 16 h in 2 ml of gelatin nanoparticle 
suspension (dispersed at 2.5 mg∙ml-1 in 5 mM HEPES buffer) at 37 °C on a shaking 
plate. The titanium disks were horizontally placed at the bottom of 24-well cell 
culture plates without any constraint for horizontal movement within the well. The 
autofluorescence of gelatin was exploited to quantify the amount of surface-bound 
gelatin nanoparticles by fluorescence microscopy using an automated axio Imager 
Z1 microscope (Carl Zeiss Micro Imaging GmbH, Göttingen, Germany) and digital 
image analysis (Image J, NIH) after thoroughly rinsing the disks with Milli-Q water 
to remove the unbound gelatin nanoparticles. The affinity of gelatin nanoparticles to 
the hydroxyapatite surfaces was quantified by dividing the areas covered by gelatin 
nanoparticles to the entire hydroxyapatite-covered surface area of the titanium disks 
using the autofluorescence detected from gelatin nanoparticles.
164
Chapter 5 | Dual-functionalized Gelatin Nanoparticles
Statistical Analysis
All results are depicted as mean ± standard deviation. The statistical analyses were 
performed using GraphPad Prism (version 5.03) software. Differences among groups 
were determined by one-way analysis of variance (ANOVA) with a Bonferroni 
(multiple comparisons) post hoc test, and a value of p < 0.05 was considered as 
significantly different.
Results and Discussion
Preparation and Characterization of Pt-BP
The dinuclear Pt(II) complex bis-{ethylenediamineplatinum(II)}-2-amino-1-
hydroxyethane-1,1-diyl-bisphosphonate (Pt-BP, Figure 5.1) was prepared according to 
a method described previously.16 Briefly, the barium salt of the aminobisphosphonate 
was first prepared and subsequently treated with two equivalents of [Pt(OSO
3
)(OH
2
)
(en)] (en = ethylenediamine). The reaction mixture was left under magnetic stirring 
overnight at higher temperature (40 °C) as compared to the previously reported 
procedure.9 The elemental analysis and the spectroscopic features were consistent 
with the data reported in the literature (data not shown).9,10,65
Figure 5.1. Chemical structure of platinum-bisphosphonate.
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Preparation and Characterization of Gelatin Nanoparticles
Effect of Functionalization Scheme
Gelatin nanoparticles (either functionalized or unfunctionalized) were prepared using 
an established two-step desolvation method60,61 resulting in the formation of spherical 
nanoparticles. Average diameters of the nanoparticles in lyophilized and swollen state 
are provided in Table 5.2. SEM micrographs revealed that the morphology and size 
of Pt-BP-functionalized or dual-functionalized gelatin nanoparticles in lyophilized 
state did not change upon functionalization, as compared to the unfunctionalized 
ones (Gel) (Figure 5.2). DLS measurements confirmed that the size of functionalized 
gelatin nanoparticles in swollen state did not change upon functionalization (Table 
5.2). Similar results were obtained for gelatin nanoparticles that were lyophilized and 
rehydrated/resuspended in Milli-Q water, 5 mM HEPES buffer, or phosphate buffered 
saline (PBS). It is well reported that intracellular uptake of nanoparticles in tumor 
tissue is strongly a function of their size.52,66 Macromolecules or nanoparticles with 
cutoff size of >400 nm have been shown to preferably accumulate in tumor tissue 
rather than healthy tissues, possibly as a result of increased permeability of tumor 
vasculature and enhanced permeation and retention effect (EPR).52,67–69 Therefore, 
the size of gelatin nanoparticles prepared herein (~400 nm in swollen state) is in the 
suitable range for accumulating in tumor tissue by EPR effect.
Water content and, hence, the degree of crosslinking, of either Pt-BP-functionalized 
or dual-functionalized gelatin nanoparticles did not change as compared to 
unfunctionalized gelatin nanoparticles (Table 5.2), as ALN and/or Pt-BP were added 
after completion of the crosslinking reaction and functioned mainly as blocking agents 
for the unreacted aldehyde groups. These results were in agreement with our previous 
findings for ALN-functionalized gelatin nanoparticles.12
ζ-potential values shown in Table 5.2 are related to gelatin nanoparticles (dual-)
functionalized at a Pt-BP/GA molar ratio of 0.06 and/or an ALN/GA molar ratio of 
5. These data revealed that functionalization of gelatin nanoparticles with negatively 
charged ALN rendered the nanoparticles more negatively charged, irrespective of 
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the functionalization scheme or the Pt-BP/GA molar ratio (data not shown). The 
Pt-BP complex is positively charged, and becomes neutral after conjugation with 
GA and formation of an imine bond between the pending NH
2
 and the aldehydes. 
However, functionalization of gelatin nanoparticles with Pt-BP complex rendered the 
nanoparticles more negatively charged, which was similar to the ζ-potential of ALN-
functionalized gelatin nanoparticles. This phenomenon may not be explained by the 
experiments performed in this study. Nevertheless, we speculate that the change in 
ζ-potential may only be a result of avoiding glycine blocking the unreacted aldehyde 
groups on the surface of gelatin nanoparticles. Another possible explanation is the 
hydrolysis of the Pt−O−P bonds in the conjugated Pt-BP complex, that could occur at 
neutral pH with entering of one or more water molecules in the coordination sphere 
of platinum and formation of P−O− groups. Water molecules coordinated to positively 
charged platinum ions are acidic and tend to deprotonate with formation of neutral 
platinum–hydroxido species.70,71 The overall result would be the presence of P−
O− groups on the surface of nanoparticles, which could contribute to lowering the 
ζ-potential of the Pt-BP-functionalized gelatin nanoparticles.
Table 5.2. Particle size, ζ-potential, and water content of unfunctionalized and (dual-)functionalized 
gelatin nanoparticles*.
* The presented results are related to gelatin nanoparticles with Pt-BP/GA molar ratio of 0.06 and/or 
ALN/GA molar ratio of 5.
** Particle sizes of lyophilized gelatin nanoparticles were measured by analyzing at least 200 particles 
using electron microscopy, whilst the diameters of swollen nanoparticles were determined by DLS. a 
denotes statistical differences versus the other experimental groups within the same row (p < 0.05).
As shown in Figure 5.3, ICP-OES measurements confirmed the presence of platinum 
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in Pt-BP-functionalized gelatin nanoparticles. At the lowest Pt-BP/GA molar ratio of 
0.06, it was possible to link approximately 5.3 moles of Pt-BP to one mole of gelatin 
(Gel∙Pt[0.06]), whereas for Pt-BP-adsorbed gelatin nanoparticles with the same Pt-
BP/GA molar ratio (Gel∙Pt-Ads[0.06]) only 0.6 moles of Pt-BP per mole of gelatin 
was detected. By increasing the Pt-BP/GA molar ratio up to 0.48, the amount of Pt-BP 
linking increased up to approximately 28 moles of Pt-BP per mole of gelatin. The total 
amount of Pt-BP present on gelatin nanoparticles with adsorbed Pt-BP, however, was 
significantly lower as compared to those functionalized with Pt-BP at all Pt-BP/GA 
molar ratios shown in Figure 5.3.
Figure 5.2. Scanning electron micrographs of gelatin nanoparticles. (A) unfunctionalized (Gel); (B) 
ALN-functionalized (Gel∙ALN); (C) Pt-BP-functionalized (Gel∙Pt); (D) simultaneously functionalized 
with ALN and Pt-BP (Gel∙ALN∙Pt-Sim); (E) sequentially functionalized with Pt-BP/then/ALN (Gel∙Pt//
ALN); (F) sequentially functionalized with ALN/then/Pt-BP (Gel∙ALN//Pt) (scale bar = 500 nm).
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Figure 5.3. Amount of platinum in gelatin nanoparticles measured by ICP-OES (the left Y-axis represents 
relative weight percentage of Pt-BP present in gelatin nanoparticles (wt%), whereas the right Y-axis 
represents the molar ratio of Pt-BP relative to gelatin) (p < 0.05).
Figure 5.4 shows the weight percentages of platinum and phosphorus for all 
functionalization schemes in Pt-BP- and dual-functionalized gelatin nanoparticles (at 
a fixed Pt-BP/GA molar ratio of 0.06). The ALN content in samples was calculated by 
subtracting the amount of phosphorus derived from Pt-BP from the total amount of 
detected phosphorus. Corresponding molar ratios of detected Pt-BP or ALN relative 
to gelatin can be found in Supplementary Figure S5.1. As shown in Figure 5.4 and 
Supplementary Figure S5.1, the efficiency of Pt-BP conjugation reaction decreased 
regardless of the applied ALN/GA molar ratio by simultaneous addition of ALN and 
Pt-BP to gelatin nanoparticles after completion of the GA crosslinking reaction. This 
was attributed to the competition between Pt-BP and ALN to react with available free 
aldehyde groups on gelatin nanoparticles. Moreover, Pt-BP molecules were less likely 
to link to the available free aldehyde groups on gelatin nanoparticles since ALN/GA 
molar ratios were higher than Pt-BP/GA ratios.
The amount of Pt-BP linked to gelatin nanoparticles decreased considerably for all 
ALN/GA molar ratios (Figure 5.4) when the nanoparticles were first functionalized 
with ALN. Obviously, the majority of available free aldehyde groups on gelatin 
nanoparticles were already consumed by the reaction with ALN. The amount of either 
Pt-BP or ALN linked to gelatin nanoparticles did not decrease when the nanoparticles 
were first functionalized with Pt-BP prior to the reaction with ALN. Therefore, the 
latter dual-functionalization scheme and the highest ALN/GA molar ratio were 
selected for further experiments.
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By increasing the Pt-BP/GA molar ratio up to 0.48, the efficiency of the Pt-BP 
conjugation reaction for dual-functionalized gelatin nanoparticles increased (Figure 
5.5; molar ratios of detected Pt-BP or ALN in different samples can be found in 
Supplementary Figure S5.2), which was similar to our results for Pt-BP-functionalized 
gelatin nanoparticles shown in Figure 5.3. However, no significant change was 
observed with respect to the efficiency of the ALN conjugation reaction (Figure 5.5 
and Supplementary Figure S5.2), which indicated that the ALN-functionalization 
reaction was independent from the preceding reaction with Pt-BP.
Figure 5.4. Effect of functionalization scheme and ALN/GA molar ratio on the efficiency of dual-
functionalization of gelatin nanoparticles measured by ICP-OES (Y axis represents wt% of Pt-BP and 
ALN present in gelatin nanoparticles; Letters "a" and "b" denote statistically significant differences 
versus Gel∙Pt and Gel∙ALN[0.06], respectively) (p < 0.05).
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Figure 5.5. Effect of Pt-BP/GA molar ratio on the efficiency of dual-functionalization of gelatin 
nanoparticles measured by ICP-OES (Y axis represents wt% of Pt-BP and ALN present in gelatin 
nanoparticles) (p < 0.05).
Retention of Pt-BP and Alendronate to Gelatin Nanoparticles
To evaluate the extent and stability of the covalent linking between Pt-BP and 
gelatin, the retention of Pt-BP to gelatin nanoparticles was studied as a function of 
soaking time in Milli-Q water. Retention tests showed that at the lowest Pt-BP/GA 
molar ratio of 0.06 up to 97 wt% of the Pt-BP initially present on Pt-BP-functionalized 
gelatin nanoparticles (Gel∙Pt[0.06]) was retained to the nanoparticles after 14 days of 
soaking (Figure 5.6A), and released Pt-BP was not detected in the supernatant. On 
the contrary, less retention of Pt-BP was observed for gelatin nanoparticles containing 
adsorbed Pt-BP (Gel∙Pt-Ads[0.06]) as compared to the functionalized ones, since 
85 wt% of the initially bound Pt-BP was retained to Gel∙Pt-Ads[0.06] after only 14 
days of soaking. Considering the cumulative release of Pt-BP from the same samples 
(Figure 5.6B), however, no significant differences were observed between the Pt-BP-
functionalized and Pt-BP-adsorbed gelatin nanoparticles at the lowest Pt-BP/GA ratio 
of 0.06 (Gel∙Pt[0.06] versus Gel∙Pt-Ads[0.06]; Figure 5.6C and D show statistical 
analysis of Figure 5.6A and B, respectively, for day 14 only). On the contrary, for 
higher Pt-BP/GA molar ratios of 0.12, 0.24, and 0.48, considerable differences could 
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be observed with respect to the cumulative Pt-BP release from Pt-BP-functionalized 
gelatin nanoparticles as compared to the corresponding gelatin nanoparticles with 
adsorbed Pt-BP (Figure 5.6B and D). As shown in Figure 5.6B and D, the cumulative 
Pt-BP release increased with increasing Pt-BP/GA molar ratio, whereas no difference 
was observed for gelatin nanoparticles with Pt-BP absorbed at different Pt-BP/GA 
molar ratios. This could also be attributed to the fact that the total amount of Pt-BP 
present on gelatin nanoparticles with adsorbed Pt-BP was significantly lower at all 
Pt-BP/GA molar ratios as compared to those chemically functionalized with Pt-BP 
(Figure 5.3).
When the Pt-BP/GA molar ratio was increased to 0.12, 0.24, and 0.48, gelatin 
nanoparticles functionalized with Pt-BP did not show more Pt-BP retention as 
compared to the corresponding gelatin nanoparticles containing adsorbed Pt-BP 
(Figure 5.6A and C). Interestingly, even at the highest Pt-BP/GA ratio of 0.48, 
more than 80 wt% of the Pt-BP initially present on the gelatin nanoparticles was 
retained to the nanoparticles after 14 days of soaking. Pt-BP generally showed strong 
retention (higher than 75 wt%) to both types of gelatin nanoparticles containing Pt-
BP (adsorbed or functionalized) after 14 days (Figure 5.6A and B). Nevertheless, the 
extent at which Pt-BP can be loaded onto (Figure 5.3), and subsequently, released 
from gelatin nanoparticles is very limited when Pt-BP is adsorbed (Figure 5.6B). For 
gelatin nanoparticles, on the other hand, it is possible to easily adjust the desired 
amount of released Pt-BP by varying the Pt-BP/GA molar ratio.
The size of the gelatin nanoparticles, which is favorable for a long blood circulation 
and a good propensity for extravasation through the vascular fenestration of the tumor, 
together with the sustained release of platinum allows us to envisage a prolonged 
cytotoxic effect selectively at the tumor site and reduction of the systemic toxicity 
typical of platinum-based drugs.
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Figure 5.6. (A) Weight percentage of Pt-BP retained to Pt-BP-functionalized versus Pt-BP-adsorbed 
gelatin nanoparticles as a function of soaking time and Pt-BP/GA molar ratio; (B) cumulative release of 
total amount of Pt-BP (µg) released from 10 mg of gelatin nanoparticles as a function of soaking time 
and Pt-BP/GA molar ratio; (C) and (D) statistical analysis of Figure 5.6A and B, respectively, for day 14 
only (*: p < 0.05; NS: not statistically different).
Figure 5.7A compares the retention of Pt-BP to dual-functionalized gelatin 
nanoparticles versus gelatin nanoparticles functionalized with Pt-BP only. The 
results revealed that dual-functionalization did not have a considerable influence 
on the retention efficiency of Pt-BP to gelatin nanoparticles as compared to those 
functionalized with Pt-BP only. Furthermore, Pt-BP generally showed strong 
retention (higher than 80 wt%) to dual-functionalized gelatin nanoparticles. Similarly, 
considering the cumulative release of total amount of Pt-BP from gelatin nanoparticles 
(Figure 5.7B), no significant differences were observed between Pt-BP-functionalized 
and dual-functionalized gelatin nanoparticles when compared at the same Pt-BP/
GA molar ratio (Figure 5.7C and D show statistical analysis of Figure 5.7A and B, 
respectively, for day 14 only). The total cumulative amount of Pt-BP released from 
dual-functionalized gelatin nanoparticles increased by increasing the Pt-BP/GA 
molar ratio, which was similar to gelatin nanoparticles functionalized with Pt-BP only 
(Figure 5.7B).
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Figure 5.7. (A) Weight percentage of Pt-BP retained to dual-functionalized versus Pt-BP-functionalized 
gelatin nanoparticles as a function of soaking time and Pt-BP/GA molar ratio; (B) cumulative release of 
total amount of Pt-BP (µg) released from 10 mg of gelatin nanoparticles as a function of soaking time 
and Pt-BP/GA molar ratio; (C) and (D) statistical analysis of Figure 5.7A and B, respectively, for day 14 
only (*: p < 0.05; NS: not statistically different).
Similar to the results obtained for Pt-BP-adsorbed and Pt-BP-functionalized gelatin 
nanoparticles (Figure 5.6B), dual-functionalized gelatin nanoparticles displayed 
increased cumulative Pt-BP release (Supplementary Figure S5.3B and D) for all 
Pt-BP/GA molar ratios, when compared to those with adsorbed Pt-BP and ALN. 
For dual-functionalized gelatin nanoparticles, however, it was possible to detect 
differences in Pt-BP retention, when compared to those with adsorbed Pt-BP and 
ALN (Supplementary Figure S5.3A and C). Nevertheless, it should be emphasized 
that even gelatin nanoparticles adsorbed with Pt-BP and ALN showed high Pt-BP 
retention properties after more than 14 days (approximately higher than 65% for the 
group with the highest Pt-BP/GA molar ratio of 0.48 (Gel∙Pt∙ALN-Ads[0.48])).
Results shown in Figure 5.6B and Supplementary Figure S5.3B indicated that 
the amounts of Pt-BP release were higher from chemically functionalized gelatin 
nanoparticles as compared to those containing adsorbed Pt-BP (and ALN). This 
phenomenon was caused by the higher amounts of initial Pt-BP loading on these 
nanoparticles (Figure 5.3). The Pt-BP conjugation reaction seemed not to considerably 
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influence the retention properties of Pt-BP-functionalized gelatin nanoparticles 
at the studied Pt-BP/GA molar ratios in comparison to those with adsorbed Pt-BP 
(Figure 5.6A). However, it significantly improved the retention of Pt-BP to dual-
functionalized gelatin nanoparticles, when compared to those adsorbed with Pt-BP 
and ALN. The increased amount of Pt-BP linked to chemically functionalized gelatin 
nanoparticles (Figure 5.3) and the improved Pt-BP retention of dual-functionalized 
gelatin nanoparticles (Supplementary Figure S5.3) was attributed to the formation 
of covalent imine linkages between aldehyde groups at the nanoparticle surface and 
the pending amine group of the Pt-BP complex. The hydrolytic stability of this bond 
was more than two weeks, which would be sufficient for the intended applications. 
Moreover, in the tumor microenvironment, where protease such as matrix 
metalloproteinases (collagenase and gelatinase) are highly expressed, the proteolytic 
degradation of the gelatin nanoparticles could occur at a faster rate than in the blood 
with the simultaneous increased release of the Pt-BP complex.72,73
The fast release of ~15–20 wt% of Pt-BP from (dual-)functionalized gelatin 
nanoparticles at 012, 0.24, and 0.48 Pt-BP/GA molar ratios (Figure 5.6, Figure 5.7, 
and Supplementary Figure S5.3) was attributed to physically entrapped Pt-BP rather 
than cleavage of imine bonds. This phenomenon was in line with the broadly reported 
burst release of various biomolecules adsorbed onto or encapsulated inside gelatin 
nanoparticles without formation of covalent bonds between the biomolecules and the 
polymeric macromers.12,45,74–76
By comparing the ALN retention of dual-functionalized gelatin nanoparticles with 
ALN-functionalized gelatin nanoparticles12 (Supplementary Figure S5.4), we observed 
that dual-functionalization decreased the retention of ALN to gelatin nanoparticles 
from approximately 70 wt% down to approximately 50 wt%. Increasing the Pt-BP/GA 
molar ratio, however, did not affect the retention of ALN of the dual-functionalized 
gelatin nanoparticles. These findings suggest that the affinity of mineral-binding ALN-
functionalized gelatin nanoparticles to calcium phosphate (CaP) could be maintained 
even after dual-functionalization with high amounts of Pt-BP.
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Affinity of Gelatin Nanoparticles to Calcium Phosphate
To investigate the effect of Pt-BP-functionalization as well as dual-functionalization 
on the affinity of unfunctionalized and ALN-functionalized gelatin nanoparticles 
to CaP surfaces, hydroxyapatite-coated titanium disks (corresponding XRD and 
ATR-FTIR spectra shown in Supplementary Figure S5.5A and B, respectively) 
were immersed in gelatin nanoparticle suspensions. Titanium disks, hydroxyapatite 
coating, ALN, and Pt-BP did not demonstrate any autofluorescence. Consequently, 
the detected fluorescence could be attributed to the autofluorescence of gelatin 
nanoparticles. Digital image analysis of fluorescence micrographs of hydroxyapatite-
coated titanium disks revealed that Pt-BP-functionalization (Figure 5.8A–C) did not 
increase the affinity of gelatin nanoparticles to hydroxyapatite surfaces (Figure 5.8F). 
This finding is not surprising, since all the oxygen atoms of the bisphosphonate are 
bound to platinum. ALN- (Gel∙ALN) or dual-functionalization (Gel∙Pt//ALN[0.48]) 
of gelatin nanoparticles (Figure 5.8D and E, respectively), however, resulted into 
approximately sixfold higher fluorescence intensity on the hydroxyapatite surfaces 
compared to unfunctionalized or Pt-BP-functionalized gelatin nanoparticles. Gelatin 
nanoparticles dual-functionalized with lower Pt-BP/GA molar ratios (0.06, 0.12, and 
0.24) also showed similar fluorescence intensities on the hydroxyapatite surfaces 
as shown in Figure 5.8E for Pt-BP/GA molar ratio of 0.48 (data not shown). These 
results demonstrate that mineral-binding gelatin nanoparticles can be functionalized 
with Pt-BP molecules without losing their mineral-binding capacity.
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Figure 5.8. Fluorescence images of hydroxyapatite-coated titanium disks immersed in suspensions of 
(A) Gel, (B) Gel∙Pt[0.06], (C) Gel∙Pt[0.48], (D) Gel∙ALN, and (E) Gel∙Pt//ALN[0.48] (scale bar = 1 
mm). (F) Quantification of the fluorescence intensity derived from the autofluorescence of surface-bound 
gelatin nanoparticles (p < 0.05).
Conclusions
This study presents a conjugation strategy for the preparation of gelatin nanoparticles 
functionalized with a chemotherapeutic platinum-bisphosphonate (Pt-BP) complex or 
dual-functionalized with Pt-BP and mineral-binding alendronate (ALN). The degree of 
functionalization could be tuned by varying the molar ratio of Pt-BP and ALN relative 
to glutaraldehyde used as crosslinker. Sustained and tunable release of platinum was 
observed from both Pt-BP- and dual-functionalized gelatin nanoparticles. Moreover, 
dual- and ALN-functionalized gelatin nanoparticles displayed a high affinity to calcium 
phosphate as a result of functionalization with ALN. After specific accumulation of 
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the gelatin nanoparticles at tumor site, assisted by the mineral-binding moiety and also 
possibly by EPR effect, the release of the pharmacologically active Pt-BP could be 
favored by the proteolytical degradation of the organic matrix by metalloproteinases, 
which are generally highly expressed in the tumor interstitial space. Summarizing, 
it can be concluded that mineral-binding gelatin nanoparticles can be functionalized 
with chemotherapeutic drugs, which may benefit the development of bone-seeking 
and potentially chemotherapeutically active carriers for treatment of bone tumors.
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Supplementary Data
Figure S5.1. Effect of functionalization scheme and ALN/GA molar ratio on the efficiency of dual-
functionalization of gelatin nanoparticles measured by ICP-OES (Y axis represents the molar ratio of 
Pt-BP and/or ALN relative to gelatin; Letters "a" and "b" denote statistical differences versus Gel∙Pt and 
Gel∙ALN[0.06], respectively) (p < 0.05).
Figure S5.2. Effect of Pt-BP/GA molar ratio on the efficiency of dual-functionalization of gelatin 
nanoparticles measured by ICP-OES (Y axis represents the molar ratio of Pt-BP and/or ALN relative to 
gelatin) (p < 0.05).
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Figure S5.3. A) Weight percentage of Pt-BP retained to dual-functionalized versus Pt-BP+ALN-adsorbed 
gelatin nanoparticles as a function of soaking time and Pt-BP/GA molar ratio; B) cumulative release of 
total amount of Pt-BP (µg) released from 10 mg of gelatin nanoparticles as a function of soaking time 
and Pt-BP/GA molar ratio; C, D) statistical analysis of Supplementary Figure S5.3A and B, respectively, 
for day 14 only (*: p < 0.05; NS: not statistically different).
Figure S5.4. (A) Weight percentage of ALN retained to dual-functionalized gelatin nanoparticles as a 
function of soaking time and Pt-BP/GA molar ratio; (B) statistical analysis for day 14 only (*: p < 0.05; 
NS: not statistically different).
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Figure S5.5. (A) XRD pattern (* shows the main reflection peaks of hydroxyapatite; ● indicates 
titanium), and (B) ATR-FTIR spectra (# shows characteristic phosphate absorptions) of hydroxyapatite 
sputter coating on titanium disks.
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Introduction
Tumor metastasis is the spreading of tumor cells from the primary site to other organs, thereby dramatically decreasing the likelihood of survival of the patient.1,2 
Bones are common sites for metastasis due to their physiological environment, which 
facilitates the formation and growth of tumors.1 In fact, bone is not only the most 
common tissue affected by metastatic cancer, but also the site that produces the greatest 
morbidity.3–5 Treatment of bone tumors is highly dependent on the type of tumor and 
may include (a combination of) surgery, chemotherapy, and/or radiotherapy.6–10
The pharmacological efficacy of conventional drug formulations can be improved 
through the use of drug delivery systems.11 By delivering pharmacologically high 
concentrations of active agents more selectively to pathological sites, drug delivery 
systems aim to improve the balance between efficacy and toxicity, thereby overcoming 
the shortcomings of systemic delivery of conventional drug formulations.12,13 Drug 
delivery systems are designed to amend the pharmacokinetics and biodistribution of 
incorporated drugs or biomolecules, or to function as reservoirs (i.e., as sustained 
release systems), or both.11 Targeted drug delivery entails a selective and effective 
localization of pharmacologically active compounds at pre-defined targeted site(s), 
thus minimizing undesired side effects and maximizing therapeutic efficacy.14 
Targeted delivery can be achieved by either passive or active targeting.15 Passive 
targeting involves the use of drug delivery carriers or reservoirs (such as nanocarriers), 
which can be applied for local or non-local (systemic) delivery.15 Active targeting, 
on the contrary, relies on the use of targeting moieties such as antibodies, peptides, 
proteins, or other small bioactive molecules with specific binding affinity for antigens 
or receptors preferentially expressed in the diseased tissues.16,17 Many approaches 
have been demonstrated for site-specific drug delivery, but strategies to obtain bone-
specific delivery are still scarce.18,19
Platinum complexes are a specific class of chemotherapeutic drugs, which exhibit 
antitumor properties by interacting with DNA and suppressing its replication.20 Cisplatin 
was the first clinically approved chemotherapeutic platinum-based complex; however, 
its severe side effects have required the development of alternative platinum-based 
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complexes, such as carboplatin and oxaliplatin.21 These second and third generation 
platinum-based complexes, however, are also associated with toxicity, drug resistance 
developed by specific tumors, and lack of tumor selectivity. To overcome these side 
effects, the design of a new generation of molecules to target traditional anticancer 
platinum-based drugs to bone tissue is warranted.22 To this end, platinum-bisphosphonate 
complexes (i.e., bis-{ethylenediamineplatinum(II)}-2-amino-1-hydroxyethane-1,1-
diyl-bisphosphonate (Pt-BP) and bis-{ethylenediamineplatinum(II)}-medronate)) 
were recently developed.23–25 Bisphosphonate-functionalized platinum-based 
molecules not only target bone as a result of the bone-seeking properties of 
bisphosphonate moieties,14,26,27 but also specifically target bone tumors28 due to their 
higher metabolic activity as compared to healthy tissues.29
Tumor-targeted delivery of platinum has great potential to overcome the above-
mentioned drawbacks of the current generation of clinically applied platinum-based 
drugs. Improved tumor selectivity and activity towards cancer cells has been reported 
for active tumor targeting of platinum-based complexes, but their mechanism of 
action is not yet well understood.30 A recent in vitro study on the above-mentioned 
two Pt-BP complexes revealed that these complexes can be loaded onto and released 
from injectable calcium phosphate cements in a sustained manner by exploiting their 
mineral-binding affinity.29 The bone-seeking properties of these Pt-BP complexes, 
however, have not yet been confirmed in vivo. Herein, we studied the in vivo bone-
seeking capacity of the Pt-BP complex with strongest mineral-binding affinity (i.e., bis-
{ethylenediamineplatinum(II)}-2-amino-1-hydroxyethane-1,1-diyl-bisphosphonate; 
Figure 6.1) 24 h after intravenous injection in the tail of C57Bl/6 mice. The 
bisphosphonate-free [Pt(NO
3
)
2
(en)] (en = ethylenediamine) was selected as control 
for this in vivo study, since this complex was used as precursor for the synthesis of the 
Pt-BP complex as tested in the current study (Figure 6.1). The [Pt(NO
3
)
2
(en)] control 
compound was hypothesized to lack bone-seeking properties due to the absence of 
mineral-binding bisphosphonate moieties in its chemical structure. To monitor the 
biodistribution of the injected platinum complexes, the concentration of platinum in 
various organs was measured using Inductively Coupled Plasma-Mass Spectrometry 
(ICP-MS) after retrieval and subsequent digestion of tibia, femur, humerus, spine, 
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blood, heart, lungs, kidney, liver, and spleen.31
Figure 6.1. Chemical structures of platinum complexes.
Material and Methods
Materials
Na
2
SO
4
 and Ba(OH)
2
 were purchased from Sigma-Aldrich. 2-amino-1-
hydroxyethane-1,1-diyl-bisphosphonic acid (AHBP-H
4
) was prepared following the 
procedures reported previously.24 Milli-Q water was used to dissolve the compounds. 
All other reagents were purchased from Sigma-Aldrich and used without further 
purification.
Preparation and Characterization of [Pt(NO3)2(en)]
[Pt(NO
3
)
2
(en)] (en = ethylenediamine) was synthesized according to a previously 
reported procedure.32 Briefly, K
2
PtCl
4
 (100 mg, 0.241 mmol) was dissolved in Milli-Q 
water (2.5 ml) and stirred at room temperature. Upon complete dissolution, the 
solution was filtered using a sintered glass filter to remove undissolved platinum. 
Subsequently, potassium iodide (KI; 239.9 mg, 1.445 mmol) was added to the filtrate 
at room temperature, agitating for approximately 5 min. 16.08 µl (0.441 mmol) of 
ethylenediamine diluted in 400 µl of Milli-Q water was then added slowly and drop-
wise under constant magnetic stirring and left at room temperature for approximately 
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2 h. The obtained yellow precipitate was filtered with a sintered glass filter. The solid 
phase was washed with cold Milli-Q water, absolute ethanol, and finally with diethyl 
ether, followed by drying under vacuum. The obtained [PtI
2
(en)] (58.6 mg, 0.115 
mmol) was suspended in 16.4 ml of Milli-Q water at 55 °C in the dark and treated 
with AgNO
3
 (39.12 mg, 0.23 mmol) previously dissolved in 131 µl Milli-Q water 
protected from light. The mixture was stirred for approximately 4 h in the dark. The 
flask was then cooled down to room temperature prior to filtration through a plug 
of Celite® to remove AgI. The filtrate was dried using a rotary evaporator (at 40 °C) 
followed by vacuum drying. Electrospray Ionisation-Mass Spectrometry (ESI-MS) 
was carried out to measure the molecular weight of the obtained [Pt(NO
3
)
2
(en)] using 
an electrospray interface and ion trap mass spectrometer (1100 Series LC/MSD Trap 
system Agilent, Palo Alto, CA): Anal. Calc. for [Pt(NO
3
)
2
(en)]: (C
2
H
8
N
2
O
6
Pt, Mw = 
378.9 g∙mol-1). Spectroscopic characterization of the complex with Attenuated Total 
Reflectance-Fourier Transform Infrared spectroscopy (ATR-FTIR; Spectrum Two™, 
Perkin Elmer) was consistent with literature data (Supplementary Figure S6.1).
Preparation and Characterization of Pt-BP Complex
A solution containing 2-amino-1-hydroxyethane-1,1-diyl-bisphosphonic acid 
(AHBP-H
4
) (3.33 mg, 0.015 mmol; in 2.2 ml Milli-Q water) was maintained at 40 °C 
and then treated with Ba(OH)
2
∙8H
2
O (4.97 mg, 0.01575 mmol). The mixture was left 
under stirring at 40 °C and then treated with a solution of [Pt(NO
3
)
2
(en)] (12.5 mg, 0.033 
mmol) and Na
2
SO
4
 (2.24 mg, 0.01575 mmol) in 1.7 ml Milli-Q water. The obtained 
suspension was subsequently added drop-wise to the main vial containing AHBP-H
4
 
and Ba(OH)
2
∙8H
2
O agitating at 40 °C. A white suspension was formed which was left 
overnight under constant stirring at 40 °C. Subsequently, the suspension was cooled 
down for approximately 1 h in an ice bath to facilitate the precipitation of BaSO
4
 prior 
to filtration through a plug of Celite®. The volume of the filtrate, which contained 
the final product, was reduced using a rotary evaporator (at 40 °C) and the pH of the 
concentrated filtrate was brought to ~1 using H
2
SO
4
 (95–97%). Addition of methanol 
induced the precipitation of the desired product as a white precipitate that was filtered 
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and washed with methanol and diethyl ether, and subsequently dried under vacuum. 
Elemental analyses were carried out using a Hewlett Packard 185 C and N analyzer. 
ESI-MS was carried out to measure the molecular weight of the obtained Pt-BP 
complex using an electrospray interface and ion trap mass spectrometer. Anal. Calc. 
for [{Pt(en)}
2
(μ-AHBP-H
2
)](HSO
4
)∙3H
2
O (C
6
H
29
N
5
O
14
P
2
Pt
2
S, Mw = 879.4 g∙mol
-1): 
C, 8.19%; N, 7.96%. Found: C, 7.99%; N, 7.45%. Spectroscopic characterization of 
the Pt-BP complex was carried out using 1H and 13P Nuclear Magnetic Resonance 
(NMR) spectroscopy and ATR-FTIR.
In Vivo Biodistribution of Platinum Species and Quantification 
of Platinum Accumulation
10 male C57Bl/6N mice (Charles River), with an average weight of ~25 g and an 
age of approximately 6–8 weeks, were housed in filter-topped cages (5 mice per cage) 
under non-sterile standard conditions with free access to standard animal chow and 
water. The mice were allowed to adapt to laboratory conditions for 1 week before 
experimental use. To evaluate the in vivo biodistribution of Pt-BP and [Pt(NO
3
)
2
(en)] 
after intravenous administration, these complexes were separately injected in the tail 
vein of C57BL/6N mice (n = 5 per each platinum complex). All mice were male 
with an average weight of 25–26 g and an age of approximately 8 weeks. Sterile 
saline solution (0.9% NaCl) was used for the dissolution of platinum complexes and 
subsequent injection in mice. Sterile 23-G needles and 1 ml syringes were used for 
the injection. The concentration of injected Pt-BP or [Pt(NO
3
)
2
(en)] solutions was 0.5 
µmol platinum, calculated based on the maximum tolerated dose (MTD) for cisplatin 
of 6 mg per kg body weight of the mice.33
The mice were euthanized with CO
2
 24 h after injection, after which blood 
(approximately 600 mg per mouse), liver, spleen, kidneys, heart, lungs, and bone 
tissues (femur, humerus, tibia, and spine) were harvested. Approximately half of the 
organs from all mice were dissected, weighed, and stored for future DNA extraction 
(data not yet available). The remaining half of the organs were prepared for inductively 
coupled plasma-mass spectrometry (ICP-MS) analysis by digestion in 65% (v/v) nitric 
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acid at 75 °C for approximately three days until the tissues were digested completely.
Each organ was cut into three samples and the samples were weighed prior to digestion 
in nitric acid. The digested solutions were diluted with up to 6 ml of Milli-Q water to 
obtain 2% (v/v) nitric acid in order to measure platinum concentrations by ICP-MS (X 
series I, Thermo Electron Corporation). The detection limit for determining platinum 
concentration with ICP-MS was 1 ppb. The standard solutions were prepared from 
1,000 mg∙l-1 platinum ICP standard Certipur (1.70341.0100, Merck) ranging from 1 
ppb to 2,500 ppb. The measured isotopes for platinum were 194Pt, 195Pt, 196Pt, and 198Pt. 
Furthermore, scandium (45Sc) was added as an internal standard, which was prepared 
with 1,000 mg∙l-1 scandium standard Certipur (1.19513.0100, Merck) to correct for 
matrix effects and long-term fluctuations of the measurement signal. The platinum 
concentrations in the various organs were calculated relative to 1 mg of the specific 
organ and represented as ng Pt/mg
tissue
.
Three replicates of Pt-BP and [Pt(NO
3
)
2
(en)] solutions with volumes and platinum 
concentrations identical to the solutions injected to the mice (200 µl and 0.5 µmol 
platinum, respectively) were also measured for their platinum content using ICP-
MS as control measurements. The percentage of injected dose (%ID) of Pt-BP and 
[Pt(NO
3
)
2
(en)] in each mouse organ 24 h after injection was calculated by dividing 
the total amount of platinum per organ through the total amount of platinum detected 
in the control solutions.
All in vivo work was conducted in accordance with ISO standards and the 
principles set forth by the Revised Dutch Act on Animal Experimentation. The in 
vivo experiments were approved by the institutional Animal Welfare Committee of 
the Radboud University Medical Center (Radboudumc), Nijmegen, the Netherlands 
(RUDEC 2014 208).
Statistical Analysis
All results are depicted as mean ± standard deviation. The statistical analyses 
were performed using GraphPad Prism (version 6.0) software. Two-way analysis 
of variance (ANOVA) with a Bonferroni (multiple comparisons) post hoc test was 
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used to determine the differences among the two groups. A value of p < 0.05 was 
considered as significantly different.
Results and Discussion
Preparation and Characterization of Pt-BP Complex
In this study, we improved the synthesis of the dinuclear bis-
{ethylenediamineplatinum(II)}-2-amino-1-hydroxyethane-1,1-diyl-bisphosphonate 
complex (Pt-BP; Figure 6.1) as compared to a previously reported synthesis 
strategy23,24,29,34 by using [Pt(NO
3
)
2
(en)] as platinum precursor instead of [Pt(OSO
3
)
(OH
2
)(en)]. In the current synthesis, [Pt(NO
3
)
2
(en)] was selected as platinum 
precursor to facilitate the synthesis of radioactive Pt-BP complexes using 195mPt for 
future applications as a theranostic agent.
In this new procedure, we successfully prepared dinuclear bis-
{ethylenediamineplatinum(II)}-2-amino-1-hydroxyethane-1,1-diyl-bisphosphonate 
using [Pt(NO
3
)
2
(en)] as platinum precursor. The elemental analysis, Electrospray 
Ionisation-Mass Spectrometry (ESI-MS) measurements, and spectroscopic features 
(Figure 6.2 and Figure 6.3) were consistent with previous studies.23,24 Figure 6.2 shows 
the FTIR spectra obtained from the Pt-BP complex prepared using [Pt(NO
3
)
2
(en)] as 
platinum precursor (“New Procedure”), which is similar to the Pt-BP prepared using 
[Pt(OSO
3
)(OH
2
)(en)] as platinum precursor (“Old Procedure”).23,24,34
Figure 6.3A shows the 1H-NMR spectrum of Pt-BP complex, where two broad 
singlets at 5.93 and 5.43 ppm are assigned to the aminic protons of coordinated 
ethylenediamine (en; geminal protons of each aminic group are made inequivalent by 
the lack of symmetry with respect to the coordination plane).24 The acid conditions 
decelerate the exchange of the aminic protons with the deuterium of the solvent, 
allowing detection of the aminic protons in aqueous solution. The doublet of doublets 
centered at 3.34 ppm was assigned to the protons of the methylene group of the 
bisphosphonate. The 31P-NMR spectrum (Figure 6.3B) of the Pt-BP in D
2
O shows 
a singlet with unresolved platinum satellites (platinum satellites usually broaden 
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with an increase in molecular size and chemical shift anisotropy) positioned at 37.60 
ppm and assigned to the two phosphorus atoms of the phosphonic groups, which are 
magnetically equivalent and shifted at lower field (Δδ = 21 ppm) with respect to the 
free AHBP ligand at the same pH.24 These results (Figure 6.3), together with the FTIR 
spectra depicted in Figure 6.2, show identical spectroscopic characteristics of the Pt-
BP complex synthesized using [Pt(NO
3
)
2
(en)] as platinum precursor as compared to 
the Pt-BP complex reported in literature synthesized using [Pt(OSO
3
)(OH
2
)(en)] as 
platinum precursor. This novel strategy for the synthesis of Pt-BP complexes can be 
used as well for the synthesis of these complexes using radioactive 195mPt to allow 
monitoring of the spatiotemporal biodistribution of radioactive Pt-BP complexes 
using micro-SPECT/CT imaging.
Figure 6.2. FTIR spectra of Pt-BP complex prepared using [Pt(NO
3
)
2
(en)] as the precursor ("New 
Procedure") versus Pt-BP complex prepared using [Pt(OSO
3
)(OH
2
)(en)] as the precursor ("Old 
Procedure").23,24,34
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Figure 6.3. 1H (A) and 31P (B) NMR spectra of Pt-BP complex in D
2
O.
In Vivo Biodistribution of Platinum Species and Quantification 
of Platinum Accumulation
To evaluate the bone-seeking properties of Pt-BP complex as compared to its 
bisphosphonate-free precursor [Pt(NO
3
)
2
(en)], the biodistribution of Pt-BP complex 
and [Pt(NO
3
)
2
(en)] (as control) was quantified using Inductively Coupled Plasma-
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Mass Spectrometry (ICP-MS) by measuring platinum concentrations in tibia, femur, 
humerus, spine, blood, heart, lungs, kidney, liver, and spleen. Sterile saline solutions 
containing Pt-BP or [Pt(NO
3
)
2
(en)] with identical platinum concentration were 
intravenously injected into the tail vein of mice, and the mice were euthanized 24 h 
after injection. The harvested organs were weighed and digested in acid for further 
ICP-MS analysis of their platinum content. Figure 6.4 shows the organ concentrations 
of platinum 24 h after injection, normalized against the specific weight of the harvested 
organs. The Pt-BP complex was clearly bone-seeking as evidenced by a comparable 
amount of platinum in different skeletal sites (~3 ng Pt/mg
tissue
) including the tibia, 
femur, humerus, and spine. On the contrary, significantly lower platinum (~1 ng Pt/
mg
tissue
) was found in these bones upon injection of [Pt(NO
3
)
2
(en)] as control complex.
Figure 6.4. Biodistribution profile of Pt-BP and [Pt(NO
3
)
2
(en)] in mice 24 h after injection. Data from 5 
mice per each group are represented as ng Pt/mg
tissue
 ± SD (* p < 0.05).
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To study the specificity of the two different platinum species towards bone tissue 
relative to other soft tissues, the detected platinum is depicted in Figure 6.5 as 
percentage of injected dose (%ID) for each tissue type. Higher uptake of the Pt-BP 
complex was observed for excretory organs, i.e., kidney (5.7 ± 0.15 %ID/g) and liver 
(2.3 ± 0.17 %ID/g), as compared to [Pt(NO
3
)
2
(en)]. Platinum localization in blood, 
heart, and spleen was low for both platinum species (less than ~ 1%ID/g
tissue
).
Figure 6.5. Percentage of injected dose (%ID) of Pt-BP and [Pt(NO
3
)
2
(en)] in mice 24 h after injection. 
Data from 5 mice per each group are represented as %ID ± SD of specific tissue type (* p < 0.05).
The Pt-BP complex exhibited a 4.6-fold higher affinity for bone tissue as compared 
to [Pt(NO
3
)
2
(en)] (Figure 6.5) with approximately 9.32 ± 0.16 %ID Pt-BP found in 
bone, as compared to 2.02 ± 0.07 %ID [Pt(NO
3
)
2
(en)]. The following organs for the 
accumulation of Pt-BP and [Pt(NO
3
)
2
(en)] were liver (3.27 ± 0.19 %ID for Pt-BP and 
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2.21 ± 0.12 %ID for [Pt(NO
3
)
2
(en)]) and kidney (2.18 ± 0.04 %ID for Pt-BP and 1.20 
± 0.07 %ID for [Pt(NO
3
)
2
(en)]).
The in vivo results obtained in this study correspond to lower accumulation of Pt-
BP in soft tissues 24 h after injection as compared to phosphonate analogues such 
as 99mTc-labeled methylene diphosphonate and alendronate, which are frequently 
used for bone imaging.35 Although higer accumulation can possibly lead to sustained 
therapeutics effects, they may also alleviate off-target toxicity.36 Nevertheless, the 
percentage of detected platinum for Pt-BP was high in kidney, which should be 
investigated by histopathology in more detail to avoid nephrotoxicity for application 
of Pt-BP complexes as a bone-seeking theranostic agent.
Conclusions
This study presents a new procedure for the synthesis of dinuclear bis-
{ethylenediamineplatinum(II)}-2-amino-1-hydroxyethane-1,1-diyl-bisphosphonate 
(Pt-BP) by using [Pt(NO
3
)
2
(en)] as platinum precursor instead of [Pt(OSO
3
)(OH
2
)
(en)]. The bone-seeking capacity of this Pt-BP complex was confirmed by preferential 
accumulation of platinum in various bones, whereas significantly lower amounts of 
platinum were observed in the same bones for the control [Pt(NO
3
)
2
(en)] complex. 
Pt-BP complex exhibited a 4.6-fold higher affinity for bone tissue as compared to 
[Pt(NO
3
)
2
(en)]. Furthermore, lower accumulation in soft tissues was observed 24 
h after injection for Pt-BP as compared to phosphonate analogues such as 99mTc-
labled methylene diphosphonate and alendronate, which are frequently used for bone 
imaging.
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Summary
The pharmacological efficacy of conventional drug formulations can be improved through the use of drug delivery systems. Controlled drug delivery systems 
are intended to deliver drugs locally at predetermined rates for predefined periods 
of time. By delivering pharmacologically high concentrations of active agents more 
selectively to pathological sites, drug delivery systems aim to improve the balance 
between efficacy and toxicity as compared to systemically administered therapeutics, 
thereby overcoming the shortcomings of systemic delivery of conventional drug 
formulations.
Targeted drug delivery entails a selective and effective localization of 
pharmacologically active compounds at pre-defined targeted site(s), thus minimizing 
undesired side effects and maximizing therapeutic efficacy. Although many approaches 
have been demonstrated for site-specific drug delivery, strategies to obtain bone-
specific delivery are still scarce. The main aim of the current PhD thesis, therefore, 
was to develop bone-specific delivery strategies.
In order to design bone-specific delivery systems, the cellular and extracellular 
components of bone tissue should be well understood. Therefore, the interactions 
between the inorganic and organic components of the extracellular matrix of bone 
tissue were thoroughly reviewed in Chapter 2. This review was the basis for the 
design of bone-specific drug delivery strategies based on the use of bisphosphonates 
as described in this thesis.
Conventional therapeutic agents generally do not bind to bone tissue, except for 
bisphosphonates, which are drugs developed for treatment of osteoporosis. These 
drugs owe their efficacy to both medicinal effects (by inducing osteoclasts apoptosis) 
as well as their bone-seeking properties. Bisphosphonate molecules are synthetic 
analogues for pyrophosphates that display a remarkable affinity to bone mineral. 
This property is mediated through (HO)
2
−OP−C−PO−(OH)
2
 moieties that act as 
chelators of Ca2+ cations. Interestingly, the distance between deprotonated oxygens 
in phosphonates is 2.9–3.1 Å, which is in the same range as the oxygen anions in the 
calcium phosphate (CaP) mineral crystals as present in bone tissue. Apparently, this 
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distance is optimal for the chelation of Ca2+ ions in hydroxyapatite. In view of their 
strong mineral-binding properties as well as their potent anti-osteoclastic activity, 
bisphosphonates are widely applied as drugs for treatment of osteoporosis. They have 
also been used as moieties for targeted delivery of radio-pharmaceuticals, estrogen, 
corticoids, anti-inflammatory agents, and proteins.
Based on these unique features, bisphosphonates were selected for the development 
of bone-specific delivery strategies for treatment of bone tumors using platinum-
based drugs. To this end, bisphosphonates were either linked to drug delivery carriers 
(Chapter 4), to chemotherapeutic platinum-based drugs (Chapter 3 and 6), or both 
(Chapter 5).
In addition to the devastating effect of cancer on bone tissue, current treatment 
modalities that are unspecific to cancer cells damage healthy tissues. In fact, a major 
disadvantage of anticancer drugs is their lack of selectivity for tumor tissue, which 
causes severe side effects and results in low cure rates. For instance, therapy with 
platinum-based chemotherapeutic molecules such as cisplatin (cis-diamminedichlo
ridoplatinum(II)), which are a group of key drugs used in the treatment of cancers, 
are associated with various secondary effects including anemia, nausea, vomiting, 
neurotoxicity, and nephrotoxicity. These side effects impair the quality of life for 
patients and can be life-threatening. To overcome these side effects, a new generation 
of bisphosphonate-functionalized platinum-based (Pt-BP) complexes (i.e., bis-
{ethylenediamineplatinum(II)}-2-amino-1-hydroxyethane-1,1-diyl-bisphosphonate 
and bis-{ethylenediamineplatinum(I}-medronate)) was recently developed which 
target traditional anticancer platinum-based drugs to bone tissue. Pt-BP complexes 
not only target bone as a result of the bone-seeking properties of bisphosphonate 
moieties, but also specifically target bone tumors due to the higher metabolic activity 
of tumor cells as compared to the healthy ones.
The potential use of these anticancer complexes for loading and subsequent release 
from injectable calcium phosphate cements (CPCs) was studied in Chapter 3. The 
main aim of this chapter was to develop chemotherapeutically active CPCs by 
incorporating hydroxyapatite nanoparticles (HA NPs) loaded with these anticancer Pt-
BP complexes. Following this strategy, we aimed to obtain sustained and controlled 
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release of chemotherapeutic platinum species from apatitic CPCs. To this end, Pt-BP-
loaded HA NPs were added at different ratios to the powder phase of the cements, 
which contained poly(D,L-lactic-co-glycolic) acid (PLGA microspheres as porogens 
to accelerate their degradation. In vitro release kinetics of Pt-BP complexes revealed 
that the release rate of platinum species can be tuned by varying the amount of drug-
loaded HA NPs as well as modifying the chemical structure of the Pt-BP complex 
to tailor its affinity with HA NPs. In addition, we observed that the incorporation of 
PLGA microspheres into the CPCs increased the degradation rate of the materials 
without affecting the release rate of platinum species. Finally, the antiproliferative 
activity of the free Pt-BP complexes and Pt-BP-loaded CPCs was evaluated using 
both human osteosarcoma cancer cells (MG-63) and human bone marrow-derived 
mesenchymal stromal cells (h-BMMSCs). This study demonstrated that both free 
Pt-BP complexes and the releasates from the CPCs were antiproliferative in a dose-
dependent manner. Moreover, their antiproliferative activity was higher on MG-63 
cells compared to h-BMMSC primary cells. In summary, it was shown that injectable 
CPCs can be rendered chemotherapeutically active by incorporation of HA NPs 
loaded with HA-binding Pt-BP complexes.
In Chapter 3 the mineral-binding capacity of bisphosphonates was exploited to 
facilitate loading and release of platinum species from inorganic nanoparticles. In 
Chapter 4, another approach was explored by rendering organic nanoparticles mineral-
binding through conjugation with bisphosphonates. In this chapter, the main aim was 
to develop bisphosphonate-functionalized organic gelatin nanoparticles with enhanced 
affinity towards the CaP mineral phase of bone for bone-specific drug delivery. Gelatin 
is a particularly attractive candidate material for drug delivery, since it is a low-cost 
proteinaceous biopolymer that has been extensively used for biomedical purposes 
due to its biocompatible, biodegradable, and non-toxic properties. Different types 
of gelatin can offer various physicochemical properties to allow modification using 
simple functionalization schemes. Gelatin nanoparticles can be tuned with respect to 
their drug loading efficiency, degradation rate, and release kinetics, which renders 
these drug carriers highly suitable for a wide variety of biomedical applications. The 
ease of functionalization renders gelatin an interesting candidate material to introduce 
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specific motifs for selective targeting to specific organs, but gelatin nanoparticles 
have not yet been modified to increase their affinity to mineralized tissue. By means 
of conjugating mineral-binding alendronate groups to gelatin nanoparticles, we 
developed a simple method for the preparation of gelatin nanoparticles which exhibit 
strong affinity to mineralized surfaces. We showed that the degree of alendronate 
functionalization could be tuned by controlling the glutaraldehyde crosslinking 
density, the molar ratio between alendronate and glutaraldehyde, as well as the 
pH of the conjugation reaction. Moreover, we showed that the affinity of gelatin 
nanoparticles to CaP increased considerably upon functionalization with alendronate. 
In summary, gelatin nanoparticles were developed which exhibit great potential for 
use in bone-specific drug delivery and regenerative medicine.
These bisphosphonate-functionalized gelatin nanoparticles were further functionalized 
with an anticancer Pt-BP complex in order to develop gelatin nanoparticles dual-
functionalized with mineral-binding bisphosphonate groups and chemotherapeutic Pt-
BP complexes (Chapter 5). In that way, we aimed to obtain controlled and sustained 
release of chemotherapeutics from bone-specific gelatin nanoparticles (Chapter 5). We 
showed that the degree of functionalization could be tuned by varying the molar ratio of 
Pt-BP and alendronate relative to glutaraldehyde as crosslinker. Sustained and tunable 
release of platinum was observed from both dual- and Pt-BP-functionalized gelatin 
nanoparticles. Moreover, dual- and alendronate-functionalized gelatin nanoparticles 
displayed a high affinity to CaP as a result of functionalization with alendronate. 
Summarizing, it was concluded that mineral-binding gelatin nanoparticles can be 
functionalized with chemotherapeutic drugs, which may benefit the development of 
bone-seeking and potentially chemotherapeutically active carriers for treatment of 
bone tumors.
In the last experimental chapter of this thesis (Chapter 6), a carrier-free approach 
towards tumor-targeted delivery of anticancer platinum-based drugs was pursued. 
Tumor-targeted delivery has shown great potential to overcome the drawbacks 
exhibited by conventional systemic delivery of clinically applied chemotherapeutic 
drugs. Recently developed bisphosphonate-functionalized platinum compounds 
have both mineral-binding (see Chapter 3) as well as antitumor properties due to 
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the presence of bisphosphonate ligands and platinum, respectively. In Chapter 6 we 
aimed—for the first time—to confirm the in vivo bone-seeking properties of an amino-
bisphosphonate platinum complex after tail intravenous injection in C57Bl/6 mice 
as compared to a platinum precursor complex without bone-seeking bisphosphonate 
moieties ([Pt(NO
3
)
2
(en)]). Inductively Coupled Plasma-Mass Spectrometry (ICP-
MS) was used for platinum detection in selected organs, i.e., tibia, femur, humerus, 
spine, blood, heart, lungs, kidney, liver, and spleen. The bone-seeking properties 
of the Pt-BP complex were confirmed by preferential accumulation of platinum in 
various skeletal sites (including the tibia, femur, humerus, and spine), whereas much 
less platinum was detected in the same bone tissues upon injection of the control 
[Pt(NO
3
)
2
(en)]. The Pt-BP complex exhibited a 4.6-fold higher affinity towards bone 
tissue as compared to [Pt(NO
3
)
2
(en)]. Furthermore, a lower in vivo accumulation in 
soft tissues was observed for Pt-BP as compared to previously reported values for 
99mTc-methylene diphosphonate and 99mTc-alendronate.
Closing Remarks and Future Perspectives
This thesis describes the development of bone-specific delivery strategies either by 
linking bisphosphonates to drug delivery carriers or to chemotherapeutic platinum-
based drugs. The drug delivery carriers were made of either inorganic or organic 
materials, and bisphosphonates were applied as the targeting moieties. These drug 
delivery systems were designed to be used for local or non-local targeted delivery of 
chemotherapeutic platinum-based drugs to bone tumors.
With respect to the inorganic drug delivery vehicles developed in this thesis, clinically 
used injectable CPCs were successfully rendered chemotherapeutically active by 
incorporating drug-loaded HA NPs. Drug release from these cements was shown 
to be sustained in in vitro tests, while their antiproliferative activity was higher on 
human osteosarcoma cancer cells (MG-63) compared to human bone marrow-derived 
mesenchymal stromal cells (h-BMMSCs). However, several experiments should be 
carried out before their tumor specificity can be claimed and clinical translation can 
be considered. First, only in vitro studies on the release behavior of platinum species 
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from these CPCs have been performed to date. Generally, however, in vitro and in 
vivo data on drug release cannot be correlated. Therefore, in vivo characterization of 
platinum release needs to be performed in future studies to understand and optimize 
the release dose as well as release rate of platinum species. CPCs containing Pt-BP-
loaded HA NPs can be either implanted as molded CPCs or injected directly to defects 
which remain after tumor resection in animal models. PLGA-containing CPCs should 
also be tested as additional experimental groups. Although PLGA microspheres did 
not influence the platinum release from CPCs in vitro (Chapter 3), their influence on 
the degradation of CPCs might be beneficial and promote the regeneration capacity of 
bone tissue in vivo. Second, before claiming specificity or selectivity towards cancer 
cells over non-cancerous cells independent of their proliferation rate, more detailed 
in vitro experiments should be performed prior to in vivo experiments. Regarding 
the in vitro experiments, cancer cells and non-cancerous cells can be co-cultured 
and, as a result, the cytotoxicity—or antiproliferative capacity—of platinum species 
can be simultaneously analyzed using different markers for the different cell types. 
Furthermore, CPCs can be placed in inserts and release the platinum species into 
the medium used to culture the seeded cells. In this way, the real-time response of 
cells exposed to gradually released platinum species can be compared to the effect of 
instantaneous changes in the cell culture medium by replacing platinum-free media 
for media containing specific concentrations of platinum.
With respect to the organic drug delivery vehicles developed in this thesis, gelatin 
nanoparticles with enhanced affinity to CaP mineral phase of bone were successfully 
prepared (Chapter 4), which exhibit great potential for use in bone-specific drug 
delivery and regenerative medicine. As a next step, these promising drug delivery 
vehicles were rendered chemotherapeutically active by dual-functionalization with an 
anticancer Pt-BP complex (Chapter 5). We hypothesized that these nanoparticles would 
accumulate at bone tumor sites due the mineral-binding capacity of alendronate and 
the enhanced permeation and retention effect (EPR) for nanoparticles. Consequently, 
the release of the pharmacologically active platinum species would be induced by 
proteolytical degradation of the gelatin nanocarriers by metalloproteinases, which are 
generally highly expressed in the tumor interstitial space. These dual-functionalized 
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drug delivery vehicles may benefit the development of bone-seeking and potentially 
chemotherapeutically active carriers for treatment of bone tumors. Although the size 
of gelatin nanoparticles prepared herein (~400 nm in swollen state) might possibly be a 
concern with respect to limitations on their systemic administration in vivo, according 
to many reports in literature it is in the suitable range for accumulation in tumor tissue 
through the EPR effect. Macromolecules or nanoparticles with cutoff size of >400 
nm have been shown to preferably accumulate in tumor tissue rather than healthy 
tissues, possibly as a result of increased permeability of tumor vasculature and the 
EPR effect. Nevertheless, both the CaP binding affinity and the release behavior of the 
functionalized gelatin nanoparticles were only evaluated in in vitro tests in the current 
thesis. In addition, the in vitro cytocompatibility of the bone-specific bisphosphonate-
functionalized gelatin nanoparticles has not yet been evaluated. Therefore, the in vitro 
cytocompatibility of the bisphosphonate-functionalized gelatin nanoparticles should 
be tested first without loading of drugs. As a second step, the bone-targeting capacity 
of these nanoparticles needs to be evaluated in vivo upon both systemic and local 
administration. Furthermore, the release behavior of the drug-loaded nanoparticles, 
their anticancer activity, potential lack of activity, and possible side effects need to be 
evaluated by means of in vivo experiments.
With respect to the in vivo biodistribution study performed in Chapter 6, the bone-
seeking properties of a Pt-BP complex upon systemic administration were evident 
by uniform distribution of platinum in different bone tissues (tibia, femur, humerus, 
and spine), whereas much lower platinum contents were measured observed upon 
injection of the platinum precursor lacking the bone-seeking bisphosphonate moieties 
([Pt(NO
3
)
2
(en)]). Furthermore, Pt-BP complexes exhibited a higher affinity towards 
bone tissue as compared to [Pt(NO
3
)
2
(en)], and lower in vivo accumulation in soft tissues 
(such as heart, lungs, kidney, liver, and spleen) were observed 24 h after injection for 
Pt-BP as compared to similar compounds previously reported in literature. However, 
to improve our understanding of the mechanism of action of Pt-BP complexes, the 
potential formation of Pt−DNA adducts need to be investigated after genomic DNA 
extraction from major organs of interest. Subsequently, Pt-BP complexes could be 
synthesized from radioactive 195mPt precursors ([Pt(NO
3
)
2
(en)]), which would allow 
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for in vivo visualization of the biodistribution of Pt-BP complexes as a function of 
time using advanced imaging techniques, such as single photon emission computed 
tomography (SPECT). Subsequently, the anticancer capacity as well as selectivity 
of systemically administered Pt-BP complexes towards cancer cells relative to non-
cancerous cells should be tested in suitable animal models with skeletal metastases 
before clinical translation can be considered.
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Samenvatting
De farmacologische werkzaamheid van conventionele geneesmiddelen kan worden verbeterd door gebruik te maken van afgiftesystemen. Deze 
afgiftesystemen kunnen geneesmiddelen op gecontroleerde wijze afgeven volgens een 
van tevoren bepaalde tijdsduur en snelheid. Afgiftesystemen dienen daarbij de balans 
tussen effectiviteit en toxiciteit te verbeteren ten opzichte van systemisch toegediende 
medicijnen door de selectieve en lokale afgifte van hoge geneesmiddelconcentraties. 
Op deze wijze kunnen de huidige tekortkomingen van conventionele systemische 
geneesmiddelafgifte worden overwonnen.
Gerichte afgifte van geneesmiddelen streeft ernaar om farmacologisch werkzame 
verbindingen selectief en effectief te lokaliseren op vooraf bepaalde bestemmingen, 
waardoor ongewenste bijwerkingen afnemen en de therapeutische effectiviteit 
toeneemt. Alhoewel gerichte afgifte van medicijnen al op diverse manieren is 
bewerkstelligd, is er nog weinig onderzoek uitgevoerd naar bot-specifieke afgifte van 
medicijnen. Het belangrijkste doel van dit proefschrift was dan ook om een bijdrage 
te leveren aan de ontwikkeling van bot-specifieke afgifte-strategieën.
Het ontwerp van bot-specifieke afgiftesystemen vereist een goed begrip van de 
cellulaire en extracellulaire componenten van botweefsel. Daarom is de interactie 
tussen de anorganische en organische componenten van de extracellulaire matrix 
van botweefsel uitgebreid beschreven in Hoofdstuk 2. Deze studie was de basis voor 
het ontwerp van het bot-specifieke afgifte-strategieën gebaseerd op het gebruik van 
bisfosfonaten, zoals beschreven in dit proefschrift.
Conventionele geneesmiddelen binden in principe niet aan botweefsel. 
Bisfosfonaten daarentegen zijn medicijnen voor de behandeling van osteoporose 
die wel aan bot binden. Deze medicijnen danken hun effectiviteit aan zowel hun 
medicinale werking (door osteoclast-apoptose te induceren) en hun botbindende 
eigenschappen. Bisfosfonaat moleculen zijn synthetische versies van pyrofosfaten 
die een opmerkelijke affiniteit voor botmineraal ten toon spreiden. Deze eigenschap 
wordt mogelijk gemaakt door (HO)
2
–OP–C–PO–(OH)
2
 groepen die Ca2+ kationen 
kunenn cheleren. De afstand tussen gedeprotoneerde zuurstofatomen in fosfonaten 
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bedraagt 2.9–3.1 Å, wat sterk overeenkomt met de afstand tussen zuurstof anionen 
in calciumfosfaat (CaP) kristallen zoals aanwezig in botweefsel. Blijkbaar is deze 
afstand optimaal voor de chelatie van Ca2+ ionen in hydroxyapatiet. Gezien hun sterke 
binding aan CaP mineraal en hun krachtige activiteit tegen osteoclasten worden 
bisfosfonaten op grote schaal toegepast als geneesmiddelen voor de behandeling van 
osteoporose. Deze medicijnen worden tevens toegepast voor de gerichte afgifte van 
radiofarmaca, oestrogeen, corticoïden, anti-ontstekingsmiddelen en eiwitten.
Dankzij deze unieke eigenschappen werden bisfosfonaten in dit proefschrift 
geselecteerd voor de ontwikkeling van bot-specifieke afgifte-strategieën voor de 
behandeling van bottumoren op basis van platina-gebaseerde geneesmiddelen. 
Hiertoe werden bisfosfonaten gekoppeld aan dragermaterialen (Hoofdstuk 4), 
chemotherapeutische platina-gebaseerde geneesmiddelen (Hoofdstuk 3 en 6) of beide 
(Hoofdstuk 5).
INaast het verwoestende effect van kanker op botweefsel, beschadigen ook de huidige 
behandelmethoden die onspecifiek zijn voor kankercellen gezonde (bot)weefsels. Een 
groot nadeel van antikanker medicijnen heeft betrekking op hun gebrek aan selectiviteit 
voor tumorweefsel, waardoor ernstige bijwerkingen en lage genezingspercentages 
worden bereikt. Zo leiden platina-gebaseerde chemotherapeutische moleculen zoals 
cisplatine (cis-diamminedichloridoplatinum(II)) tot diverse bijwerkingen zoals 
bloedarmoede, misselijkheid, braken, neuro- en nefrotoxiciteit. Deze bijwerkingen 
doen afbreuk aan de kwaliteit van leven voor patiënten en kan zelfs levensbedreigend 
zijn. Om deze bijwerkingen te overwinnen is recentelijk een nieuwe generatie van 
botbindende bisfosfonaat-gefunctionaliseerde platina-gebaseerde (Pt-BP) complexen 
ontwikkeld (d.w.z bis-{ethylenediamineplatinum(II)}-2-amino-1-hydroxyethaan-
1,1-diyl-bisfosfonaat en bis-{ethyleendiamineplatinum(II)}-medronaat)). Pt-BP 
complexen binden niet alleen gericht aan botweefsel als gevolg van de botbindende 
eigenschappen van bisfosfonaat groepen, maar ook specifiek aan bottumoren door de 
hogere metabole activiteit van tumorcellen.
De mogelijkheid om deze antikanker complexen vanuit injecteerbare calciumfosfaat 
cementen (CPCs) af te geven werd bestudeerd in Hoofdstuk 3. Het belangrijkste 
doel van dit hoofdstuk was de ontwikkeling van chemotherapeutisch actieve CPCs 
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door hydroxyapatiet nanodeeltjes (HA) in te bouwen die beladen waren met deze 
antikanker Pt-BP complexen. Op deze wijze streefden we ernaar om langdurige en 
gecontroleerde afgifte van chemotherapeutisch actief platina uit CPCs te verkrijgen. 
Hiertoe werden HA nanodeeltjes beladen met Pt-BP complexen in verschillende 
verhoudingen toegevoegd aan de poederfase van het cementen, die tevens 
polymelkzuur-co-glycolzuur (PLGA) microsferen bevatten om de afbraak van de 
cementen te versnellen. De in vitro afgiftesnelheid kon ingesteld worden door variatie 
van de hoeveelheid HA nanodeeltjes en modificatie van de chemische structuur 
van de Pt-BP complexen. Bovendien ontdekten we dat de PLGA microsferen de 
degradatiesnelheid van de cementen verhoogden zonder dat de afgiftesnelheid van 
platina werd beïnvloed. Tenslotte werd de antiproliferatieve activiteit van zowel Pt-
BP complexen als cementen die met Pt-BP beladen waren geëvalueerd met behulp van 
zowel humane osteosarcoom kankercellen (MG-63) als humane beenmerg-afgeleide 
cellen. Deze studie toonde aan dat zowel vrije Pt-BP complexen als de afgifteproducten 
vanuit het cement de proliferatie van bovengenoemde cellen reduceerden op een 
dosisafhankelijke wijze. Bovendien was de antiproliferatieve activiteit van de 
complexen hoger bij MG-63 cellen ten opzichte van primaire beenmerg-afgeleide 
cellen. Samengevat is aangetoond dat injecteerbare CPCs chemotherapeutisch actief 
gemaakt kunnen worden door inbouw van HA nanodeeltjes die beladen zijn met HA-
bindende Pt-BP complexen.
In Hoofdstuk 3 werd het mineraal-bindend vermogen van bisfosfonaten benut 
om de gecontroleerde afgifte van platina vanaf anorganische nanodeeltjes te 
vergemakkelijken. In Hoofdstuk 4 werd voor een andere benadering gekozen door 
organische nanodeeltjes mineraal-bindend te maken door middel van conjugatie 
met bisfosfonaten. In dit hoofdstuk was het belangrijkste doel de ontwikkeling 
van bisfosfonaat-gefunctionaliseerde organische gelatine nanodeeltjes met 
verbeterde affiniteit voor de minerale fase van bot ten behoeve van bot-specifieke 
afgifte van geneesmiddelen. Gelatine is een bijzonder aantrekkelijk materiaal 
voor geneesmiddelafgifte omdat het een goedkope eiwitachtige biopolymeer is 
dat uitgebreid wordt toegepast voor biomedische doeleinden vanwege de gunstige 
biocompatibiliteit en afbreekbaarheid. Verschillende types gelatine beschikken over 
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specifieke fysisch-chemische eigenschappen waardoor modificatie mogelijk wordt 
met behulp van eenvoudige functionalisatiemethoden. De efficiëntie van de belading 
van geneesmiddelen alsmede de degradatiesnelheid en afgiftekinetiek kan zeer goed 
gecontroleerd worden voor gelatine nanodeeltjes, waardoor deze dragermaterialen 
uitermate geschikt zijn voor een groot aantal biomedische toepassingen. Omdat 
gelatine makkelijk te functionaliseren valt, is gelatine zeer geschikt voor de gerichte 
afgifte naar specifieke organen, maar gelatine nanodeeltjes zijn tot op heden nog niet 
gemodificeerd met als doel om hun affiniteit voor gemineraliseerd weefsel te verhogen. 
Door alendronaat groepen aan gelatine nanodeeltjes te conjugeren, ontwikkelden 
we een eenvoudige werkwijze voor de bereiding van gelatine nanodeeltjes met een 
sterke affiniteit voor gemineraliseerde oppervlakken. We toonden aan dat de mate van 
alendronaat functionalisatie kan worden ingesteld door variatie van de glutaaraldehyde 
crosslinkdichtheid, de molaire verhouding tussen alendronaat en glutaaraldehyde 
en de pH van de conjugatiereactie. Bovendien toonden we aan dat de affiniteit van 
gelatine nanodeeltjes voor calciumfosfaat  aanzienlijk toenam na functionalisatie met 
alendronaat. Samengevat hebben we gelatine nanodeeltjes ontwikkeld met een groot 
potentieel voor toepassing in bot-specifieke geneesmiddelafgifte en regeneratieve 
geneeskunde.
Deze bisfosfonaat-gefunctionaliseerde gelatine nanodeeltjes werden verder 
gefunctionaliseerd met een Pt-BP complex om gelatine nanodeeltjes ontwikkelen 
die zowel gefunctionaliseerd waren met botbindende bisfosfonaat groepen als 
chemotherapeutisch actieve Pt-BP complexen (Hoofdstuk 5). Op deze wijze trachtten 
we controle te verkrijgen over de afgifte van chemotherapeutica vanuit botbindende 
gelatine nanodeeltjes (Hoofdstuk 5). We toonden aan dat de mate van functionalisatie 
gevarieerd kan worden door variatie van de molaire verhouding tussen Pt-BP 
en alendronaat ten opzichte van glutaaraldehyde als crosslinker. Langdurige en 
controleerbare afgifte van platina werd waargenomen vanuit gelatine nanodeeltjes 
gefunctionaliseerd met Pt-BP complexen. Bovendien vertoonden en alendronaat-
gemodificeerde gelatine nanodeeltjes een sterke affiniteit met calciumfosfaat als 
gevolg van de functionalisatie met alendronaat. Samenvattend werd geconcludeerd 
dat mineraal-bindende gelatine nanodeeltjes kunnen worden gefunctionaliseerd met 
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chemotherapeutica. Deze deeltjes kunnen gebruikt worden voor verdere ontwikkeling 
van chemotherapeutisch actieve dragermaterialen voor de behandeling van 
bottumoren.
In het laatste experimentele hoofdstuk van dit proefschrift (Hoofdstuk 6), 
werd een carrier-vrije benadering onderzocht voor de tumor-specifieke afgifte 
van platina-gebaseerde chemotherapeutica. Tumor-specifieke afgifte maakt het 
mogelijk om de nadelen te overwinnen die gepaard gaan met systemische afgifte 
van klinisch toegepaste chemotherapeutica. Recentelijk ontwikkelde bisfosfonaat-
gefunctionaliseerde platinaverbindingen beschikken over zowel botbindende (zie 
Hoofdstuk 3) als antitumor eigenschappen. In Hoofdstuk 6 was het doel om de 
botbindende eigenschappen van een amino-bisfosfonaat platinacomplex voor het 
eerst in vivo aan te tonen (na intraveneuze injectie in C57bl/6 muizen) in vergelijking 
tot een platinacomplex zonder botbindende liganden ([Pt(NO
3
)
2
(en)]). Inductief 
gekoppeld plasma-massaspectrometrie (ICP-MS) werd gebruikt voor de detectie van 
platina in geselecteerde organen, d.w.z. tibia, femur, humerus, wervelkolom, bloed, 
hart, longen, nieren, lever en milt. Het botbindende potentieel van het Pt-BP complex 
werden bevestigd doordat het platina preferentiële accumuleerde in verschillende 
onderdelen van het skelet (met inbegrip van het scheenbeen, dijbeen, opperarmbeen 
en de wervelkolom), terwijl veel minder platina werd aangetoond in bot na injectie 
van het bisfosfonaat-vrije complex [Pt(NO
3
)
2
(en)]. Het Pt-BP complex vertoonde 
een 4 tot 5 keer hogere affiniteit voor botweefsel in vergelijking tot [Pt(NO
3
)
2
(en)]. 
Bovendien werd een kortere verblijftijd in zachte weefsels waargenomen voor Pt-BP 
vergeleken met eerder gerapporteerde waarden voor 99mTc-methyleen difosfonaat en 
99mTc-alendronaat.
Slotopmerkingen en Toekomstperspectief
Dit proefschrift beschrijft de ontwikkeling van bot-specifieke afgiftestrategieën door 
het koppelen van bisfosfonaten aan dragermaterialen of chemotherapeutische platina-
gebaseerde geneesmiddelen. De geselecteerde dragermaterialen waren van ofwel 
anorganische of organische oorsprong en bisfosfonaten werden gebruikt om gerichte 
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afgifte aan botweefsel mogelijk te maken. Deze geneesmiddelafgiftesystemen 
zijn ontworpen om te worden gebruikt voor lokale of niet-lokale afgifte van 
chemotherapeutische platina-gebaseerde geneesmiddelen bij bottumoren.
Wat betreft de anorganische dragermaterialen zoals onderzocht in dit proefschrift kan 
worden geconcludeerd dat injecteerbare CPCs chemotherapeutisch actief gemaakt zijn 
door inbouw van HA nanodeeltjes die beladen waren met antikanker medicijnen. De 
afgifte van medicijnen uit deze cementen was langdurig, terwijl de antiproliferatieve 
activiteit op humane osteosarcoom kankercellen (MG-63) hoger was in vergelijking 
met humane beenmerg- afgeleide cellen. Er moeten echter nog diverse experimenten 
uitgevoerd worden voordat de tumorspecificiteit kan worden geclaimd en klinische 
toepassingen kunnen worden overwogen. Ten eerste zijn tot op heden alleen in vitro 
studies uitgevoerd naar het afgiftegedrag van platina uit deze CPCs. In het algemeen 
geldt echter dat in vitro en in vivo gegevens met betrekking tot geneesmiddelafgifte 
niet kunnen worden gecorreleerd. Daardoor dient de afgiftekinetiek van platina ook 
middels in vivo studies onderzocht te worden om de dosering en afgiftesnelheid 
te optimaliseren. CPCs die met Pt-BP complexen zijn beladen kunnen worden 
geïmplanteerd als uitgeharde cementen of direct worden geïnjecteerd in defecten 
die achterblijven na tumorresectie. CPCs die PLGA microsferen bevatten moeten 
daarbij ook worden getest. Alhoewel de inbouw van PLGA microsferen de afgifte 
van platina vanuit CPCs in vitro niet beïnvloedde (Hoofdstuk 3), kan de versnelling 
van de degradatie door PLGA microsferen nuttig zijn en de regeneratiecapaciteit 
van botweefsel in vivo bevorderen. Ten tweede dienen meer gedetailleerde in vitro 
experimenten uitgevoerd te worden voordat specificiteit of selectiviteit van de Pt-BP 
complexen op kankercellen geclaimd kan worden.  Kankercellen en  gezonde cellen 
kunnen samen gekweekt worden waarna de cytotoxiciteit—of antiproliferatieve 
capaciteit—van de platina-gebaseerde medicijnen kan worden geanalyseerd. 
Bovendien kunnen CPC samples in inserts worden geplaatst om het platina in het 
medium af te geven dat wordt gebruikt voor celkweek. Op deze wijze kan het directe 
effect van platina vrijgegeven uit cementen vergeleken worden met het effect van 
plotselinge concentratie-veranderingen in het celkweekmedium.
Wat betreft de organische dragermaterialen zoals beschreven in dit proefschrift 
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kan worden geconcludeerd dat gelatine nanodeeltjes met een sterke affiniteit voor 
CaP als minerale fase van botweefsel zijn ontwikkeld (Hoofdstuk 4). Deze deeltjes 
zijn veelbelovend voor toepassingen in bot-specifieke geneesmiddelafgifte en 
regeneratieve geneeskunde. Deze veelbelovende dragermaterialen zijn vervolgens 
chemotherapeutisch actief gemaakt door functionalisatie met antikanker Pt-BP 
complexen (Hoofdstuk 5). Onze hypothese was dat deze nanodeeltjes zouden ophopen 
in bottumoren dankzij de botbindende eigenschappen van alendronaat en het “enhanced 
permeation and retention effect (EPR)” van nanodeeltjes. Het farmacologisch 
actieve platina zou vrijgegeven kunnen worden door proteolytische afbraak van de 
gelatine nanodeeltjes dankzij hoge concentraties van metalloproteïnasen in tumoren. 
Deze dragermaterialen kunnen bijdragen aan de ontwikkeling van botbindende en 
chemotherapeutisch actieve dragermaterialen voor de behandeling van bottumoren. 
Hoewel de afmeting van gelatine nanodeeltjes (~400 nm in gezwollen toestand) een 
beperking kunnen vormen voor systemische toediening in vivo, is het op basis van 
literatuur nog steeds mogelijk dat deze nanodeeltjes accumuleren in tumorweefsel 
dankzij het EPR effect. Macromoleculen of nanodeeltjes groter dan 400 nm hoopten 
in eerdere studies op in tumorweefsel, wat mogelijk veroorzaakt wordt door de 
toegenomen permeabiliteit van de tumorvasculatuur alsmede het EPR effect. De CaP-
bindende affiniteit en afgifte-kinetiek van de gefunctionaliseerde gelatine nanodeeltjes 
zijn tot op heden echter alleen geëvalueerd middels in vitro testen. Bovendien is de in 
vitro cytocompatibiliteit van bot-specifieke bisfosfonaat-gefunctionaliseerde gelatine 
nanodeeltjes nog niet onderzocht. Daarom dient de in vitro cytocompatibiliteit van 
bisfosfonaat-gefunctionaliseerde gelatine nanodeeltjes eerst te worden getest zonder 
belading van geneesmiddelen. Daarnaast dient te botbindende capaciteit van deze 
nanodeeltjes geëvalueerd te worden middels in vivo studies na zowel systemische als 
lokale toediening. Bovendien dient de afgiftekinetiek van de nanodeeltjes middels in 
vivo studies onderzocht te worden alsmede hun activiteit tegen kanker en mogelijke 
bijwerkingen.
Op basis van de in vivo biodistributie studie zoals uitgevoerd in Hoofdstuk 6 kan 
worden geconcludeerd dat de botbindende eigenschappen van het Pt-BP complex na 
systemische toediening duidelijk aangetoond waren zoals bleek uit de gelijkmatige 
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verdeling van platina over de verschillende botten (tibia, femur, humerus en 
wervelkolom), terwijl veel minder platina werd aangetroffen in botweefsel na injectie 
van bisfosfonaat-vrije ([Pt(NO
3
)
2
(en)]) complexen. De Pt-BP complexen vertoonden 
dus een hogere affiniteit voor botweefsel dan [Pt(NO
3
)
2
(en)] complexen, terwijl de 
in vivo verblijfstijd in zachte weefsels zoals hart, longen, nieren, lever en milt korter 
waren dan soortgelijke verbindingen die in de literatuur gerapporteerd zijn. Echter, om 
het inzicht in het werkingsmechanisme van Pt-BP complexen te verbeteren dient de 
mogelijke vorming van Pt-DNA adducten te worden onderzocht na genomische DNA 
extractie uit relevante organen. Vervolgens kunnen Pt-BP complexen gesynthetiseerd 
worden op basis van radioactief 195mPt, waardoor de biodistributie in beeld gebracht kan 
worden als functie van de tijd met behulp van geavanceerde beeldvormingstechnieken 
zoals single photon emission computed tomography (SPECT). Vervolgens dient 
de effectiviteit en selectiviteit van systemisch toegediende Pt-BP complexen voor 
kankercellen ten opzichte van gezonde cellen aangetoond te worden in geschikte in 
vivo tumormodellen  alvorens klinische toepassingen kunnen worden overwogen.
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